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Dissertation Abstract 
Development of Novel Zika and Anthrax Viral 
Nanoparticle Vaccines 
By Elizabeth A. Henderson 
Keck Graduate Institute of Applied Life Sciences: 2019 
Vaccines protect against numerous infectious diseases and prevent millions of deaths annually, but 
there are still many infectious diseases for which no licensed vaccine exists.  Developing a new vaccine 
requires balancing safety and efficacy, and viral nanoparticle (VNP) vaccines possess both of these 
characteristics.  The work herein demonstrates how tobacco mosaic virus (TMV) nanoparticles can serve 
as a platform to create candidate vaccines for Zika virus (ZIKV) and anthrax.  In the first study, a ZIKV-
specific epitope was genetically fused to TMV to create a safe and inexpensive vaccine that proved 
highly immunogenic in mice and led to the discovery of ZIKV-specific neutralizing antibodies that may 
have applications in therapeutics and diagnostics.  In the second study, anthrax toxin domains were 
expressed, purified, and conjugated to the outer surface of modified TMV nanoparticles.  These VNPs 
were readily recognized by anthrax immune serum, but further studies will be necessary to ascertain 
their ability to induce a protective immune response.  As demonstrated in these studies, genetic fusions 
and chemical conjugations to TMV each have distinct benefits and limitations. However, both methods 
result in the production of TMV-based VNPs, in which the TMV virion acts as both a scaffold and delivery 
mechanism, ensuring that the foreign antigens are taken up by DCs, transported to lymph nodes, and 
stimulate robust, antigen-specific B and T cell responses.   In summation, this work shows how TMV 














I would first like to thank my supervisors, Dr. Larry Grill, and Dr. Mikhail Martchenko, for their 
guidance, support, encouragement, and advice.   Larry, thank you for allowing me to join your lab, giving 
me the opportunity to pursue my PhD, and the beautiful trip to Africa.  I am grateful to you for giving me 
the freedom to pursue these projects and for putting up with me for so many years.  Mikhail, your 
expertise in infectious disease proved invaluable, and your passion for science always kept me 
motivated.  Thank you for facilitating intense scientific discussion and for teaching me how to throw 
spaghetti at the wall.  
   I would also like to thank my committee members, Dr. Craig Adams and Dr. Hal Padgett, for 
their support and scientific input.  Craig, thank you for sharing your knowledge on expressing and 
purifying proteins and for letting me conduct some of my work in your lab; it has been a privilege 
working with you and Jamie Liu.  I am also grateful to you for teaching me how to question everything, 
think outside of the box, and to always err on the side of caution.  And to Hal, thank you for letting me 
visit your facilities and allowing me to work with the Dock-and-Lock system.  I sincerely appreciate your 
continued willingness to help, from sharing vectors to providing business plan ideas, and for allowing me 
to explore the business side of science.   
I couldn’t have done this without the training, guidance, and day-to-day input provided by Dr. 
Ryan McComb, Dr. Kelvin Phiri, and (soon-to-be Dr.) Andrea Gochi.  Thank you for your friendship and 
for putting up with all my idiosyncrasies in the lab.   
Many thanks to Dr. Matt McGee of Novici Biotech for providing guidance and technical support; 




Thank you to our collaborators on the Zika project: Luisa W. Chang and Christina C. Tam at the 
USDA, and Sujan Shresta, Annie Elong Ngono, and Anh-Viet Nguyen at the La Jolla Institute for Allergy 
and Immunology.  
To all of the KGI professors, staff, and students that I have met while on this journey, it has been 
a pleasure working with you.   
Finally, and most importantly, I would like to acknowledge my entire family for their support and 
love.  To my mom, thank you for being my role model; you have taught me how to be strong and 
independent.  I would also like to thank my step-father, Robert O. Crapo, for igniting my passion for 










TABLE OF CONTENTS 
Overview ____________________________________________________________________ 1 
The Immune system ________________________________________________________________ 1 
Innate immunity ___________________________________________________________________________ 1 
Adaptive immunity _________________________________________________________________________ 3 
Antigens and immunogenicity ________________________________________________________________ 8 
Vaccines _________________________________________________________________________ 9 
Live-attenuated vaccines ___________________________________________________________________ 11 
Inactivated vaccines _______________________________________________________________________ 13 
Subunit vaccines __________________________________________________________________________ 13 
Virus-like particle vaccines __________________________________________________________________ 15 
Nucleic acid-based vaccines _________________________________________________________________ 16 
Viral vector vaccines _______________________________________________________________________ 17 
Nanoparticle vaccines _____________________________________________________________________ 18 
Vaccine development ______________________________________________________________________ 19 
Vaccine manufacturing ____________________________________________________________________ 20 
Plant-made Biopharmaceuticals _____________________________________________________ 22 
Nicotiana benthamiana ____________________________________________________________________ 25 
Agrobacterium-mediated expression _________________________________________________________ 26 
Plant virus-based expression vectors _________________________________________________________ 28 
Tobacco mosaic virus ______________________________________________________________________ 29 
TMV viral vectors _________________________________________________________________________ 31 
Summary ________________________________________________________________________ 33 




Introduction _____________________________________________________________________ 34 
Background ______________________________________________________________________ 38 
Immune response to ZIKV __________________________________________________________________ 40 
Pathology of ZIKV _________________________________________________________________________ 51 
ZIKV envelope protein _____________________________________________________________________ 54 
ZIKV lineages and polymorphisms ____________________________________________________________ 57 
Zika vaccine candidates ____________________________________________________________________ 60 
Materials and Methods ____________________________________________________________ 63 
Zika virus epitope selection _________________________________________________________________ 63 
Expression vectors and cloning ______________________________________________________________ 63 
Agroinfiltration of plants ___________________________________________________________________ 66 
Plant growth and incubation ________________________________________________________________ 66 
Viral nanoparticle extraction, purification, and characterization____________________________________ 66 
Preparation of TMV-E and rE (Novici Biotech) __________________________________________________ 69 
Immunization of mice and generation of hybridomas (USDA) ______________________________________ 70 
Evaluation of serum antibody levels by ELISA (USDA) ____________________________________________ 73 
Flow cytometry-based neutralization assays (LJIAI) ______________________________________________ 73 
Human serum samples _____________________________________________________________________ 74 
Dot blot and ELISA analysis of Z3L1 binding ____________________________________________________ 74 
Dot blots with mouse sera, human sera, or hybridoma supernatants________________________________ 75 
Results__________________________________________________________________________ 76 
TMV-FL and TMV-GL were cloned into pTRBO __________________________________________________ 76 
Expression of ZIKV epitopes on TMV nanoparticles in Nicotiana benthamiana ________________________ 78 
Purification of TMV-GL and WT TMV _________________________________________________________ 81 




IgM and IgG antibodies in the sera of ZIKV patients react to TMV-GL ________________________________ 87 
TMV-GL is immunogenic in mice _____________________________________________________________ 87 
Sera from immunized mice neutralize ZIKV in vitro ______________________________________________ 91 
ZIKV-neutralizing monoclonal antibodies bind to unglycosylated glycan loop _________________________ 92 
Discussion _______________________________________________________________________ 95 
Fusion loop construct ______________________________________________________________________ 96 
Glycan loop construct _____________________________________________________________________ 97 
TMV-GL as a vaccine candidate ______________________________________________________________ 98 
Monoclonal antibodies ___________________________________________________________________ 103 
Conclusion _____________________________________________________________________ 109 
Chapter Two: Anthrax _______________________________________________________ 111 
Introduction ____________________________________________________________________ 111 
Background _____________________________________________________________________ 112 
Anthrax virulence factors and their biological effects ___________________________________________ 112 
Immune response to B. anthracis ___________________________________________________________ 114 
Anthrax vaccines ________________________________________________________________________ 118 
The Dock-and-Lock system ________________________________________________________________ 121 
Materials and Methods ___________________________________________________________ 122 
Generation of TMV-EFCA __________________________________________________________________ 122 
Cloning, expression, and purification of PA domain fusion proteins in Nicotiana benthamiana __________ 123 
Expression of PA domain fusion proteins in Escherichia coli ______________________________________ 124 
Analysis by SDS-PAGE and western blotting ___________________________________________________ 126 
Analysis by ELISA ________________________________________________________________________ 127 





Expression of PA domain fusion proteins in Nicotiana benthamiana _______________________________ 128 
Expression and purification of PA domain fusion proteins in E. coli ________________________________ 131 
Functional analysis by ELISA Production and purification of TMV-EFCA _____________________________ 141 
Production and purification of TMV-EFCA ____________________________________________________ 143 
Dock-and-Lock reactions to create VNPs _____________________________________________________ 144 
Discussion ______________________________________________________________________ 147 
Plant-based Expression of PA Fusion proteins _________________________________________________ 147 
E. coli-based Expression of PA Fusion Proteins _________________________________________________ 148 
Docking reactions ________________________________________________________________________ 151 
Animal studies __________________________________________________________________________ 153 
Alternative B. anthracis antigens ____________________________________________________________ 154 
Conclusion _____________________________________________________________________ 155 










LIST OF ABBREVIATIONS 
ADE antibody-dependent enhancement 
AIM agroinduction media 
APC antigen-presenting cell 
AVA anthrax vaccine adsorbed (anthrax vaccine licensed in the United States) 
AVP anthrax vaccine precipitated (anthrax vaccine licensed in the United Kingdom) 
BARDA Biomedical Advanced Research and Development Authority 
BCA bicinchoninic acid 
BIDMC Beth Israel Deaconess Medical Center 
BME β-mercaptoethanol 
bp base pair 
BSA bovine serum albumin 
cAMP cyclic adenosine monophosphate 
CDC Centers for Disease Control and Prevention 
cDNA complementary deoxyribonucleic acid 
cHM hybridoma medium supplemented with 10% fetal calf serum  
CLR C-type lectin receptor 
CMG2 capillary morphogenesis gene-2 (receptor) 
CNS central nervous system 
CP coat protein  
CR complement receptor 
CTL cytotoxic T lymphocyte 
CZS congenital Zika syndrome 




DC dendritic cell 
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
DENV dengue virus 
DF diafiltration 
DNA deoxyribonucleic acid 
DPI days post-infection 
EDE envelope dimer epitope 
EDTA ethylenediaminetetraacetic acid 
EF edema factor (Bacillus anthracis) 
EFCA glutamic acid, phenylalanine, cysteine, alanine 
ELISA enzyme-linked immunosorbent assay 
EME envelope monomer epitope 
ER endoplasmic reticulum 
ET edema toxin (Bacillus anthracis) 
FBI Federal Bureau of Investigation 
FDA Food and Drug Administration 
FL fusion loop of the Zika virus envelope protein 
FRNT focus reductions neutralization test 
g gravity 
GBS Guillain-Barré syndrome 
GFP green fluorescent protein 
GL glycan loop of the Zika virus envelope protein 
GST glutathione S-transferase 





HIV human immunodeficiency virus 
HM hybridoma medium  
HPV human papillomavirus 
hr hour 
HRP horseradish peroxidase 
HRV human rhinovirus 
IC inhibitory concentration 
IFN interferon 
Ig immunoglobulin  
IL interleukin 
InaD inactivation-no-after-potential D protein (Drosophila melanogaster) 
IPTG isopropyl-β-D-1-thiogalactopyranoside 
JEV Japanese encephalitis virus 
kan kanamycin 
kbp kilobase pair 
kDa kilodalton 
LAV live-attenuated vaccine 
LB Luria Broth 
LF lethal factor (Bacillus anthracis) 
LJIAI La Jolla Institute for Allergy and Immunology 
LT lethal toxin (Bacillus anthracis) 
M membrane protein 
MφCM macrophage conditioned medium  
mAb monoclonal antibody 




MBP maltose-binding protein 
MES 2-(N-morpholino)ethanesulfonic acid 
MHC major histocompatibility complex 
min minute 
MWCO molecular weight cut-off 
MyD88 myeloid differentiation primary response 88 (protein) 
NAb neutralizing antibody 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
Ni-NTA nickel-nitrilotriacetic acid 
NIAID National Institute of Allergy and Infectious Diseases 
NK natural killer (cell) 
NLR nucleotide-binding oligomerization domain-like receptor 
Nlrp nucleotide-binding oligomerization domain-like receptor protein 
NOD nucleotide-binding oligomerization domain (receptor) 
NorpA no receptor potential A (Drosophila melanogaster) 
NP nanoparticle 
NS non-structural (protein) 
NT neutralization titer 
OD optical density 
OPD o-Phenylenediamine dihydrochloride 
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PEG polyethylene glycol 
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rE recombinant envelope protein 
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The purpose of this work was to examine the utility of TMV-based viral nanoparticles as vaccines 
against infectious diseases.   This dissertation is broken down into two chapters that are based on the 
two different projects that I worked on during my Ph.D.  While these projects all fit within the overall 
theme of plant-produced vaccines, they differ in their aims and methods.  Thus, each chapter contains a 
project-specific introduction, followed by background information, materials and methods, results, and 
discussion.  The following overview lays the groundwork for the subsequent chapters by providing brief 
introductions to central topics such as the immune system, vaccines, and the plant-based production of 
biopharmaceuticals.   
THE IMMUNE SYSTEM 
Innate immunity 
The innate immune system is the first line of defense against pathogens and is non-specific.  It 
consists of physical and chemical components, the complement system, and cellular defenses that 
prevent pathogens from entering and spreading throughout the body.  When pathogens enter the body, 
they are detected by pattern recognition receptors (PRRs), which recognize a vast array of structural 
motifs on the surface of pathogens, called pathogen-associated molecular patterns (PAMPs).  PRRs can 
either be soluble (i.e., complement proteins), on the surface of host cells (e.g., Toll-like receptors (TLRs), 
or in the cytoplasm of cells (e.g., NOD-like receptors (NLRs) 1.    
Complement is a group of soluble proteins that circulate in the bloodstream and bind to 
pathogens, which tags the pathogen for destruction by other parts of the immune system.  PRRs of the 
complement system include mannan-binding lectin, C-reactive proteins, ficolins, and C1q.  Complement 
activation can occur via three different proteolytic cascades: the classical pathway, the lectin pathway, 




the surface of certain pathogens or when C1q bind to the Fc portion of an antigen-antibody complex on 
the surface of a pathogen.  Because activation can be antibody-dependent, the classical pathway is also 
considered to be part of the adaptive immune response 2.  The lectin pathway is activated when lectin 
proteins, such as mannan-binding lectin and ficolin L, bind to carbohydrate or glycoprotein residues on 
pathogens 3.  Unlike the classical and lectin pathways, activation of the alternative pathway does not 
require a PRR.  Instead, it is activated by the spontaneous cleavage of C3 proteins.  C3 is a normal 
constituent of plasma, and, therefore, this pathway is constitutively active.  These three proteolytic 
cascades all occur on the surface of the pathogen, and converge at the cleavage of C3, which results in 
four effector functions: 1) a large number of activated complement proteins complement and 
generated, which bind to pathogens (opsonization) and induce phagocytosis; 2) the formation of 
membrane attack complexes that lyse cells; 3) the recruitment of inflammatory cells and the secretion 
of immunoregulatory molecules, which increases vascular permeability and enhances migration of 
immunoglobulins, phagocytes, and more complement proteins to the infection site; and 4) the 
solubilization and clearance of immune complexes through the liver and spleen 4.  
Transmembrane PRRs, such as TLRs and C-type lectin receptors (CLRs) and cytosolic PRRs, such 
as NLRs and retinoic acid-inducible like receptors (RLRs) are expressed by phagocytes and leukocytes of 
the innate immune system including neutrophils, macrophages, DCs, natural killer cells, eosinophils, and 
basophils 5,6.  When one of these PRRs binds to its cognate PAMP ligand, a signaling cascade is activated, 
which results in the expression of cytokines.  Cytokines are soluble proteins that act as chemical 
messengers to regulate the innate and adaptive immune responses.  There are many types, including 
interferons (IFNs), tumor necrosis factor-α (TNF-α) and interleukins (ILs); all of them are pleiotropic and 
redundant 7.  Cytokines that regulate the innate immune system include TNF-α, IL-1, IL-12, chemokines, 
and type I IFNs.  Examples of their effector functions include: TNF-α and IL-1 mediate acute 




immune cells to the site of inflammation and type I IFNs initiate the antiviral state.  Cytokines also 
activate the adaptive immune response.  For example, in addition to mediating the early innate immune 
response, IL-12 also induces cell-mediated immunity by stimulating the differentiation of naïve CD4⁺ T 
lymphocytes 8.  
In summation, the innate immune system employs PRRs to recognize pathogens and quickly 
responds by activating complement, inducing inflammation, and promoting phagocytosis.  However, 
some pathogens have developed methods of evading these innate immune responses. For example, 
Mycobacterium tuberculosis secretes proteins that prevent phagosome maturation 9 and proteins 
produced by poxviruses bind to and block the activity of chemokines 10.  Thus, the innate immune 
system in vertebrates can also recruit the appropriate adaptive immune response to help in the fight 
against pathogens.     
Adaptive immunity 
When the innate immune system fails to control an infection, a threshold level of antigen is 
reached, which initiates the adaptive immune response.  In contrast to the innate immune system, the 
adaptive immune responses are specific to particular pathogens and provide long-lived protection.  
However, activation of the adaptive immune system is a complex process that involves multiple types of 
cells, extensive intercellular communication, cellular proliferation, and signals from the innate immune 
system 4.  Consequently, adaptive immune responses occur approximately 3-5 days after exposure to a 
pathogen, in contrast to the almost immediate response from the innate immune system.  The adaptive 
immune response includes the activation of T cells (i.e., cell-mediated immunity) and the activation of B 
cells and subsequent production of antibodies (i.e., humoral immunity).   
Cell-mediated Immunity 
Antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), have pattern 




pathogens.  After the pathogen is ingested and degraded, DCs migrate to peripheral lymph nodes and 
present antigens on a specific cell surface protein called major histocompatibility complex class II (MHC 
II).   Naïve helper T cells, also known as naïve CD4+ T cells, become activated upon binding to antigens 
presented on MHC II molecules and then proliferate and differentiate into specific types of CD4+ T cells.  
Differentiation depends on multiple factors, including the concentration of antigens, the type of APC, 
and the presence of specific cytokines and costimulatory molecules 11.  There are various types of CD4+ T 
cells, including Th1, Th2, Th3, Th17, and regulatory CD4+ T cells.  Each type expresses distinct cell surface 
molecules and secretes specific cytokines, which facilitate their various effector functions 12.  This review 
will focus on Th1, Th2, and Th17, as these CD4+ T cell subsets play the most critical roles in the immune 
response against pathogens.   
DCs produce interleukin-12 (IL-12) in response to intracellular bacteria and viruses, which 
stimulates the development of Th1 cells.  Th1 effector functions include: 1) secreting interferon-ɣ (IFN-ɣ), 
which activates macrophages to phagocytose and kill bacterial pathogens; 2) activating cytotoxic T 
lymphocytes (CTLs) and natural killer cells (NKs) to kill virus-infected cells and tumors; and 3) 
contributing to T cell memory by secreting IL-2 13.  The cytokine released by APCs to induce Th2 
differentiation remains unknown, but IL-2 and IL-4, which are mainly produced by Th2 cells themselves, 
are known to drive further Th2 differentiation 14.  Th2 cells are responsible for activating and maintaining 
the antibody-mediated immune response against extracellular parasites, toxins, and bacteria.  This is 
achieved through the production of various cytokines, including 1) IL-4, which is a positive feedback 
cytokine for Th2 differentiation and mediates class-switching in B cells; 2) IL-5, which stimulates and 
recruits specialized immune cells, like eosinophils and basophils, to the site of infection; 3) IL-9, which 
activates eosinophils, neutrophils, and airway epithelial cells and causes the hypersecretion of mucus; 
and 4) IL-13, which activates and recruits eosinophils, and defends against parasite infection. Exposure 




mucosal surfaces, like the lining of the gastrointestinal tract and the epithelial barrier 15.  The Th17 
response targets extracellular pathogens and fungi, primarily through the production of IL-17, which 
recruits and activates neutrophils and promotes the production of antimicrobial peptides, and IL-22, 
which helps strengthen epithelial barrier functions to prevent pathogen entry and has proinflammatory 
functions 15.    In summation, there are many subsets of CD4+ T cells, and they various roles in innate 
immune response, including the recruitment of granulocytes, macrophage induction, providing help to 
other types of effector cells, and the production of chemokines and cytokines.  
In contrast to MHC II, MHC class I molecules are present on most cells types.  MHC I molecules 
present endogenous proteins (i.e., proteins found in the cytoplasm of the cell) to cytotoxic T cell 
lymphocytes (CD8+ cells).  Binding of CD8+ T cells to the antigen-MHC class I complexes on infected or 
aberrant cells induces apoptosis in a process called T cell-mediated cytotoxicity.  All viruses, as well as 
some bacteria and protozoans, replicate and/or produce proteins in the cytoplasm of host cells, where 
they are inaccessible to antibodies. Thus, T-cell mediated cytotoxicity is particularly important for the 
clearance of viruses and other intracellular pathogens 16.  Certain DCs are also capable of loading 
exogenous particulate antigens onto MHC class I molecule, in a process called cross-presentation 17-19.  
This allows exogenous antigens to induce CD8+ T cell responses in the presence of pathogens that do not 
directly infect APCs. 
Armed effector T cells (i.e., CD8+ and CD4+ Th1 cells) migrate from the lymphatic tissue to the 
site of infection via endothelium that has already activated by the innate immune system’s 
inflammatory response (e.g., through the production of TNF-α).  At the site of infection, only the 
effector T cells that recognize the invading pathogen carry out their effector function, undergo clonal 
expansion, and produce more cytokines to recruit more armed effector T cells and non-specific 
inflammatory cells to the site of infection.  In contrast to armed T cells, Th2 cells interact directly with, or 




activated Th2 cells produce the cytokine IL-4, which stimulates B cell proliferation, maturation, and class 
switching 20.  In addition, activated, antigen-specific Th2 must interact with naïve antigen-binding B cells 
to initiate the T cell-dependent antibody response.   
Thus, in the cell-mediated immune response, APCs migrate to the lymph nodes where they 
activate T cells.  Activated T cells then migrate to the site of infection to perform their effector functions 
(CD8+ T cells control infection by inducing apoptosis while CD4+ cells secrete cytokines to activate cells of 
the innate immune system or induce inflammation) or remain in the lymph node to initiate the humoral 
immune response.  In addition, memory T cells can be formed from effector CD4+ or CD8+ T cells that 
persist in peripheral tissues and in the bloodstream after an infection has been cleared.  Memory T cells 
are rapidly activated to perform their respective effector functions upon re-stimulation by their cognate 
antigens 21.  
Humoral immunity 
In humoral immunity, B cells are activated and mature into cells that secrete antibodies.  
Depending on the nature of the antigen, TLR signals, and cytokine and costimulatory signals, B cells 
differentiate into plasmablasts, plasma cells, or memory B cells 22.  Membrane-bound immunoglobulins 
(Ig) on the surface of B cells act as receptors that are capable of recognizing and internalizing a wide 
range of microbial antigens.  Repetitive arrays of antigens lead to cross-linking of multiple B cell 
receptors, which form aggregates rapidly internalized 23.  The binding of a foreign antigen to B cell 
receptors provides the first of two signals required for B cell activation.  B cell receptors on follicular B 
cells recognize protein antigens, and the binding of these antigens triggers two processes within the B 
cell:  First, it induces B cells to migrate to secondary lymphoid tissues that are rich in T cells; second, the 
antigen is internalized, degraded, and displayed on MHC II molecules.  CD4+ helper T cells, typically Th2 
cells, displaying the same antigen, although not necessarily the same epitope, that initially activated the 




molecules, like CD40L and IL-4, which act as a second signal for B cell activation.  Activated B cells 
undergo clonal expansion and somatic hypermutation, and then form germinal centers where they 
differentiate into either antibody-secreting plasma cells or memory B cells 24.  Plasma cells are short-
lived and immediately secrete antibodies, while memory B cells do not secrete antibodies and persist 
long after the infection has been cleared.  Upon re-exposure to their cognate antigen, memory B cells 
rapidly differentiate into plasma cells that secrete high titers of high-affinity antibodies 25.  Thus, plasma 
cells secrete antibodies to control the current infection, while memory B cells remain dormant until they 
are reactivated by subsequent infections by the same pathogen.  
B cell receptors on B1 and marginal zone (MZ) B cells recognize carbohydrate and phospholipid 
antigens.  However, such antigens are not good at activating T cells and are called T cell-independent 
antigens because they do not rely on T cell help to produce antibodies.  Instead, TLRs expressed by B1 
cells and some MZ B cells allow the second activation signal to come from the binding of TLR ligands.   
Following antigen and TLR-ligand recognition, these B cells rapidly differentiate into short-lived 
plasmablasts, which secrete low-affinity IgM, polyreactive IgA, or isotype-switched IgG antibodies to 
provide immediate protection against pathogens 22,24.  B cells also contribute to cellular immunity in 
multiple ways.  For example, B cells can act as antigen-presenting cells and produce cytokines that 
contribute to enhanced T cell activation and differentiation 22.  Plasmablasts can also mature in the bone 
marrow or infected tissues to become long-lived memory plasma cells.  Unlike memory B cell, memory 
plasma cells secrete specific antibodies in the absence of additional antigenic stimulation, and they do 
so for extended periods without dividing 26. 
Antibodies are large, y-shaped, glycoproteins that contain two regions important to their 
immune functions:  the antigen-binding fragment (Fab) recognizes antigens, while the crystallizable 
fragment (Fc) interacts with other parts of the immune system, such as cell surface receptors and 




protect against pathogens in three primary ways: 1) Neutralization, in which antibodies bind to viral 
particles, toxins, or intracellular bacteria to prevent them from binding to and entering cells; 2) 
Opsonization, in which antibodies bind to extracellular bacteria and make it easier for macrophages and 
neutrophils to ingest and destroy them; and 3) Complement activation, in which the Fc region of a 
pathogen-bound antibodies initiates the complement cascade, which kills the pathogen directly or leads 
to phagocytosis 27.  
Antigens and immunogenicity 
While the terms antigen and immunogen tend to be used interchangeably, they are different.  
Antigens are defined as structures that are recognized by products of an immune response (i.e., T cells, 
B cells, and antibodies) while immunogens are molecules capable of eliciting an immune response.  The 
term immunogenicity thus refers to the capacity of an antigen to induce an immune response 28, and 
epitopes are the specific region of an antigen to which an individual antibody, B cell receptor binds, or T 
cell receptor binds.   Antibodies and B cells primarily interact with whole pathogens and intact antigens, 
so they recognize epitopes in their three-dimensional conformation (i.e., conformational epitopes).  On 
the other hand, T cells recognize antigens that have been processed and presented on APCs, and these 
are typically short linear peptides (i.e., linear epitopes).  Many factors influence the immunogenicity of 
an antigen, including its size, structure, chemical properties, and degradability 29.  High molecular weight 
proteins or polysaccharides tend to be highly immunogenic, although lipids, nucleic acids, polypeptides, 
and other non-infectious and non-replicating antigens can also be immunogenic if they are attached to a 
carrier protein or used with an adjuvant.     
The process of vaccine development involves selecting an antigen that is not homologous to 
human proteins and is able to elicit the appropriate immune response without being toxic.  As discussed 
in the subsequent section, small antigens that are not inherently immunogenic are sometimes used to 




meningococcal membrane proteins, H. influenzae protein D to increase their immunogenicity 30.  
Adjuvants can also be used to improve the immunogenicity of an antigen.  Adjuvants are molecules that 
enhance the immunogenicity of an antigen either by acting as PRR ligands to activate the innate immune 
system or by inducing adaptive immune responses 31.  Adjuvants effect these responses by forming 
antigen depots, recruiting immune cells, activating the inflammasome, enhancing antigen presentation 
by MHC molecules, or inducing the production of cytokines 31.  Adjuvants that are currently licensed for 
use in vaccines include aluminum derivatives, oil-in-water emulsions, virosomes, and monophospholipid 
A, a bacterial lipopolysaccharide 32,33.    
VACCINES 
Following exposure to pathogens, our innate immune system quickly mounts a non-specific 
immune response, followed by a primary adaptive immune response during which the adaptive immune 
system eliminates the pathogen while also retaining an immunological memory of the pathogen.  Upon 
re-exposure to the same pathogen, a rapid secondary adaptive immune response is generated, which 
allows the pathogen to be quickly neutralized and/or eliminated.  This ability to induce long-lived 
antigen-specific protection against reinfection is the foundation by which vaccines elicit protective 
immunity.  Vaccines also induce a primary immune response, which leads to the formation of 
immunological memory, and a rapid secondary response.  Unlike a natural infection, vaccination does 
not typically lead to disease.  Thus, vaccines provide a safe way of priming our immune systems.  In 
addition to their use for pre-exposure prophylaxis, vaccines have also be used for post-exposure 
prophylaxis 34,35 and as cancer treatments 36,37.   
The primary objective of vaccination is to induce a long-lasting immune response capable of 
preventing disease.  Most licensed vaccines are thought to prevent disease by generating neutralizing or 




38,39.   However, highly variable pathogens, such as HIV, and pathogens kept in check primarily by T cells, 
such as tuberculosis, may require a combination of both cellular and humoral immunity to prevent 
infection 38, and therapeutic vaccines for cancer or chronic infections depend on robust pro-
inflammatory CD8+ T cell responses 39.  In addition to ensuring that the appropriate types of responses 
are induced (i.e., B cell and T cell), the duration of the immune response must be considered.  Vaccines 
that induce short-term protection require that booster immunizations be administered to maintain 
protective immunity 40.  Such booster requirements decrease patient compliance to immunization 
regimens and increase both cost and risks associated with vaccination.   Therefore, the ideal vaccine 
induces long-term immunological memory, but the mechanisms required long-lasting immunity are still 
largely unknown 41.  Under certain conditions, naïve antigen-specific B and T cells become memory B 
and T cells, which confer long-term immunological memory 42.  This requires multiple processes, like 
antigen uptake and processing, APC activation, T cell activation, B cell activation, and then the formation 
of immunological memory.   For example, antibody responses are short-lived without helper T cells 
functions such as class-switching and the generation of long-lived plasma cells 39.  Consequently, both 
cellular and humoral immune responses are likely required for optimal vaccine efficacy and long-term 
protection.    
Vaccines are one of the greatest public health successes in the last century and have 
significantly reduced the global burden of infectious diseases 43.  They have also proven to be one of the 
most cost-effective means of disease prevention, and are estimated to save 2-3 million lives each year 
38.   In addition to protecting vaccinated individuals, vaccines can also provide indirect protection to 
unvaccinated individuals if a large proportion of the population is vaccination, in a process called herd 
protection 44.  One of the biggest challenges in vaccine development is designing vaccines that are safe 
but also induce potent and long-lasting immune responses 39.  And, although vaccines have been 




essential as vaccine-preventable diseases are still a major cause of morbidity and mortality in developing 
countries 45,46.  In addition, effective vaccines still need to be developed for many widespread diseases, 
such as dengue, HIV, malaria, and tuberculosis 46.  Historically, vaccine development involved isolating, 
inactivating, purifying, and then injecting a whole pathogen or parts of a pathogen.  Live-attenuated 
virus vaccines date back to 1796 when Edward Jenner used material from a milkmaid’s cowpox pustule 
to inoculate a boy against smallpox.  Since then, a wide array of vaccine production platforms have been 
developed, each with its own advantages and limitations as discussed below and summarized in Table 1.  
Live-attenuated vaccines 
The traditional approach to vaccine development utilizes a weakened version of the pathogen 
that closely resembles the wild-type pathogen, but either does not cause disease or causes a very mild 
form of the disease.   For viral vaccines, attenuation is typically accomplished by passaging the virus 
multiple times through a non-human host or by selecting a virus that is pathogenic in a different 
mammalian host (e.g. Jenner’s use of cowpox to protect humans from smallpox), but temperature-
sensitive strains (i.e., strains that grow poorly at 37°C) have also been used 47.  The most modern 
method of attenuation uses recombinant DNA technology to modify or delete specific genes responsible 
for virulence. These attenuated viruses are still capable of replicating, so they provide continual 
antigenic stimulation to the immune system.  However, it can be challenging to find the right balance 
between immunogenicity and ability to cause disease 48.  Thus, most LAVs cause mild disease but induce 
strong cellular and humoral immunity.  Drawbacks of LAVs include their instability, the need for cold-
chain storage, the possibility that the virus could revert to a form capable of causing disease, and the 
risk that attenuated pathogens could replicate unchecked in immunocompromised individuals resulting 
in severe illness or death 49.  Thus, LAVs are contraindicated for anyone with an immunodeficiency.  In 
pregnant women, a fetal infection could theoretically lead to congenital diseases, so LAVs are also 




Table 1. Summary of the advantages and disadvantages associated with various types of vaccines.      
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be easily cultured, have latent stages, or have developed effective immune-evasion strategies 33.  
Despite these drawbacks, LAVs have proven to be a cost-effective way to produce effective vaccines 
against viral diseases such as yellow fever 51 and rabies 52.  The production of LAVs for bacterial 
pathogens has proven more difficult because reversion rates are much higher, but several live-
attenuated bacterial vaccines have been licensed including Bacille Calmette-Guerin (BCG) for 
tuberculosis 53 and oral cholera and typhoid vaccines 54.   
Inactivated vaccines 
Inactivated vaccines offer increased stability and safety compared to LAVs because the 
pathogens they contain are inactivated or killed.  Inactivated vaccines typically do not require cold 
storage, and physical and/or chemical inactivation processes, such treatment with heat or formalin, 
ensure that pathogens cannot replicate or revert to their virulent state.  Because these pathogens 
cannot replicate, inactivated vaccines are safe for immunocompromised individuals, but the inactivation 
process can destroy key epitopes.  Inactivated vaccines must also be administered in larger doses or 
more frequently to build up and maintain immunity, and the immune response is mainly humoral 47.  In 
addition, inactivated vaccines are more expensive to produce than LAVs.  Both bacterial and viral 
inactivated vaccines have obtained licensure, including IPV for polio and a whole-cell pertussis vaccine 
55.   
Subunit vaccines 
Like inactivated vaccines, subunit vaccines are considered very safe because they do not contain 
live pathogenic material.  However, instead of utilizing the whole pathogen, subunit vaccines contain 
only specific antigenic pieces of the pathogen.  Designing this type of vaccine thus requires detailed 
knowledge of which particular parts of the pathogen will adequately stimulate the immune system to 




on the external surface of the pathogen.  Subunit vaccines do not induce immune responses as potently 
as whole-pathogen vaccines though, so adjuvants and boosters are necessary to ensure long-term 
protective immunity 56.  Furthermore, peptide and polysaccharide antigens are prone to enzymatic 
degradation rapid clearance giving them less time to stimulate an immune response 57.  The most 
common types of subunit vaccines are protein vaccines, toxoid vaccines, conjugate vaccines, and virus-
like particles.    
Protein vaccines 
Immunogenic peptides and proteins can be produced and purified from cultured pathogens that 
are chemicals broken down (e.g., detergent disrupted viruses), manufactured recombinantly in a 
heterologous host (e.g., yeast-based expression of hepatitis B antigens), or chemically synthesized 58.  
While producing proteins in a heterologous host eliminates the risks involved with using a pathogenic 
organism for production, recombinant peptides and proteins can fold in a non-native manner and 
present an antigenic landscape different than that of the native peptide.  Furthermore, proteolysis is a 
common problem when expressing heterologous proteins.  The hepatitis B vaccine Heplisav-B™, which is 
composed of the hepatitis B virus surface antigen, is an example of a licensed purified protein vaccine.   
Toxoid vaccines 
Some bacterial pathogens, such as Clostridium tetani, secrete toxins that are largely responsible 
for illness.  Once inactivated by formalin, toxins can be safely used as a vaccine antigen to elicit humoral 
immunity.  Like subunit vaccines, toxoid vaccines are relatively stable and safe because they cannot 
cause disease or revert to their virulent form.  Examples of licensed toxoid vaccines include the tetanus 
toxoid vaccine and the diphtheria toxoid vaccine 49.  Many toxins are only weakly immunogenic, which 
necessitates the use of adjuvants and boosters.  However, some toxins are highly immunogenic and are 
used as adjuvants/carrier proteins in vaccines against heterologous pathogens.  An inactive and nontoxic 




pneumococcus, and meningococcus 59, and the tetanus toxoid possesses multiple CD4+ T cell epitopes 
and has been used to create the conjugate meningococcal vaccine Nimerix 60.  
Polysaccharide vaccines 
Many pathogenic bacteria, like Streptococcus pneumonia, are coated with capsular 
polysaccharides that protect them from being phagocytosed by the host macrophages and neutrophils.   
However, these bacteria can be efficiently phagocytosed if they are covered with antibodies.  Thus 
carbohydrate-based subunit vaccines can be used to induce an antibody response to bacterial capsids.  
Pure polysaccharide vaccines, such as Pneumovax 23, contain only polysaccharides that are either 
purified from whole bacteria or synthesized 49.  Such vaccines were shown to be poorly immunogenic in 
adults and inconsistently immunogenic in young children while providing only short-term protection 
mediated mostly by an IgM response 61.  Glycoconjugate vaccines, in which polysaccharides are 
chemically linked to a carrier protein, have proven to be much more immunogenic due to the induction 
of a T-cell-dependent response (as opposed to the T-cell independent response seen in polysaccharide-
only vaccines).  However, such conjugate vaccines require complex methods of production and can, 
therefore, be costly to produce 33.  Examples of licensed polysaccharide vaccines include Haemophilus 
influenza type B polysaccharides conjugated to tetanus toxoids and Neisseria meningitidis 
polysaccharides conjugated to diphtheria toxoids 62.  
Virus-like particle vaccines 
Virus-like particles (VLPs) are multimeric nanostructures composed of one or more viral 
structural proteins that self-assemble to mimic the structure of a native virus but do not contain the 
viral genome.  The highly-ordered, repetitive structure of VLPs induces strong cellular and humoral 
immune responses without the need for adjuvants, and are therefore considered the most effective 
type of subunit vaccine 63.  While many VLPs can bind to and enter host cells, they cannot replicate, 




vaccines 63,64.  Licensed VLP vaccines include human papillomavirus vaccines, such as Cervarix and 
Gardasil, as well as hepatitis B virus vaccines, such as Recombivax HB 65.   
Nucleic acid-based vaccines 
For nucleic acid-based vaccines, DNA or RNA encoding antigenic proteins from a pathogen is 
delivered to host cells for expression.  Both DNA and RNA vaccines can be rapidly manufactured for 
relatively low costs at large scale and can be given to immunocompromised patients 66.  However, both 
are limited to peptide or protein antigens, lead to a comparatively weak immune response, and can 
elicit anti-nucleic acid antibodies.  For DNA vaccines, plasmid DNA encoding for antigens is delivered into 
the nuclei of host cells for transcription, and then the antigens are then translated in the cytoplasm and 
secreted.  The secreted antigens provoke an antibody response, and antigen-presenting cells display 
processed peptides MHC molecules 67.  However, getting the DNA into the host cell nuclei is a challenge; 
examples of delivery systems include Inovio’s electroporation system 68, NIAID’s pressure-based delivery 
system 69, and Pharos’ nanoparticle-based delivery system 70.  While several DNA vaccines have been 
licensed for veterinary use, none are currently licensed for human use mainly due to their inability to 
generate a protective immune response in clinical trials, even when administered with an alum adjuvant 
or a genetic adjuvant 70,71.  If they do elicit a protective immune response, at least three doses over 12 
weeks are required 72,73.  Additionally, the transfected DNA can integrate into the host cell’s genome and 
cause dysregulated gene expression and mutations 71.   
On the other hand, the advantages of RNA vaccines include that they are easy to manufacture 
and can be transported without a cold-chain 70.  Unlike DNA vaccines, RNA vaccines do not need to enter 
the nuclei of cells to be effective 70.  Instead, they rely on endogenous expression of antigens in the 
cytoplasm and thus avoid the risk of introducing genetic material into the hosts’ genome 74.  However, 
the cellular environment contains a multitude of enzymes and effectors of the innate immune system 




lipid nanoparticles to deliver mRNA 75, making modifications to the mRNA sequence that increase their 
stability 76-78, and using self-amplifying RNA replicon particles 79.   
Viral vector vaccines 
Viral vectors vaccines are essentially a combination of a LAV and a nucleic acid vaccine.  Non-
pathogenic or attenuated virus, such as adenovirus or pox virus, are recombinantly modified to contain 
a payload, typically DNA or RNA encoding protein antigens from the pathogen of interest.  Thus, viral 
vector vaccines capitalize many inherent features of viruses, including their natural ability to effectively 
insert genetic material into host cells, the specificity with which they can deliver genes to particular 
cells, and the induction of both cellular and humoral immune responses 80.  Both replicating and non-
replicating viral vectors have been used, but replicating vectors are more immunogenic as their active 
invasion and replication in host cells increase the immune response 80.  Viral vector vaccines that contain 
oncolytic agents or tumor antigens have also been used for cancer immunotherapy 81.  Similar to LAVs, 
viral vector vaccines carry the risk of recombination or reversion, both of which could lead to 
pathogenesis.  Thus, the optimization of viral vector vaccines involves finding the right balance between 
immunogenicity and safety.  Also, like subunit vaccines, protective antigens from the pathogen of 
interest much be known to design a viral vector vaccine.  Pre-existing vector-specific immunity can 
impair the ability of these vaccines to elicit a strong immune response against their payload.  Thus, 
multiple vaccinations with one type of viral vector or with a viral vector that the person has already 
been exposed to naturally would be ineffective.  Certain vectors also pose additional safety risks; for 
example, retroviruses and lentiviruses have the potential for tumorigenesis 82.  While several viral vector 
vaccines have been licensed for veterinary use, none are currently available for human use likely due to 





Nanoparticle (NP) vaccines utilize various materials to create nanostructures capable of either 
encapsulating vaccine antigens or displaying them on their surface.  When used in vaccines, NPs can 
serve a variety of functions including protecting antigens from proteolytic degradation, stimulating the 
immune system or increase immunogenicity (i.e., they can be used as an adjuvant), improving antigen 
delivery to APCs, or ensuring that immune cells have prolonged exposure to the antigen (i.e., the depot 
effect)  83-86.  NPs can be made from a variety synthetic, inorganic, or organic materials including gold, 
silica,  synthetic polymers (e.g., poly(D,L-lactic-coglycolic acid (PGLA), chitosan, liposomes, and viral 
particles.  Based on the size, shape, composition, and surface chemistry, nanoparticles can activate 
specific immune responses or be targeted to different tissues 87.  Attaching viral, bacterial, or parasitic 
antigens to NPs can be achieved by chemical conjugation, encapsulation, adsorption, or translational 
fusion (in the case of viral nanoparticles) 83.  For example, the licensed liposome-based vaccine against 
hepatitis A, Epaxal, is composed of inactivated, purified hepatitis A virions absorbed to the surface of a 
self-assembling bilayer of phospholipids 88.  In summation, NPs can serve as both an adjuvant and a 
carrier molecule for antigens, and thus can be used to create safe and effective vaccines.  However, 
there can be material-specific drawbacks, such as limited antigen loading, poor targeting to immune 
cells, limited manufacturability, and accumulation in organs that leads to toxicity 86,87,89,90.   
Viral nanoparticle vaccines 
While many articles tend not to differentiate viral nanoparticles (VNPs) and VLPs, there are two 
notable differences 63,83,86.  First, VLPs are typically composed of a subset of viral proteins and don’t 
contain viral genetic material, while VNPs usually consist of whole viruses, including genetic material 91.  
Second, viral nanoparticles are typically used to display antigens from a heterologous pathogen, while 
VLPs typically only display homologous antigens 63.  However, some VLPS have been used to display 




epitopes 92,93 and influenza VLPs displaying Mycobacterium tuberculosis epitopes have been developed 
94, but these VLP vaccines do not contain viral genetic material.  In contrast, the viral nanoparticle 
vaccine ALVAC-HIV is composed live-attenuated recombinant canarypox virus expressing HIV-1 epitopes 
from gp120, gp41, Gag, and Pro and is currently being tested in a phase IIb/III clinical trial 95.    
Vaccine development  
Even though there are many different types of vaccines, the processes by which they are 
developed are relatively analogous.  Developing an effective vaccine first requires extensive knowledge 
of the pathogen (e.g., structure, cellular receptors, pathogenesis, etc.) and the demographics of those at 
risk for infection.  Second, a thorough understanding of the interactions between the pathogen and the 
host immune system is required so that the appropriate antigen can be selected and a vaccine candidate 
can be properly formulated.  Third, preclinical and clinical testing of the vaccine candidate is required to 
determine its immunogenicity, safety, and efficacy 33.  Once a vaccine is developed, it must gain 
licensure before it can be deployed.  This process includes filing an application with the appropriate 
agencies, receiving authorization, and beginning post-licensure studies.  As shown in Figure 1, this 








    Figure 1. The vaccine development process (adapted from Han 97).  
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Developing vaccines also requires walking the fine line between safety and efficacy.  In general, 
immune responses are better if the form of the vaccine is similar to the pathogenic form of the 
organism, but, as demonstrated by LAVs, this often entails greater safety issues.  Thus, each type of 
vaccine has its own advantages and disadvantages (Table 1), and all must be taken into account during 
the development process.  The technical hurdles are high, but they are not the only ones.  The bigger 
picture includes defining the vaccine’s target population and ensuring that the target population has 
equal access to the vaccine 46.  Data from the World Health Organization suggests that 1.5 million people 
die annually from vaccine-preventable diseases primarily due to the underuse of vaccines in developing 
countries 100.  Cost, lack of medical infrastructure, and lack of cold storage facilities all contribute to 
under-vaccination 43,101-103.  Some of these issues could be addressed by employing a high-yield low-cost 
production platform to create heat-stable vaccines that can elicit long-term protective immunity after a 
single dose.   
Vaccine manufacturing  
Many viral vaccines, including seasonal flu vaccines, are manufactured using fertilized 
embryonic chicken eggs. Egg-based vaccine production started in the 1940s and has a yield of 
approximately one vaccine dose for every 1-2 eggs 104.  Disadvantages of this system include 1) egg-
based vaccines can induce egg allergies in some people; 2) production is limited by the available supply 
of eggs 105; 3) viral mutation can take place during propagation; 4) long lead times of at least 4-6 months 
make it impractical for pandemic situations 106,107.  To address these shortcomings, cell-based vaccine 
manufacturing was started in the 1990s.  In this process, cultured mammalian cells are infected with the 
virus, which replicates inside the cells, and can then be harvested.  The method takes approximately half 
the time of the egg-based process, avoids the egg allergy issue, and is amenable to the production of 
biosafety level 3 viruses.  However, cell culture costs are high, the volumetric yield is lower than in eggs, 




much easier to manufacture, as the pathogenic bacteria can be grown directly in culture.  This process is 
amenable to the production of live-attenuated bacterial vaccines, inactivated bacterial vaccines, and 
bacterial subunit vaccines.  Alternatively, both bacterial and viral antigens can be recombinantly 
produced in a variety of host cells, including mammalian cells, yeast, E. coli, transgenic animals, and 
insect cells 108,109.  However, none of the aforementioned technologies can produce heat-stable vaccines 
in less than two months at lows costs (i.e., less than $1 per dose) 104.  Most vaccines are inherently 
unstable, and thus must be stored under controlled conditions until they are administered.  Live-
attenuated viral vaccines are particularly sensitive to high temperatures and must be stored frozen or at 
2-8 °C, and vaccines that utilize aluminum adjuvants lose potency if they are frozen, so they must be 
kept at 2-8 °C 103.  
Irrespective of the type of vaccine being produced or the manufacturing platform used, vaccine 
production is expensive.  Fixed costs, such as construction and maintenance of production facilities, 
research and development, quality control and quality assurance, as well as storage and distribution,   
can constitute up to 90% of total cost per dose 110.  Increasing productivity and taking advantage of 
economies of scale can reduce the cost per dose, but vaccines that rely on recombinant DNA technology 
or complex manufacturing processes, such as conjugating polysaccharides to protein carriers, are not 
very amenable to scale-up.  In addition to high fixed costs, the high costs and risk associated with 
vaccine research and development, complex manufacturing processes, and the relatively small market 
for vaccines create a high barrier to entry for vaccine manufacturers 110,111.  Once a vaccine is 
manufactured, low profit margins and the relatively small size of the vaccine market make vaccines 
much less attractive than traditional drugs to pharmaceutical companies that produce them 112.  Thus, 
there is limited financial incentive for pharmaceutical companies to develop and produce vaccines in 





Many types of pharmaceutical proteins have been recombinantly produced in plants, including 
antibodies, subunit vaccines, toxins, VLP vaccines, and therapeutic enzymes.  Diverse plant species have 
been used as expression hosts, ranging from leafy crops, like tobacco and lettuce, to fruits, legumes, oil 
crops and even simple plants like duckweed 113.  The advantages of plant-based production are product 
and host-species specific, but can include:  
1) Low cost- plants can be used to produce recombinant proteins at low costs and do not require 
the same capital-intensive facilities, equipment, and media used for bacterial or mammalian 
cells cultures 114,115.  Most plant-made biopharmaceuticals can be produced using basic 
agricultural methods and require only inorganic nutrients, water, carbon dioxide, and sunlight to 
grow 116.  In fact, Nandi et al. showed that plant-based production platforms reduce capital 
investment and the cost of goods by at least 50% compared to expression in mammalian cells 
117.      
2) Shorter lead times- Vaccine antigens transiently expressed in tobacco plants require only 3-10 
days for production once the appropriate vectors have been created 43 115.  
3) Glycosylation- The majority of biopharmaceuticals are glycosylated, and glycosylation profiles 
can affect the stability, functionality, and immunogenicity of therapeutic proteins 118.  
Mammalian cells are notoriously difficult to work with because they produce a heterogeneous 
mixture of glycoforms.  Conversely, plant glycoforms are largely homogeneous, and thus plant-
produced recombinant proteins tend to have better batch consistency 118.  Furthermore, there 
are only minor differences between plant and mammalian glycans 119.  As in all eukaryotes, the 
initial stages of N-glycosylation in plants occurs in the endoplasmic reticulum.  Glycan processing 
steps in the Golgi apparatus then lead to high-mannose glycan biosynthesis.  In plants, the last 




structures, as opposed to α1,6‐fucose and  β1,4 galactose produced in mammalian cells 120.  
Despite these differences in N-glycosylation, no allergic or hypersensitive responses to plant-
glycosylated therapeutics have been reported in humans 121,122.  Nevertheless, transgenic plants 
and plant cells capable of producing recombinant proteins with mammalian N- 123 and O-
glycosylation 124,125 have been engineered.  Thus, the overexpression of mammalian 
glycosylation enzymes allows plant-based production biopharmaceuticals with better-defined N- 
and O-glycans.   
4) Proper folding and secretion- Plants can properly fold and assemble complex proteins, such as 
homodimeric vascular endothelial growth factor (VEGF) and antibodies 126-128. 
5) Scalability- Transgenic plants can easily be expanded to agricultural scales; Buyel et al. estimate 
that recombinant proteins could be produced at 100 kg ha-1 y-1 115.  Vertical farming could also 
be used to achieve similar yields if controlled conditions are required.  For example, Caliber 
Biotherapeutics designed a commercial-scale manufacturing facility with the capacity to grow 
over 4 million plants at a time which can produce at least 150 kg of plant-made products per 
year 129. 
6) Low risk of adventitious human pathogens- While human pathogens easily replicate in animal-
based expression systems, such as eggs and mammalian cell cultures, they cannot replicate in 
plants 130.  In addition, there is no risk of prions.  Thus, the risk of contamination in plant-
produced products is much lower.   
7) High Yields – Recombinant protein yields of up to 80% of the total soluble protein in a plant 
have been demonstrated 131,132, although yields ranging from 0.01% to 15% of total soluble 




8) Thermo-stability- Vaccines antigens recombinantly produced in plant seeds remain stable for 
over 18 months without refrigeration 136, and transgenic rice expressing cholera toxin subunits 
can be stored for more than three years at ambient temperatures 137. 
9) Reduced ecological footprint- Waste material from plant-based production is biodegradable, 
unlike the ~61 kg of plastic required for every 1,000 L cell culture process in which single-use 
bioreactors are used 115.  Plants also absorb carbon dioxide, which can offset the emissions that 
are causing global warming, and any residual biomass that remains after the target product is 
extracted could be used to generate biofuel 115.  
Despite these advantages, only a few plant-produced products have been licensed for human use.  
These include CaroRx™, an anti-caries monoclonal antibody licensed in the European Union, and 
Taliglucerase™, an enzyme replacement therapy for patients with Gaucher’s disease 138.  While the lack 
of licensed plant-made pharmaceuticals is at least in part due to the resistance of major pharmaceutical 
companies to switch from established production platforms to a new production platform 139, it can also 
be attributed to the perceived and actual drawbacks to plant-based production. These include: similar 
downstream production costs as other recombinant proteins, the presence of plant host-cell proteins 
and metabolites (e.g., flavonoids, alkaloids, and pigments) that can cause difficulties in downstream 
processing, yields that are still relatively low compared to other cell culture platforms, the 
environmental risks of producing transgenic crops, and regulatory uncertainty 140-143 144,145. 
Recombinant protein production in plants can be accomplished either through stable 
transfection or transient transfection technologies.  Stable transfection involves inserting foreign genes 
into the host plant’s genome in a way that allows the foreign gene to be retained over multiple 
generations 43.  For example, the Pharma-Planta Consortium stably expressed an anti-HIV monoclonal 
antibody for the prevention of HIV transmission in transgenic tobacco plants 146.  However, stably 




labor-intensive 147.  In contrast, transient expression employs viral or bacterial vectors for the short-term 
expression of foreign transgenes 43.  Transient expression can be used to quickly produce vaccines 
during pandemics 148, for emerging infectious diseases 149, or for patient-specific cancer treatments.  For 
example, Large Scale Biology Corporation created a TMV-based transient expression vector for the 
production of idiotype vaccines (i.e., single-chain antibodies derived from each patient’s tumor) for the 
treatment of non-Hodgkin’s lymphoma 150.  The advantage of using plants for this process was that the 
personalized vaccines could be produced quickly (within weeks of obtaining a biopsy from a patient’s 
tumor).  Plant cell cultures can also be used to produce pharmaceutical proteins.  For example, Protalix 
Therapeutics utilizes carrot cell cultures to manufacture β-glucocerebrosidase, a treatment for 
Gaucher’s disease 151.  It should be noted that plant cell culture eliminates some of the cost-savings 
associated with plant-based production requiring capital-intensive facilities and equipment comparable 
to mammalian- or yeast-cell production systems 152,153.  In summation, plant-based production has 
proven to be both scalable and economical with production costs that are far lower than production 
systems based on E. coli or eukaryotic cells and a better safety profile than products produced in 
mammalian cells 117,147,153-155. 
Nicotiana benthamiana 
Nicotiana benthamiana belongs to the Solanaceae family and is indigenous to Australia.  A close 
relative of Nicotiana tabacum (tobacco), N. benthamiana possesses multiple traits that make it an ideal 
production system, including that it has a fast growth rate 149 and is a non-food, non-feed crop that can 
easily be cultivated in growth rooms 28.  Because N. benthamiana is not grown for food or feed, the risk 
of transgene spread is low 113,130.  Furthermore, when transient expression is used, transgenes are not 
stably incorporated into the plant genome, so transgene flow is not a problem 130.  N. benthamiana also 
possesses a mutated RNA-dependent RNA polymerase gene, which reduces gene silencing, thereby 




In fact, it is widely used to study plant virology and plant host-pathogen interactions because it can be 
easily infected by a large number of plant viruses and other plant pathogens 157.  For these reasons, N. 
benthamiana is the most routinely used species for transient expression of biopharmaceuticals in plants 
149,157.   
The anti-Ebola virus antibody cocktail, ZMAPP, is produced in N. benthamiana 158, and it is 
currently in phase II/III clinical trials 159.  Other biopharmaceuticals produced in N. benthamiana that 
have been tested in clinical trials include Medicago’s VLP influenza and rotavirus vaccines 160,161 and Icon 
Genetics’ idiotype vaccines for non-Hodgkin’s lymphoma 162.  The fast growth rate and high yields 
associated with N. benthamiana are particularly amenable to producing vaccines during pandemics 
when they can be used to create large amounts of vaccines in a short period of time.  For instance, with 
funding from the Defense Advanced Research Agency (DARPA), Medicago produced 10 million doses of 
their H1N1 influenza vaccine in just 30 days using N. benthamiana 163.  A single plant can produce up to 
50 doses of a flu vaccine, and, if scaled-up, a single manufacturer could theoretically produce 1 billion 
doses per year 164 at a cost of less than $0.12 per dose 129.  A similar egg-based influenza vaccine 
production facility produces only 100 million doses per year, with a yield of 1-2 doses per egg and a cost 
of $1.50 per dose 165,166.  Plant-based production of VLP and VNP vaccines has thus proven to be both 
scalable and economical with production costs are far lower than egg-based or mammalian cell culture-
based production systems 43.     
Agrobacterium-mediated expression 
Agrobacterium tumefaciens is a gram-negative, soil-dwelling bacterium that possesses the 
ability to transfer DNA sequences (i.e., T-DNA) from its Ti plasmid into the nuclei of plant cells, a trait 
which usually leads to the formation of crown gall disease 167.  This ability has been exploited to produce 
exogenous proteins by replacing some of the tumor-inducing genes on the Ti plasmid with DNA 




agroinoculation, in which a small amount of bacterial culture is pipetted onto an abraded leaf, or by 
agroinfiltration, which uses negative pressure to flood the interstitial spaces of plant leaves with 
Agrobacterium culture 169 (Figure 2).  After inoculation, the T-DNA region of the modified Ti plasmid can 
become stably integrated into plant genome to create transgenic plants 170.  Copies of the T-DNA are 
also transiently transcribed in the nuclei of the plant cells, which leads to transient expression 171.   By 
co-cultivating Agrobacterium with plant calluses, this process can also be used to transiently express 
proteins in plant cell cultures 172.  Thus, stable and transient expression of recombinant proteins in 
whole plants and plant cell cultures can be accomplished through Agrobacterium-mediated expression.  
 
 
Figure 2. Agroinfiltration of Nicotiana benthamiana.  Plants are placed in Agrobacterium culture (water is used here for clarity) 
and a vacuum chamber is used to create negative pressure. Upon releasing the vacuum, the bacterial culture floods the 




Plant virus-based expression vectors 
A variety of plant virus-based vectors have been used to transiently express proteins in plants, 
including tobamoviruses, potexviruses, and comoviruses 169.  These plant viral vectors contain full copies 
of the viral gene into which a foreign gene has been inserted, which are known as full viral vectors, or 
they can be deconstructed viral vectors 173.  Initially, double-stranded cDNA copies of single-stranded 
DNA viral genomes were used to mechanically inoculate plant leaves using diatomaceous earth (i.e., 
rub-inoculation).  Similarly, double-stranded cDNA copies of single-stranded RNA viral genomes could be 
reverse transcribed in vitro to make infectious RNA, which could then be used to rub-inoculate plants 174.  
Rub-inoculation limits the use of viral vectors because it requires that the virus be mechanically 
transmitted and is a very inefficient, low-throughput process 169.  Thus, second-generation viral vectors 
included sequences from the Ti plasmid of Agrobacterium and the 35s promoter from cauliflower 
mosaic virus (CaMV) to create agroinfection-compatible plant-virus expression vectors 175-177.  When 
used with agroinfiltration, these vectors are delivered to the majority of leaf cells leading to high levels 
of heterologous protein expression 169.    
Such expression vectors can also be used to create VNPs in which a heterologous immunogen is 
expressed on the surface of plant viruses, such as cowpea mosaic virus (CPMV) or tobacco mosaic virus 
(TMV).  The advantages of plant VNPs over other types of VNPs are that they have a favorable safety 
profile (i.e., they are unable to replicate in animals 178) and they can easily be produced and purified at 
large-scale using low-cost plant hosts.  To create plant VNPs, the heterologous immunogen is typically 
cloned into the viral vector so that it is produced as a translational fusion to the viral coat protein 
because maximum immunogenicity is achieved when the heterologous peptide is surface exposed 179.  
However, these translational fusion restrain the size of the immunogen because large heterologous 
proteins tend to destabilize viral particles or hinder their assembly 180.   Mammalian viruses, such as 




these common viruses because of prior exposure 181.  Pre-existing antibodies to these viral scaffolds can 
neutralize the VNPs before an immune response can be triggered against the heterologous immunogen 
they carry, leading to low efficacy.   
Tobacco mosaic virus 
TMV was the first virus to be identified, purified, visualized via electron microscopy, and studied 
by x-ray crystallography 182,183.  TMV-infected tobacco plants produce TMV in such abundance that viral 
inclusion bodies can be seen using a light microscopy 184.  Despite its name, TMV is capable of infecting 
over 150 types of plants, including tobacco, tomatoes, cucumbers, and peppers 185.  TMV-infected plants 
display symptoms such as flexion of the upper part of the stem, mottled light and dark green leaves (i.e., 













Figure 3. Symptoms of tobacco mosaic virus infection in Nicotiana benthamiana. a) Uninfected Nicotiana benthamiana.            
b) Nicotiana benthamiana showing symptoms of TMV infection, including mottled leaves, stunted growth, and leaf curling.   




TMV consists of over 2,100 cylindrical coat proteins arranged in a helical manner around a 
single-stranded, positive-sense RNA genome to form rods approximately 300 nm long and 18 nm wide 
182.  Due to the densely packed nature of its coat proteins, TMV is extraordinarily stable and purified 
virions stored at 5°C remain viable for at least 50 years 182.  This inherent stability of TMV allows it to be 
used with a wide variety of buffers and even some organic solvents over a pH range of 3.5-9, which 
allows for chemical surface modifications and electroless deposition of metals 186.  Along with the 
intrinsic ability of TMV coat proteins to spontaneously assemble in vitro 187, this robustness has led to 
TMV nanoparticles being used in vaccines, imaging reagents, biosensors, battery components, drug 
delivery, chemical catalysis, and data storage 188.  
 In addition to robustness, TMV possesses many other properties that make it an ideal scaffold 
for displaying exogenous epitopes.  These include 1) it is composed of a single coat protein, which is 
easily genetically modified 183; 2) it is a non-enveloped virus that is flexible in terms of shape and 
composition 189; 3) it tolerates insertions at several surface-exposed residues on its coat protein  91,183; 4) 
large quantities of virus can easily be purified from infected plants 190; and 5) the density of epitopes 
displayed on TMV is unmatched by any other VNP or VLP system (i.e. TMV can display over 2,100 copies 
of an epitope, compared to CPMV VNPs, which display only 25 copies, and papillomavirus VLPs, which 
display 420 copies) 191,192.  TMV VNPs can also be thought of as a conjugated subunit vaccine in which 
TMV serves as a stable adjuvant, which may prove beneficial in resource-poor settings where cold-
storage dependent adjuvants are impractical 193.  In addition, when displayed on TMV, weak B cell 
antigens become high ordered, which leads to effective cross-linking of B cell receptors and elicit a 
potent antibody response 194.  In fact, the size, particulate nature, and high density of repetitive antigens 
that can be displayed on TMV VNPs efficiently trigger the innate immune response, allow for efficient 




39,181,195,196.  As a result, TMV VNPs have been used to induce humoral and cell-mediated immunity 
against a variety of pathogens (Table 2).   
Table 2. TMV VNPs created as vaccines against viral diseases, bacterial diseases, and parasitic diseases, as well as cancer 
vaccines and immunotherapies.   
 Pathogen Epitope displayed Reference 
Viral pathogens 
HIV 
HIV-1 Tat protein 197 
Envelope protein gp120 198 
Influenza virus Hemagglutinin glycoprotein 198 
Rabies virus G5-24 glycoprotein peptide 199 
Poliovirus VP1 of poliovirus type 3 200 
Foot-and-mouth disease 
virus 





Pseudomonas aeruginosa OMPF peptide 202 
Francisella tularensis 
(tularemia) OmpA, DnaK, and Tul4 
196 
Parasites Plasmodium falciparum (Malaria) B cell epitope 
203 
Cancer 
- Mouse tumor T cell epitopes 204 
- Tn (a tumor-associated carbohydrate antigen) 
205 
 
 TMV viral vectors 
Most TMV expression vectors contain a T7 promoter which means transcripts can be made in 
vitro and used to rub inoculated plants.  However, this process is inefficient, labor-intensive, expensive, 
and not conducive to scale-up 176.  Agroinfection-compatible TMV expression can be transformed into A. 
tumefaciens, cultured, and then injected or vacuum-infiltrated into the leaves of the plant 206.  The 
addition of a plant-driven 35S promoter from Cauliflower mosaic virus then allows the viral cDNA to be 
transcribed into RNA in the nuclei of the plant cells.  Once the TMV proteins are transcribed, the 




protein gene and/or other non-essential viral genes can be removed from TMV vectors to create a 
“deconstructed” vector into which large genes encoding foreign peptides can be inserted 207.  Because 
these vectors do not produce viral particles that can assemble, replicate and move to other parts of the 
plant on their own, vacuum infiltration is required to ensure every cell will produce the protein of 
interest.  
 
Figure 4. Diagram of an agroinfection-compatible TMV expression vector and a TMV-based viral nanoparticle. a) Grey boxes 
show the left and right border sequences (LB and RB) of the Agrobacterium binary plasmid delimit the region of the launch 
vector that is transferred into plant cells following infiltration of plants. Blue boxes indicate regulatory elements: 35s is a strong 
constitutive DNA promotor from cauliflower mosaic virus; Nos 3’ is the transcriptional terminator of Agrobacterium nopaline 
synthase. Green boxes indicate the TMV genes required for viral replication and movement: replicase is the TMV RNA-
dependent RNA polymerase for viral replication; movement protein (MP) allows cell-to-cell movement of TMV through the 
plasmodesmata of the plant cells; coat proteins self-assemble to form the rod-shaped virions. Orange box indicates the foreign 
epitope that can be inserted as a translational fusion to the 3’ end of the coat protein.  b) Diagram showing a TMV nanoparticle 
with foreign epitopes (orange) displayed on the coat protein (green).  Note: on a TMV VNP, the foreign epitope would be 





The mammalian immune system is complex and multi-faceted, and both T cell and B cell 
responses are essential for inducing the long-lived protective immunity required by most vaccines.  In 
general, vaccines are composed of whole pathogens that have been attenuated or inactivated or smaller 
antigenic peptides from the pathogen, but there is always a tradeoff between the immunogenicity and 
safety.  While safe and efficacious vaccines exist for many human pathogens, many people in developing 
countries do not have access to them.  A novel vaccine production platform that produces high yields of 
vaccine antigens at a low cost could increase access to vaccines in developing countries while also 
providing a means of developing new vaccines for emerging infectious diseases.  Using plants as a host 
for vaccine production may provide such a solution; it has already proven to be a cost-effective, 
scalable, and rapid means of producing other pharmaceutical products.  The following chapters explore 
the use of agroinfection-compatible, TMV-based vectors to transiently express viral nanoparticles 




CHAPTER ONE: ZIKA VIRUS 
INTRODUCTION 
Zika virus (ZIKV) belongs to the Flavivirus genus of the Flaviviridae family, which is composed of 
enveloped positive-stranded RNA viruses.  The Flaviviridae family contains many well-known human 
pathogens including yellow fever (YFV), dengue (DENV), West Nile (WNV) and hepatitis C.  Mosquitoes 
of the  Aedes genus transmit the virus to humans 208, but it can also be transmitted from one human to 
another perinatally, sexually, and through breast milk and blood transfusions 208.  In 1947, the first strain 
of  ZIKV  was isolated from sentinel monkeys in Uganda, and the first case in humans was documented in 
1952 209.  There were no significant outbreaks of ZIKV until 2007 when approximately  5,000 cases were 
recorded on Yap Island in Micronesia 210.  Thereafter,  19,000 cases were documented in 2013 (French 
Polynesia), and an estimated 440,000 to 1.3 million cases were documented in 2015 (the Americas and 
Southeast Asia) 211,212.  As a result of these explosive outbreaks, a causal link was established between 
ZIKV infection and congenital brain abnormalities 213,214.  This prompted the World Health Organization 
(WHO) to declare ZIKV a Public Health Emergency of International Concern on February 1, 2016 215.    
Most ZIKV infections are asymptomatic, and the 20% 216,217 of cases that are symptomatic 
typically manifest as a mild, self-limiting, flu-like illness 208.  Recent outbreaks have shown that ZIKV  
infections are also associated with a variety of severe neurological outcomes, including Guillain–Barré 
syndrome(GBS) 218 and congenital Zika syndrome (CZS) 219,220.  Congenital Zika syndrome (CZS) 
encompasses a wide range of abnormalities found in fetuses and infants, including microcephaly, brain 
atrophy, and macular scarring 221,222.  Risk estimates for CZS range from 6% - 42% based on the 
geographic area 223-226.  Guillain–Barré syndrome is a group of peripheral nerve disorders characterized 
by muscle weakness and progressive paralysis, which leads to severe disability in 20% of cases 227.  While 




system attacks the peripheral nervous system following a bacterial or viral infection.  Viral infections 
that have been shown to trigger GBS include cytomegalovirus and Epstein-Barr virus 228.  The incidence 
of ZIKV-induced GBS has been estimated to be as low as 0.024 % 218,229 but could be as high as 1.23% 230.  
Other complications associated with Zika virus infection include ocular lesions231,  thrombocythemia 232 
meningoencephalitis 233, and multiple organ failure 234.  
The global burden of ZIKV disease is difficult to determine.  Because it typically manifests as a 
mild disease, most people who are infected do not seek medical care.  Even if patients seek medical 
care, the clinical manifestations of Zika virus infection are very similar to infection by other flaviviruses, 
like Dengue and Chikungunya 235.  Differential diagnosis requires a serological assay to be performed in 
which viral RNA is detected by RT PCR 236, but these tests aren’t typically available in resource-poor 
areas.  If testing is available, cases are not always reported to public health officials.   Given these 
limitations, estimating the number of people at risk of ZIKV infection is primarily assessed by looking at 
the geographic distribution of the primary vector, Aedes mosquitoes (Figure 5).  For example, by taking 
into account various factors such as temperature, precipitation, vegetation and urbanicity,  Messina et 
al. created a model that showed which geographic areas were suitable for Aedes mosquitoes 237.  Based 
on this approach, a predicted 2.2 billion people live in areas that are conducive to ZIKV transmission 237.  
Furthermore, this number will likely increase as global warming increases the range of Aedes 
mosquitoes 238.   
Currently, there are no therapeutics or vaccines approved to prevent, control, or treat ZIKV 
infection.  Several approaches have been taken to limit the spread of ZIKV, such as vector management 
and educational programs, but these strategies have proven ineffective 239,240.   Numerous antiviral 
therapeutics are also being developed, such as the small molecule therapeutic bithionol 241 and 
monoclonal antibodies 242-244.  While these therapeutics have shown anti-ZIKV activity in cellular and 






Figure 5. Global maps of the predicted distribution of Aedes aegypti (a) and Aedes albopictus (b). Maps depict the probability of 
occurrence (from 0 blue to 1 red).  Adapted from Kraemer et al. 245. 
Historically, public health strategies to combat flavivirus infections have relied on vaccines to reduce the 
burden of disease 246,247.  Numerous factors must be taken into account when developing a safe and 
efficacious ZIKV vaccine, such as the limited understanding of ZIKV immunity and pathogenesis and the 
lack of an animal model that accurately mimics ZIKV infection in humans 248.  However, as explained 






ZIKV strains, and affordability are likely the most critical factors to consider when developing a ZIKV 
vaccine.  
1. Antibody-dependent enhancement (ADE) of disease - Researchers have theorized that a ZIKV 
infection or being immunized with an anti-ZIKV vaccine could generate antibodies that cross-
react with other flaviviruses 249.  Upon subsequent infection with another flavivirus, these cross-
reactive antibodies might be protective 250,251, but they could also lead to enhancement of 
disease 252 (the potential mechanisms behind ADE are discussed in the next section).  
Furthermore, many flaviviruses are transmitted by the same types of mosquitoes and co-
circulate in the same geographic areas as ZIKV 253, a situation that is conducive to ADE.  The risk 
posed by vaccine-induced ADE was recently seen in the clinical trials for a DENV vaccine in which 
children under nine had an increased risk of hospitalization following immunization 254,255.  And, 
while many in vitro and in vivo studies have looked at the role DENV antibodies might play in 
ZIKV pathogenesis, only a few in vitro studies have looked at the role that pre-existing ZIKV 
antibodies might play in ADE of DENV 256.  Even though ZIKV-induced ADE has not been 
confirmed in vivo, ZIKV vaccines should still be designed with this potential safety risk in       
mind 257.   
2. Vaccination of pregnant women and women of childbearing age - Health authorities, most 
notably the WHO, identify the highest risk group to be women of childbearing age and pregnant 
women due to the severe outcomes associated with CZS.  Morabito et al. suggest that the best 
way to protect pregnant women from ZIKV is via a high rate of ZIKV immunity in the general 
population.  Thus, vaccinating all healthy individuals over nine years of age could be the best 
strategy to decrease the risk of ZIKV transmission to pregnant women 66.  Additionally, due to 
the disproportional risk to pregnant women, the ideal ZIKV vaccine should be designed with the 




generally not administered to pregnant women because of the risk to the fetus, so inactivated 
virus, non-replicating virus-like particles, and subunit vaccines are preferred.  
3. Homology between ZIKV strains- Different vaccine development strategies are required for 
single-serotype flaviviruses, such as YFV and JEV, versus multiple serotype flaviviruses like DENV.  
Developing vaccines for viruses with numerous serotypes is difficult because neutralizing 
antibodies against one serotype typically do not cross-neutralize other serotypes 259-261.  Thus, 
multivalent vaccines may be required, and these come with additional technical and regulatory 
challenges 262,263.  Recently, several studies have shown that only a single serotype of ZIKV exists.  
For example, Dowd et al. utilized sera from patients and mice infected with different strains of 
ZIKV to show that immune sera from one strain were capable of neutralizing different strains in 
neutralization assays,  suggesting that there is only one serotype of ZIKV 264.  Aliota et al. showed 
that rhesus macaques infected with one strain were completely protected when challenged with 
a heterologous strain 265.  Furthermore, the limited diversity among ZIKV isolates (approximately 
99.2 %  sequence similarity 266  and 96% amino acid similarity 267,268 ) suggests that a vaccine 
against one strain will protect against all strains.   
4. Affordability- Most ZIKV infections occur in developing countries, so a preventative vaccine 
would have to be both affordable and ideally not require more than one dose 257,269.  Using 
various models of ZIKV transmission, studies have found that to be cost-effective, a ZIKV vaccine 
should cost no more than $10 per dose 270,271.   
BACKGROUND 
The Zika virus has a 10.8 kb positive-stranded RNA genome with a single open reading frame 
that is translated into one polyprotein 272.  Host and viral proteases cleave the polyprotein into three 




protein, the precursor membrane (prM) protein (aka the membrane (M) protein in mature viral 
particles), and the envelope (E) protein, which along with the viral genomic RNA, form Zika virions.  The 
C protein encapsidates the viral genome, the M protein facilitates fusion of the viral envelope with the 
host cell membrane, and the envelope protein is involved in receptor binding and viral assembly 273.    
The seven ZIKV non-structural (NS) proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5.  
Although functional data for the ZIKV NS is incomplete, their functions are likely similar to those of other 
flaviviral NS proteins, which play various roles in viral replication and assembly, evading the host’s 
immune response 274, and even enhancing Ae. aegypti oral susceptibility 275.  For example, NS1 and NS2A 
are cofactors in the viral replications complex, and NS1 also recruits other NS proteins to membrane 
vesicles during viral replication 276,277.  Together with NS2B, NS3 functions as a serine protease to cleave 
the ZIKV polyprotein; NS3 also serves as an RNA helicase and NTPase 278.  NS4A regulates the ATPase 
activity of the NS3 helicase, and NS4B induces the formation of ER-derived membrane vesicles for viral 
replication 278.  The role that the ZIKV NS proteins play in immune evasion and pathogenesis will be 
discussed in subsequent sections.  
Knowledge of the specific host cell receptors that facilitate ZIKV binding and entry remains 
incomplete despite numerous studies on the subject. DC-SIGN (dendritic cell-specific ICAM3-grabbing 
nonintegrin) receptors mediate antigen uptake and signaling on immune cells, such as macrophages and 
dendritic cells, and have been shown to facilitate viral entry 279-281.  In other tissues, ZIKV utilizes 
phosphatidylserine receptors TIM (T cell immunoglobulin mucin domain) and TAM (Tyro3, Axl, and MER) 
for cellular entry.  Lipids on the exposed portions of the viral membrane interact with these receptors in 
a process called apoptotic mimicry (the normal function of these receptors is to recognize 
phosphatidylserine on apoptotic cellular debris and trigger phagocytosis) 282,283.  Specifically, TIM1 has 
been implicated in ZIKV binding to placental cells 284, while TAM receptors have been implicated in skin 




no difference in viral replication or symptoms of viremia in mice with homozygous AXL knockout versus 
mice with a heterozygous AXL knockout 287.  Thus, ZIKV can likely exploit multiple receptors in different 
tissues types and in different hosts.    
Cryo-electron microscopy and X-ray crystallography studies have revealed that the glycoproteins 
(E & M) undergo conformational changes as they are converted from their immature noninfectious form 
to their mature infectious form. On the immature virus, 60 heterotrimers of prM/E project outward 
from the membrane, resulting in a spikey appearance 288 (Figure 6a).  In the acidic environment of the 
trans-Golgi network, the prM/E heterodimers rearrange so that they lie parallel to the membrane 
(Figure 6b).  prM is proteolytically cleaved, and the mature virions are released into the extracellular 
space.  These mature virions have a smooth surface composed of 180 copies of M/E heterodimers 
embedded in the viral membrane, and the 90 antiparallel E protein homodimers on the surface of the 
virion form an icosahedral herringbone pattern (Figure 6c) 289,290.  However, inefficient prM cleavage is 
common 291,292 and can lead to a wide range of partially mature virions that display a variety of 
conformational epitopes.   In addition, flavivirus glycoproteins on partially mature and even fully mature 
virions are thought to be dynamic and continuously rearranging in a process called “viral breathing” 
293,294.   During this process, the viral lipid membrane may be temporarily exposed, which accounts for 
the TIM & TAM interactions mentioned earlier. 
Immune response to ZIKV  
ZIKV induces both innate and adaptive immune responses.  Minutes to hours after infection, the 
innate immune response responds to viral infection through the interferon (IFN) system.  Type I IFNs are 
the primary mediator of the innate immune response against ZIKV, but type II and type III IFNs have also 
been implicated in protection against ZIKV infection 295-298.  Lazear et al. demonstrated the importance of 





Figure 6.  “Flavivirus structures during virion biogenesis. (a) The lipid envelope of the immature virus contains 180 copies each 
of the pre-membrane (prM) and envelope (E) structural proteins. E and prM heterodimers are further arranged into 
heterotrimeric spikes that project away from the surface of the particle. Immature virions are noninfectious and must undergo 
a maturation step that involves cleavage of prM by host furin-like serine proteases. (b) In the low-pH environment of the trans-
Golgi network, E and prM proteins rearrange to form 90 sets of antiparallel E protein homodimers that lie flat against the 
surface, with the prM proteins situated on top. This conformational change reveals a furin cleavage site in prM, resulting in a 
short membrane-bound M protein and a cleaved pr portion. The pr peptide remains associated with the virion during viral 
egress and protects the conserved fusion loop at the distal end of E-DII from prematurely initiating fusion. In the absence of 
prM cleavage, this conformational change is reversible for dengue virus when pH is returned to neutral; however, this does not 
appear to be the case for tick-borne encephalitis virus. (c) Infectious mature virions are released from cells by exocytosis. In the 
neutral pH of the extracellular space, the cleaved pr peptide dissociates from the virion, leaving a smooth particle coated by 
antiparallel E dimers. In all panels, shading of E protein dimers represents the distinct chemical environments present on the 
mature virion. Dark purple circles represent prM or cleaved pr peptide. Trimer versus dimer designation noted below each 
panel refers to the arrangement of E proteins.” 293.  Annual Review of Virology by Annual Reviews. Reproduced with permission 
of Annual Reviews in the format Thesis/Dissertation via Copyright Clearance Center. 
infection while ZIKV could not replicate efficiently in immunocompetent mice 296.  The type I IFN system 
is triggered when cellular pattern recognition receptors (PRRs), such as retinoic acid-inducible gene I-like 
receptors (RLRs) and Toll-like receptors, specifically TRL3 299 and TRL7, recognize the nucleic acid of 
flaviviruses.  RLRs are present in the cytoplasm of multiple types of cells and recognize viral RNA.  TRL3 
and TLR7 are expressed in intracellular cytoplasmic vesicles, such as endosomes, and recognize ssRNA 
and the double-stranded RNA produced during viral replication 300,301.  TLR3 is present in dendritic cells, 
macrophages, fibroblast, and epithelial cells, while TLR7 is only expressed on plasmacytoid dendritic 
cells.  After these PRRs recognize viral RNA, they activate transcription factors like interferon regulatory 




receptors, activating the JAK/STAT signaling pathway and leading to the transcription of interferon-
stimulated genes (ISGs).  ISGs are translated into proteins that exert a variety of antiviral effector 
functions.  For example, the IFITM3 has been shown to inhibit ZIKV replication and prevent ZIKV-induced 
cell death 302, CXCL10 recruits natural killer cells to inhibit ZIKV replication 303, and MxA targets ZIKV 
nucleocapsids 303.     
When PRRs recognize viral RNA, the NFκB-induced production of pro-inflammatory cytokines 
and chemokines also serves to eliminate viruses.  During ZIKV infections, pro-inflammatory cytokines 
such as IL- 1β, IL-4 IL-6, IL-8, and IL-10 have been shown to be upregulated in monocytes 303.  However, 
the pro-inflammatory immune responses to ZIKV infection are cell-type specific.   For example, 
embryonic neuroprogenitor cells 304 and dendritic cells 305 do not secrete pro-inflammatory cytokines, 
while cranial neural crest cells secrete multiple pro-inflammatory cytokines, such as LIF, IL-6, PAI-1 306.        
Natural killer (NK) cells are also part of the innate immune response to ZIKV that occurs prior to 
the adaptive immune response.  A recent study showed that sera from ZIKV-infected patients contained 
high levels of IL-18, TNF-α, and IFN-ɣ, which are all associated with the function of NK cells 307.  CD14+ 
monocytes, various chemokines (CXCL9, CXCL10, CXCL11, and CCL5), and cytokines, like IL-15, have been 
shown to activate NK cells during ZIKV infection 308.  Once activated NK cells produce and release 
cytotoxic molecules that lead to apoptosis of the infected cell, limiting the ability of the virus to replicate 
and spread to neighboring cells.  Another component of innate immunity is autophagy.  While the 
normal function of autophagy to engulf, digest, and recycle macromolecules in the cytosol, this process 
can also be used to limit viral replication through degradation of viral proteins.  This type of autophagy is 
thought to be induced by TLR7 and the adaptor proteins MyD88 and TRIF 309 and type 1 IFN signaling has 
been shown to promote autophagy of the viral proteases NS2B and NS3 310, which are necessary for viral 




ZIKV subversion of the innate immune response 
The type I IFN system is very effective at halting viral replication.  To maintain their ability to 
replicate and disseminate, flaviviruses have evolved various mechanisms to counteract the antiviral 
effects of the type I IFN system.  To varying degrees, all of the nonstructural proteins suppress IFN-β 
production by targeting components of the RIG-I pathway.  ZIKV uses NS4A and NS5 to inhibit IFR3 and 
NFkB activation 311,312, while NS1 and NS4B interact with TBK1 to impede activation of IRF3 310,311.  ZIKV 
non-structural proteins also antagonize JAK/STAT signaling: NS5 interacts with STAT2 and promotes its 
degradation 313 and NS2B/NS3 has a similar effect on JAK1 310.  Additionally, the 5’ methylated cap on 
the ZIKV genome mimics cellular mRNAs, and it is thought that this is used to evade detection by RLRs 
and other components of the I IFN pathway 314.  
Flaviviruses have also evolved pro-viral mechanisms to either subvert or enhance autophagy at 
different stages of the viral replication cycle.  For example, early in infection, the NS4A and NS4B 
proteins inhibit mTOR activity, thus upregulating non-selective autophagy.   This is thought to mobilize 
the membranes and lipids required for membrane biogenesis during ZIKV replication 315 and also play a 
role in the maternal-fetal transmission of the virus 316.  Later in infection, the NS3 and NS2B proteins 
inhibit selective autophagy by cleaving the FAM124B receptor, thereby inactivating ER-phagy.  This leads 
to expansion of the ER and thus increased viral replication 317,318.   
Adaptive immune response to ZIKV 
If the innate immune response cannot sufficiently stop viral replication, the adaptive immune 
response is activated.  The adaptive immune response includes two class of responses: the cell-
mediated response and humoral, or antibody-mediated, response. Evidence suggests that both cellular 
and humoral responses contribute to controlling ZIKV.  The cell-mediated response is carried out by T 
cells that when activated proliferate and differentiate into effector T cells, of which there are two main 




peptides bound to MHC class I molecules on antigen-presenting cells and destroy infected cells before 
the virus can proliferate and infect neighboring cells.  CD8+ T cells have been shown to mediate viral 
clearance from tissues in WNV 319 and JEV 320,  and numerous studies suggest that CD8+ T cells play a 
similar role during ZIKV infection  321-324.  Upon recognition of antigens on MHC class II molecules, CD4+ T 
cells can differentiate into Th1 cells or Th2 cells.  Cytokines produced during the innate immune response 
determine which type of CD4+ T cell develops.  Tappe et al. analyzed sera from ZIKV infected patients 
and found that levels of cytokines associated with T-cell activation were increased.  These included Th1-
promoting cytokines (IL-12 and IFN-ɣ) and Th2-promoting cytokines (IL-4, IL-13) 325.  Th1 cells secrete IFN-
ɣ and TNF-α, which activate macrophages and dendritic cells to kill phagocytosed viruses.  Th2 cells 
produce and secrete a variety of interleukins (i.e. IL-4, IL-5, IL-10, and IL-13) with different functions.  
The most critical antiviral functions are 1) activating B cell proliferation and antibody production, and 2) 
enhancing the cytotoxic functions of CD8+ T cells and aiding in the survival of memory CD8+ T cells.  
ZIKV infection induces both CD8+ and CD4+ effector T cell responses, indicating that T cell 
epitopes play an important role in the immune response to ZIKV.  In this case, T cell epitopes are short 
sequences of viral peptide sequences presented on the MHC molecules of antigen-presenting cells to 
stimulate a cellular immune response.  Ngono et al. mapped ZIKV epitopes that elicited CD8+ T cell 
responses in mice and found that these responses target all ZIKV proteins except NS1 and NS2B, but 
preferentially target the structural proteins with the immunodominant epitope being in the E protein 322.  
Pardy et al. also found a potentially immunodominant CD8+ epitope in the envelope protein 321.  Grifoni 
et al. analyzed peripheral blood mononuclear cells from ZIKV-infected donors and found that ZIKV 
structural proteins (C, E, and prM) are the primary target for both CD4+ and CD8+ T cells 326.  In a mouse 
model of DENV, CD4+ T cells were shown to contribute to viral clearance 327.  Ngono et al. found that the 




response, local control of infection in specific tissues, and viral clearance during primary ZIKV      
infection 328.   
Antibody-mediated protection 
As previously mentioned, in the humoral immune response, effector CD4+ T-cells activate B cells 
to secrete antibodies.  Antibodies then circulate in the bloodstream where they bind to cognate 
antigens on the virus and inactivate them through a variety of mechanisms, including neutralization and 
opsonization 27.  Neutralization of flaviviruses occurs when antibodies block the virus from binding to 
host cell receptors, block uptake into cells, or block the membrane fusion process 329-331.  ZIKV induces 
the production of neutralizing antibodies 332, and numerous studies have shown that neutralizing 
monoclonal antibodies (mAbs) can fully protect mice from ZIKV infection 242-244,332,333.  Neutralizing 
antibodies have also been shown to mediate long-term protection from flavivirus infections 334.  Studies 
of WNV demonstrate that antibody-mediated flavivirus neutralization might be a “multi-hit process in 
which an individual virion must be bound by a threshold number of antibody molecules to inhibit 
infection” 293,335,336.  It is thought that two factors play a role in reaching this threshold: antibody affinity 
and the accessibility of epitopes.  Studies of WNV suggest that even high-affinity antibodies require at 
least 30 accessible epitopes be present on a virion for neutralization to occur 337.  Furthermore, 
antibody-mediated neutralization is complicated by partially mature virions and viral breathing, both of 
which lead to different epitopes being displayed on the surface of ZIKV, and therefore different 
antibody-recognition sites 293.   
Antibodies also indirectly contribute to protection through their Fc-mediated functions.  When 
bound to a viral antigen, the Fc portion of the antibody’s constant region activates the complement 
system, which plays a crucial role in protection from flaviviruses.  The antiviral mechanisms of the 
complement system are diverse and include the direct inactivation of virions, recruitment and activation 




cells 338.    Evidence suggests that opsonization via the lectin pathway may be the primary mechanism by 
which the complement system neutralizes flaviviruses 338-340, because the small surface area of 
flaviviruses may limit the formation of the membrane-attack complexes (MAC) 338.  However, Schiela et 
al. demonstrated that the classical complement pathway reduced ZIKV titers and that this pathway was 
activated by IgM binding to viral particles or binding of C1q to viral proteins 341.   This would eventually 
lead to the formation of MACs and lysis of virions, which suggests that complement-mediated lysis is 
responsible for the reduction in ZIKV viral titers rather than opsonization 341.   
Antibody-dependent enhancement of disease 
In addition to hijacking the innate immune response for pro-viral purposes, flaviviruses have 
also been shown to exploit the antibody-mediated complement and FcR pathways.  For example, WNV, 
YFV, and DENV NS1 proteins have been shown to block or attenuate activation of all three complement 
pathways 340,342.  However, the Fc receptor pathway likely plays a more significant role in ADE.  When 
virus-antibody complexes form, they bind to Fcɣ receptors expressed on monocytes, macrophages, and 
dendritic cells and are phagocytosed.  In DENV infections, primary infection or immunization can elicit 
an inadequate antibody-mediated response, which leads to severe disease upon subsequent infection 
with a different serotype of DENV 343,344.  prM-targeting antibodies have been shown to increase the 
infectivity of immature and partially mature DENV particles by facilitating entry into cells through FcγII 
receptors 345.  Once the immature virus is endocytosed, conditions inside the endosome are thought to 
lead to viral maturation and initiation of membrane fusion 346,347.  Thus, by hijacking antibody-and-Fcɣ-
mediated endocytosis,  the otherwise uninfectious immature virions can become highly infectious and 
lead to severe disease 348.  This augmented viron uptake and the subsequent increase in infected cells is 
termed “extrinsic ADE”.  Antibodies-mediated entry into cells can also lead to an increase in the amount 
of virus produced by each cell through a process called “intrinsic ADE”.   This involves the 




longer and thereby increase viral replication 349.  Due to the structural similarities between flaviviruses, 
antibodies to one flavivirus can also be cross-reactive (i.e., capable of binding to other flaviviruses), 
which can lead to cross-neutralization 250,350.  Alternatively, if the cross-reactive antibodies have low 
avidity or are present at sub-neutralizing concentrations, they can increase virus production.    
 Indeed, in vitro and in vivo studies have shown that pre-existing DENV-neutralizing antibodies 
can lead to antibody-dependent enhancement of a ZIKV infection by mediating viral entry into otherwise 
unsusceptible cells or poorly susceptible cell types 249,351-354.  Additionally, a recent DENV infection, as 
measured by the level of DENV NS1-specific IgG3 antibodies in a patient’s blood, seemed to increase a 
person’s susceptibility to ZIKV infection 355.  Aside from this subset of patients with high levels of DENV 
NS1 IgG3 antibodies, the same study showed that the overall presence of preexisting DENV NS1-specific 
IgG antibodies was associated with less risk of ZIKV infection and fewer ZIKV symptoms 355.  However, 
caution must be used when interpreting this data in an ADE context though, because NS1 proteins are 
not part of flavivirus virions, and therefore would be incapable of enhancing uptake and binding of ZIKV 
virions.  Furthermore, because ZIKV-induced GBS is relatively rare, a much larger cohort would have 
been needed to definitively show a correlation between preexisting DENV antibodies and ZIKV-induced 
GBS.  Another study showed that the seroprevalence of neutralizing DENV antibodies was significantly 
lower in mothers of neonates with CZS than control groups, suggesting that cross-reactive antibodies 
may play a role in protection rather than enhancement of disease 356.  Thus, further studies are needed 
to definitively determine the role, if any, that preexisting DENV antibodies and ADE play in CZS and ZIKV-
associated GBS.  Despite the uncertainty surrounding ADE and ZIKV, ADE activity has been observed in 
several other viruses 337,357-359, indicating that ADE of ZIKV is a real possibility.  
Neutralizing monoclonal antibodies against ZIKV 
ZIKV infection leads to the production of both IgM and IgG antibodies.  IgM is the first antibody 




produced before B cells undergo somatic hypermutation.  However, because of this, most IgM binding 
sites are low-affinity, and, therefore, IgMs form pentamers that contain ten antigen-binding sites to 
increase avidity.  While the primary effector function of IgM is activating the complement system, IgMs 
can also neutralize viruses.  Ngono et al. demonstrated the vital role of IgM plays in the humoral 
immune response by chemically inactivating IgM in sera from ZIKV-infected LysMCre+Ifnar1fl/fl mice.  Sera 
collected 7 and 10 days after infection was then used in a neutralization assay that showed that IgM was 
largely responsible for the neutralizing capacity of the sera 328.    Although IgM responses typically peak 
about one week after infection and disappear within 2-3 weeks, IgM antibodies can persist for 12 weeks 
or more after a ZIKV infection 360,361.  Even though IgM seems to play a significant role in ZIKV 
neutralization, no cryo-EM or X-ray crystallography studies have been done to determine the specific 
ZIKV proteins that neutralizing IgM antibodies bind.  However, in an attempt find a ZIKV-specific 
antibody to serologically discriminate ZIKV infections from other flavivirus infections, Hansen et al. 
created a microarray of overlapping peptides from the entire ZIKV polyprotein, which was then used to 
screen sera from ZIKV-infected donors.  A comprehensive list of linear antibody targets was generated 
that showed IgM binds to epitopes across the genome polyprotein 362, suggesting that IgMs target all ten 
ZIKV proteins.   
In contrast to IgM, IgG antibodies exist as monomers with only two antigen-binding sites.  These 
sites typically have a higher affinity for antigens, as the B cells that produce them have undergone 
affinity maturation.  The IgG response usually peaks around 12-14 days after infection and persists long 
after infection.  Studies of the antibody kinetics of ZIKV-infected individuals show that anti-ZIKV IgG in 
sera peaks anywhere between at 9-28 days after infection 361,363 and is maintained at high levels for up 
to two years 361.  IgGs are especially important for inhibiting viral infections because their primary 




opsonization and activating the complement system.  The majority, if not all of, the neutralizing ZIKV 
mAbs that have been discovered are thus of the IgG isotype.    
As mentioned previously, neutralization occurs when antibodies bind to a virion and prevent 
attachment, entry, or fusion.  These functions are typically mediated by proteins on the surface of the 
virus, and the surface of ZIKV is comprised mainly of E proteins.  Indeed, studies involving other 
flaviviruses have shown that the E protein is the major target of neutralizing IgG antibodies 
251,266,294,334,335,364-366, but antibodies against prM and NS1 can also neutralize flaviviruses 367.  Studies in 
both mice and humans have revealed neutralizing epitopes within the E protein can include residues on 
an E monomer from one domain 243,368, the junction between two domains 369, and/or multiple    
domains  370.  Alternatively, envelope dimer epitopes (EDE) require quaternary structures, such as E 
dimers 250,370 or a neighboring pair of E dimers 371.  Two subsets of EDE mAbs have been defined: EDE1 
and EDE2.  EDE1 antibodies bind better in the absence of glycosylation at N154, while EDE2 antibodies 
bind better in the presence of the glycan 249,250.  Interestingly, EDE mAbs were first presented as potent 
neutralizers of DENV 249, but subsequent studies have shown that some of them also cross-neutralize 
ZIKV 250,370.   
To date, hundreds of ZIKV E IgG mAbs have been described in literature.   Some of these mAbs 
were discovered by sequencing antigen-specific memory B cells from the blood of ZIKV-infected  
patients 242,332 or creating human hybridomas 244,251.  Others were discovered by infecting mice with ZIKV 
243 or re-screening previously discovered DENV-neutralizing mAbs 250.  The characteristics of 12 E-binding 
mAbs that inhibit 50% of ZIKV at a concentration of less than 1 µg/mL are summarized in Table 3.   These 
mAbs bind to a variety of epitopes across all three ectodomains of E, have different structural 






Table 3. Monoclonal antibodies against ZIKV envelope protein that are moderately to highly neutralizing (IC50, PRNT50, or 
FRNT50 ≤ 1 µg/mL).  IC50 = Inhibitory concentration, concentration at which antibody reduces viral replication by 50%. PRNT50 = 
Plaque reduction neutralization test, concentration of antibody at which the number of plaques are reduced by 50% compared 
to no-antibody control. FRNT50 = Focus reduction neutralization test, the same as PRNT, except uses the term foci instead of 
plaque.    
mAb E Domain Epitopes E structure Neutralization Origin DENV Cross-Neutralization  Reference(s) 
















SMZAb2 DII fusion loop Monomer FRNT50 = 120-370 ng/mL 
Human 
(ZIKV) DENV-1, 2, 3 
333 




Z3L1 DI, DII, DI-DII hinge Monomer IC50 = 170 ng/mL 
Human 
(ZIKV) None 





Z23 DIII Neighboring dimers 




























A9E DIII lateral ridge, DI-DIII linker, DI- glycan loop Monomer 













Pathology of ZIKV 
Some viruses, such as poliovirus and rabies virus, are cytopathic because they interfere with 
essential cellular processes when they replicate in host cells, leading to cell death.  Other viruses, such 
as HIV and DENV, are considered poorly cytopathic or non-cytopathic because they are capable of 
replicating in host cells without interfering with essential cellular processes.  This suggests it is the host’s 
immune response that is largely responsible for disease 377.  The pathogenicity of ZIKV seems to come 
from both its cytopathic effects and the immune responses it stimulates.   For example, ZIKV-induced 
cytokines production triggers symptoms typical of flaviviral infection (e.g., fever, muscle pain, headache, 
joint pain, and rash) 378, while viral replication has been shown to cause cell cycle dysfunction and 
apoptosis in certain types of cells 379-381.  However, ZIKV is better known for distinctive neurological 
complications it can cause, specifically congenital Zika syndrome (CZS) and Guillain-Barre syndrome 
(GBS).  While the exact mechanisms behind ZIKV neuropathology have not been fully elucidated, studies 
have shown a variety of pathways are likely involved.  These include the previously mentioned inhibition 
of the IFN-triggered signaling cascade by ZIKV nonstructural proteins 310, the potential ability of non-
neutralizing cross-reactive antibodies to increase viral replication (i.e., ADE) 256, and dysregulation of 
autophagy has been known to induce myelin injury.  Also, human genetic determinants, such as single 
nucleotide polymorphisms, have been associated with an increased risk of severe flavivirus-related 
disease 382.   Other mechanisms implicated in ZIKV-associated neurological complications are discussed 
below.  
To cause CZS, ZIKV must cross the placenta.  Placenta-specific cells, such as Hofbauer cells (i.e., 
placental macrophages), trophoblasts, and placental endothelial cells, are targeted by ZIKV, and thus 
likely play a role in the vertical transmission of ZIKV 216,383.  Once it has crossed the placenta, ZIKV 
preferentially targets neuronal precursors and immature neuronal cells, such as neural progenitor cells, 




result of ZIKV-related phenotypic changes in these cells, such as autophagy, apoptosis, impaired 
neurodevelopment, and the dysregulation of mitochondria.  Investigations using mouse models have 
demonstrated that genes associated with both autophagy and apoptosis are upregulated in fetal brains 
306,387-389, and ZIKV-related upregulation of TLR3 in various tissues 299,385,390 has been shown to deplete 
neural progenitor cells 390.  Dysregulation of mitochondria has been implicated in the neuropathogenesis 
of many diseases, and a study by Khaiboullina et al. showed that genes related to mitochondrial function 
are deregulated during ZIKV infection 303.  Bayless et al. observed increased secretion of LIF, VEGF, and 
IL-6 in ZIKV-infected cranial neural crest cells, which could lead to aberrant differentiation or apoptosis 
of neural progenitor cells 306.   Further studies have also shown that ZIKV infection disrupts neural 
development in the brains of embryonic and neonatal mice 387,391 as well as human brain organoids 
392,393.  This is at least partially due to the action of the ZIKV nonstructural protein NS2A, which has been 
shown to degrade adherens junction proteins in the cortex of embryonic mice, which leads to reduced 
proliferation and premature differentiation of radial glial cells, and also disrupts the positioning of 
neurons 394.  Currently, these are the primary mechanisms thought to lead to microcephaly and other 
neurological disorders associated with CZS. 
One of the main characteristics of ZIKV-induced GBS is the demyelination of cells in the 
peripheral nervous system (PNS) 395.  A recent study by Cumberworth et al. showed that ZIKV infection 
causes both demyelination (i.e., failure of myelin to form normally) and demyelination (i.e., loss of 
previously formed myelin) in murine neuronal cell cultures 396.  Myelinating oligodendrocytes and axons 
in the central nervous system (CNS) were shown to be particularly vulnerable to damage during ZIKV 
infection.  This mirrors Chimelli’s postmortem analysis of neonates with CZS, which found that the 
hemispheric white matter lacked oligodendrocytes and myelin, and axonal changes had occurred in the 
brainstem and deep grey nuclei 397.  However, unlike CNS cells, peripheral nervous system (PNS) cells 




cause of ZIKV-associated GBS.  Instead, an autoimmune response triggered by a ZIKV infection leads to 
demyelination in the PNS, and thus GBS is only indirectly caused by ZIKV.  
Pathogens are thought to initiate or exacerbate autoimmune response is a variety of ways. One 
plausible explanation for the induction of autoimmunity is through molecular mimicry, in which the 
sequence or structure of viral protein antigens mimic self-antigens 398.  In a recent study, Koma et al. 
showed that portions of the ZIKV envelope protein are structurally similar to C1q, a component of the 
human complement system that is involved in immunity, synaptic organization, and autoimmune 
disease 399.  They also showed that ZIKV infection induced C1q-specific antibodies, which could 
contribute to the development of ZIKV- associated GBS, microcephaly, and thrombocythemia 399.  
Similarly, Homan et al. used computational analysis to compare the amino acids sequences of predicted 
ZIKV B cell epitopes to human proteins 400.  They found that ZIKV epitopes mimic a variety of human 
proteins, such as proNPY and NAV2, which are essential for neurological function and embryonic 
development.  By mimicking these proteins, ZIKV could elicit an autoimmune response in human hosts 
that compromises the function of these proteins.    Once these autoantibodies responses are induced, 
PNS damage may occur in several ways.  One current theory on autoimmune demyelination of PNS cells 
involves the binding of antibodies to epitopes on the outer surface of the myelin sheath, followed by 
complement activation, and macrophage invasion 228.  Another mechanism for the autoimmune 
destruction of PNS cells posits that acute motor axonal neuropathy occurs when autoantibodies bind to 
gangliosides, an important component of peripheral nerve cells, leading to the formation of a 
membrane-attack complex, which ultimately causes nerve-conduction failure and axonal degradation 
228,401.  Thus, while ZIKV neuropathogenesis is still not fully understood, a lot of effort has gone into 




ZIKV envelope protein 
As previously mentioned, mature ZIKV particles contain 90 M protein dimers and 90 E protein 
dimers that form an icosahedral shell 289,290.  Most of the outer surface of the virion is comprised of E 
protein dimers, while the M protein dimers form transmembrane domains beneath the E proteins and 
therefore remain mostly unexposed 288.  The ZIKV E protein mediates binding to host cell receptors and 
entry into host cells and is the target of many neutralizing antibodies 242,244,372,402.  The most potent ZIKV-
neutralizing mAbs are directed against the E protein epitopes 244,251,372.    
The E protein contains approximately 500 amino acids organized into four domains: a pair of 
transmembrane domains and three ectodomains (Figure 7) 289,368. Domain I (DI) is a β-barrel-shaped 
domain located in the middle of the E protein that contains the N terminus and a glycosylation site and 
is involved in envelope structural organization.  Domain II (DII) is an elongated finger-like domain that 
flanks DI and contains the fusion loop, which is involved in the pH-dependent fusion of the virus with 
host cell membranes 290, and the E-protein dimerization interface.  Domain III (DIII) is a C-terminal 
immunoglobulin-like domain that flanks the other side of DI 403, and likely includes the receptor-binding 
region that mediates attachment to host cells 250,289,290. 
Notable features of the flavivirus envelope protein 
The fusion loop (FL) is an internal hydrophobic loop composed of approximately 14 amino acids 
at the distal end of domain II (Figure 7b)  404.   Conformational changes occur when virions are exposed 
to low pH conditions (Figure 6), exposing FL and allowing it to interact with the endosomal membrane of 
the host cell to promote the fusion process and subsequent entry into the cell 290,405.  FL is a dominant 
antigenic site 406,407 and studies in both mice and humans have shown that FL mAbs make up 
approximately 50% of all E-binding mAbs elicited by ZIKV 244,251 as well as the E-binding mAbs elicited by 
other flaviviruses 408,409.  FL mAbs have been shown to neutralize DENV, YFV, and WNV 344,350,368,410,411, 






Figure 7. Structure of Zika virus particles and E proteins.  a) Surface representation of the herringbone arrangement of E dimers 
at the surface of a mature Zika virus particle. b) Ribbon diagrams of the Zika virus E protein dimer in a side and top view, 
respectively. Asparagine (N)-linked carbohydrates (glycans) are shown as light blue spheres. TM, transmembrane. The three E 
protein domains are displayed in red (DI), yellow (DII), and blue (DIII), and the DI-DIII as well as DIII-stem linkers are shown in 
purple. The fusion loop at the tip of domain II is shown in orange 366.  Franz X. Heinz, and Karin Stiasny Microbiol. Mol. Biol. Rev. 
2017; doi:10.1128/MMBR.00055-16, Figure 1, E and G. Reproduced and amended with permission from the American Society 




that the fusion loop region is highly conserved among flaviviruses 368 and suggests that FL could be used 
as an antigen to create a pan-flavivirus vaccine 414.   
The glycan loop (GL) is another distinguishing feature of flavivirus envelope proteins 289,290 
(Figure 7b).  The majority of flaviviruses, including ZIKV, have a single N-linked glycan attached to 
N153/154 in a looping region of DI. This conserved feature has been shown to play a role in virion 
assembly 415,416, enhancing transmission in mosquitoes 417, and increased virulence in mammals 418-420.   
For example, in DENV-4, removing N153 led to an increase in neurovirulence 421, and ablating both DENV 
E-protein glycans led to increased infectivity of insect cells, but also led to decreased virion release in 
both insect and mammalian cells 422.  Furthermore, GL is slightly longer on ZIKV, WNV, and JEV  as 
compared to TBEV, YFV, and DENV, which has been hypothesized to contribute to their neurovirulence 
290.  The ZIKV GL contains positively charged amino acids (R138, R164, and K166,) making it hydrophilic 
and it also contains the only glycosylation site on the ZIKV envelope protein, Asn154 289,290,368.  In ZIKV 
envelope protein dimers, the GL of one E monomer interacts with the FL region on the other E 
monomer, which contributes to the stability of the E dimer 423.  Goo et al. demonstrated that GL 
regulates antigenicity of ZIKV by modulating access to FL epitopes and/or overall E protein conformation 
424.  Fontes-Garfias et al. also studied the function of ZIKV N-linked glycosylation of residue N154.  A 
mutant virus encoding N154Q, and therefore lacking any glycosylation, showed improved attachment, 
virion assembly, and infectivity in C6/36 (mosquito) cells 425.  However, in BHK and Vero cells, the 
mutation did not affect viral replication.  Interestingly, the N154Q mutant ZIKV showed less virulence 
than WT ZIKV in mice but elicited a comparable level of neutralizing antibodies, which protected mice 
from a subsequent WT ZIKV challenge.  The authors noted that similar in vivo versus in vitro 
discrepancies were seen in previous flavivirus glycosylation studies, and postulated that this might be 
due to “ lack of cellular factors and complex immune systems in cell lines” 425.  Annamalai et al. 




pass through the blood-brain barrier 426.  However, this glycosylation site is conserved in both 
neuroinvasive and non-neuroinvasive flaviviruses, indicating that additional elements are also required 
for neurotropism.  In addition,  Goo et al. showed that non-glycosylated  ZIKV particles could still infect 
Raji cells expressing DC-SIGN receptors, and therefore hypothesized that a glycan on the M protein 
might be able to facilitate entry of partially mature viral particles 424.  Wen et al.  suggests that N154 
serves to antagonize  the vector’s immune defense, allowing ZIKV to invade the vector midgut and 
thereby enhance transmission 427.    In summation, while the exact biological function of the glycosylated 
N154 on ZIKV E has not yet been fully determined, it likely plays a role in assembly and infectivity 428 and 
might also be involved in neuroinvasion and vector competence.   
ZIKV lineages and polymorphisms 
Following the 1947 discovery and isolation of ZIKV in the forests of Uganda, ZIKV circulated for 
decades in Sub-Saharan African and Southeast Asia only sporadically manifesting as a mild viremia that 
posed little threat to humans 209,429.  During this time, less than 20 cases of ZIKV were documented 430.  
The 2007 Yap Island outbreak marked the first time ZIKV was in the Western hemisphere as well as the 
first large-scale outbreak of ZIKV ever reported 210,431.  The 2013 outbreak in French Polynesia and the 
subsequent 2015 outbreak in the Americas demonstrated that ZIKV infection could lead to severe 
neurological complications 219,229, raising the question of how ZIKV acquired enhanced pathogenicity and 
increased transmissibility.  The answer to this question may lie in the genetic evolution of ZIKV.  
Phylogenetic and epidemiological data suggest that around 1946 ZIKV diverged into two lineages: the 
African lineage and the Asian lineage 267,268,432-434.  The African lineage includes the prototype 1947 
Ugandan MR 766 strain, as well as strains from Nigeria (IbH 30656), Senegal (ArD 41519), and the 
Central African Republic collected between 1968 and 2001 435.  Historically, strains from the African 
lineage of ZIKV have only been responsible for sporadic infections that resulted in mild febrile  




Cambodian isolate from 2010, and all contemporary Asian strains 436.  Furthermore, genetic and protein 
analyses have shown that the strains responsible for the outbreak in French Polynesia and the American 
epidemic are also part of the Asian lineage of ZIKV 267,268,430,437-439.  Thus, it has been hypothesized that as 
ZIKV spread eastward from African to Asia, genetic changes occurred and that these genetic changes are 
responsible for increased host infectivity, enhancement of vector fitness and transmissibility, as well as 
the increased pathogenicity seen in the recent ZIKV outbreaks 434,440,441.     
Various in vitro, ex vivo, and in vivo studies comparing African strains to Asian strains have also 
provided evidence that the two lineages are phenotypically different, primarily in terms of virulence and 
pathogenicity 442.  For example, African strains of ZIKV are better at infecting and replicating in cultured 
human neural stem cells than Asian stains 443, and African strains replicated to higher titers, infected 
more cells, and induced cell death more frequently than Asian strains in cultured human neural 
progenitor cells 438.  Comparatively few in vivo studies have been done on lineage-specific phenotypic 
differences, but experiments using various mouse models of ZIKV infection also suggest that African 
strains are more virulent and pathogenic than Asian strains 296,435,444-446.  Despite this plethora of 
experimental evidence suggesting that African strains are more pathogenic and more virulent, no 
epidemics or severe complications have been documented in association with African strains even 
though seroprevalence data shows that ZIKV is circulating in Africa 447-449.  Alternatively, a handful of 
studies have demonstrated that Asian-lineage strains are equally or more pathogenic and virulent than 
African-linage strains.  In a study by Vielle et al., cultured human monocyte-derived dendritic cells 
showed similar susceptibility to African and Asian strains and both strains induced similar infection 
profiles (as measured by IFN-β, IFN-λ, and ISGs) 450, and in a ZIKV infection model of vascular endothelial 
cells, an Asian strain exhibited higher viral RNA replication rates and induced more cells death than an 
African strain 285.  Asian strains of ZIKV showed higher infectivity rate and increased cell death compared 




neurospheres more significantly than African strains, suggesting that Asian strains lead to the death of 
more neural cells 392.   
Moreover, a study by Liu et al. revealed that the Asian lineage of ZIKV more effectively infects 
Ae. aegypti mosquitoes 451.  Taken together, these disparate findings indicate that factors other than 
lineage might play a more significant role in phenotypic differences observed the various ZIKV strains.  
For example, the differences could be due to strain-specific characteristics, such as the passage history 
of viral isolates or the type of animal the virus was isolated from (human, mosquito, or non-human 
primate).  This is supported by data showing that even strains that are closely related in a 
spatiotemporal sense exhibit phenotypic differences 445,452.  Alternatively, the conflicting results of 
studies on the phenotypic differences between ZIKV lineages have been attributed to the quality of 
African-lineage ZIKV samples.  For example, the prototypic African strain, MR766, was passaged around 
150 times in the brains of suckling mice 268,453.  This extensive passaging likely led to mutations that 
made the MR766 strain progressively more neurovirulent in mice and less pathogenic in humans as this 
issue has arisen with other flaviviruses 454,455.  
Like all RNA viruses, changes are constantly introduced into ZIKV’s genome via error-prone 
replication.  The majority of these mutations do not alter viral fitness and are thus removed by purifying 
selection.  However, some of these mutations can increase viral fitness in mosquitoes and/or mammals, 
and therefore are maintained over time within sublineages.  Despite the aforementioned challenges 
with trying to categorize lineage-specific ZIKV phenotypic differences, amino-acid differences between 
lineages could hold clues to the cause of the recent ZIKV epidemics.   Concerning the phylogenetics of 
ZIKV, at least 50 lineage-specific amino acid differences have been documented 437,438,445,456, and Tripathi 
et al. found that these differences primarily occur in specific regions of the prM, E, NS2A, or NS5 
proteins 435.  Amino acid substitutions within Asian –lineage strains have also been implicated in the 




the postnatal effects of infection with a contemporary American strain (VEN/2016) to a pre-epidemic 
Asian strain from Cambodia (CAM/2010) and showed that the VEN/2016 strain was more effective at 
infecting murine brain cells and led to more severe microcephaly 391.  A subsequent paper by the same 
group revealed that an S139N substitution in the prM protein of the VEN/2016 strain substantially 
increased ZIKV infectivity of human and mouse and neural progenitor cells, and led to a more severe 
microcephalic phenotype in fetal mice as well as increased mortality rates in neonatal mice 452.  This 
substitution first emerged in 2013 during the outbreak in French Polynesia and has been stably 
maintained since then 434,441.  An alanine to valine substitution at position 188 (A188V) of the NS1 has 
been shown to increase ZIKV infectivity and prevalence in their mosquito hosts, which could have led to 
the increase in transmission thought to be at least partially responsible for the recent ZIKV epidemics 275.   
Xia et al. also demonstrated that the A188V mutation led to increased evasion of host interferon 
induction 311.  With regard to the E protein, Chavez et al. documented two mutations in domain III 
(V603I and D679E) that were not found in pre-epidemic Asian strains, and thus might have contributed 
to viral fitness that led to the recent ZIKV epidemics 457.  In conclusion, it does appear that mutations 
might have contributed to increased virulence and transmissibility of ZIKV seen in recent epidemics.  
However, it is also possible that accumulated mutations did not lead to increased virulence and that all 
strains have similar virulence.  Therefore the only reason severe outcomes were not seen before the 
2013 French Polynesian outbreak is that there were not enough cases of ZIKV in previous outbreaks, so 
the rare severe forms of ZIKV did not manifest.  Evidence suggests that the phenotypic differences 
observed are likely the result of genetic changes as well the greater number of patients observed during 
the recent ZIKV epidemics 440.   
Zika vaccine candidates 
The ideal ZIKV vaccine candidate would be safe, affordable, stable, and induce long-lasting 




women and their fetuses.  And, as previously mentioned, due to the antigenic and structural similarity of 
flaviviruses, the risk of ADE should also be considered.  Historically, flavivirus vaccines have been made 
using inactivated or live-attenuated viruses, and this approach has yielded effective vaccines against 
YFV, JEV, and TBEV 51.  Table 4 outlines the ZIKV vaccine candidates that are currently in clinical trials, 
but there are many other candidates that have not yet reached the clinical trial phase of development 
458-460.  Takeda, Valneva, WRAIR, and Bharat Biosciences are taking a traditional approach and have 
created purified-inactivated ZIKV vaccine candidates.   Five nucleic acid vaccine candidates encoding for 
pre-membrane and envelope protein (prM/E) are also in the pipeline, and each utilizes a different 
system to deliver the nucleic acid into cells.  The two NIAID candidates use a pressure-based delivery 
system 69, GeneOne Life Sciences uses electroporation 68, and Moderna has a nanoparticle-based 
delivery system for their mRNA ZIKV vaccine candidate 70.  Themis Biosciences has developed a viral 
vector-based live-attenuated vaccine candidate using their Themaxyn ® platform, which uses the 
measles virus vector to express ZIKV prM/E 461.  Similarly, NIAID has created a live-attenuated vaccine 
using a DENV-4 backbone to express ZIKV prM/E 462.  Since these vaccines are still in clinical trials, it 
remains to be seen whether any of these approaches will produce an effective, safe, and affordable 












Table 4. Zika vaccine candidates currently in clinical trials, including the vaccine platform used, the immunogen, and the 
companies and/or government agencies involved in their development.  WRAIR = Walter Reed Army Institute of Research, 
NIAID = National Institute of Allergy and Infectious Diseases, BIDMC = Beth Israel Deaconess Medical Center, BARDA = 
Biomedical Advanced Research and Development Authority. 
Candidate 
Vaccine Platform Immunogen Company Phase References 
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MATERIALS AND METHODS 
Zika virus epitope selection 
The surface of the ZIKV virion is almost completely covered by envelope protein dimers, so most 
ZIKV-neutralizing mAbs target the E protein.  For this reason, almost all ZIKV vaccine candidates contain 
the E protein or portions of the E protein.  We selected two regions of the ZIKV E protein for display on 
TMV nanoparticles: the fusion loop and the glycan loop (Table 5).  The fusion loop is highly conserved 
region and thus would serve to elicit antibodies that could neutralize multiple flaviviruses.  Thus, the 
fusion loop epitope was chosen because it could potentially serve as a universal flavivirus vaccine.  On 
the other hand, the glycan loop epitope is specific to ZIKV, so the antibodies it elicits should not cross-
react with other flaviviruses.  This could potentially negate any vaccine-induced ADE.  The amino acid 
sequences are from ZIKV strain BeH823339, an Asian-lineage Brazilian strain collected in 2015 
(GenBank accession no. AMK49164.2) 432.    









Loop 97-109 VDRGWGNGCGLFG 5.80 / 1.337 kDa II 
Glycan 
Loop 145-165 GSQHSGMIVNDTGHETDENRA 4.72 / 2.255 kDa I 
Expression vectors and cloning 
Two plasmids (pCR2.1) were ordered from Eurofins Genomics: these contained the synthetic 
gene for the TMV coat protein with each of the ZIKV epitopes (Table 5) genetically fused to the C-
terminus.  The lyophilized plasmids were resuspended per the manufacturer’s instructions and then 
used as a template for PCR-amplification of the CP-epitope sequences in preparation for NEBuilder HiFi 




6) and were designed using NEBuilder Assembly Tool and ordered from Integrated DNA Technologies.  
PCRs were then performed using the appropriate primers and annealing temperatures from Table 6 and 
Q5® High-Fidelity DNA Polymerase (New England Biolabs) according to the manufacturer’s instructions 
475.  Each PCR was performed in duplicate 50 µL reactions so that there would be enough DNA for the 
assembly reactions.  Additionally, each set of primers was used to run a no template control in which no 
template (i.e., plasmid DNA) was included to ensure there were no extraneous nucleic acids 
contaminating the reaction components.  No amplification controls, which contained no DNA 
polymerase, were also included. Positive controls could not be run because there were no templates 
that contained both the pTRBO overlaps and the CP-epitope sequences available.  
Table 6. Primers used for PCR amplification of CP-GL and CP-FL. 
Primer   Sequence (5’ - 3’)a Annealing Temperatureb 
Expected product 
size  
CP-FL Fwd ttcttgtcattaattaacggATGTCCTATTCCATAACCAC 
59.3 °C 559 
CP-FL Rev ctacctcaagttgcaggaccTTAGCCAAAGAGTCCACAAC 
CP-GL Fwd ttcttgtcattaattaacggATGAGCTATTCCATAACAAC 
57.3  °C 583 
CP-GL Rev ctacctcaagttgcaggaccTTAGGCACGATTCTCATC 
a  The lowercase portions of the primer sequences are the non-priming pTRBO overlap sequences which are required for HiFi 
Assembly. The uppercase portions of the primer sequences correspond to the gene-specific sequence of each CP-epitope, 
which are required for template priming. 
b Annealing temperatures for primer pairs determined using NEBuilder Assembly Tool 476.  
 
Nucleic acid loading dye was added to the PCR products, which were then run on a 1.4% agarose 
gel with ethidium bromide for 2 hours at 100 mAmps.  To minimize UV damage of any amplified DNA, 
the UV 365 setting was used while the bands containing the PCR products were excised from the gel. 
The amplified DNA was then purified from the excised gel bands using the Wizard® SV Gel and PCR 
Clean-Up System (Promega).   
pTRBO in Escherichia coli K12 strain DH5α was propagated in LB containing 50 µg/mL of 




Monarch Plasmid Miniprep Kit (New England Biolabs).  Restriction endonucleases AvrII and NotI (New 
England Biolabs) were used to double-digest 2 µg of pTRBO (1 µg in two 50 µL digestions) per the 
manufacturer’s instructions.  To ensure both endonucleases were functional, 1 µg of pTRBO was 
digested with AvrII only, and 1 µg of pTRBO was digested with NotI only. Nucleic acid loading dye was 
added to the digestions, which were then run on a 0.6% agarose gel with ethidium bromide for 82 
minutes at 100 mAmps.  To minimize UV damage of any amplified DNA, the UV 365 setting was used 
while an image was taken with the Azure gel imager and the bands containing the PCR products were 
excised from the gel.  The amplified DNA was then purified from the excised gel bands using the Wizard® 
SV Gel and PCR Clean-Up System (Promega).   
Digested pTRBO and the CP-epitope inserts were assembled using the NEBuilder® HiFi DNA 
Assembly Master Mix (New England Biolabs) per the manufacturer’s instructions.  The assembly reaction 
mixtures were then transformed into 10-beta Competent E. coli (New England Biolabs) per the 
manufacturer’s instructions, and after 2.5 hours of incubation in SOC media at 37°C, the transformed 
cells were plated on LB-kan plates.  The plates were incubated overnight at 37°C.  Insert size was 
confirmed via colony PCR for eight pTRBO CP-FL colonies using the primers from Table 6.  Agarose gel 
electrophoresis showed that all colonies had the right size insert, so two colonies were chosen from 
each construct and grown in LB + kan (50 µg/mL) and incubated at 37°C overnight.  Plasmid DNA was 
isolated using the Monarch Plasmid Miniprep Kit (New England Biolabs), and the plasmids were sent 
with the appropriate primers (Table 7) to Eurofins Genomics for sequencing.  Each plasmid was 
sequenced with three separate primers to ensure the accuracy of sequencing results.  Sequences were 







Table 7. Primers used for sequencing and colony PCR. 
Primer Sequence (5’ - 3’) Used to sequence 
pTRBO fwd seq        tccatctcagttcgtgttcttg pTRBO-CP-FL 
pTRBO-CP-GL pTRBO rev seq tgactacctcaagttgcaggac 
Fusion loop rev seq       GCCAAAGAGTCCACAACCAT pTRBO-CP-FL 
Glycan loop for seq   GCCTTAGGCAATCAGTTCCA pTRBO-CP-GL 
Agroinfiltration of plants 
The recombinant pTRBO plasmids were transformed into chemically competent A. tumefaciens 
strain GV3101, plated on LB-KGR plates and incubated at 30°C overnight.  Single colonies were chosen 
and cultivated at 30°C in LB containing kanamycin (50 µg/mL), gentamicin (25 µg/mL), and rifampicin (10 
µg/mL) to select for recombinant clones.  For infiltration, A. tumefaciens cultures were expanded in L-
MESA to an optical density (OD600nm) of approximately 1.0.  The cells were then spun down, resuspended 
in an equal volume of AIM, and incubated overnight at room temperature.  100 mL of AIM culture was 
diluted in 1 L of water and then used to vacuum infiltrate N. benthamiana plants at -70 kPa for 5 
minutes.   
Plant growth and incubation 
N. benthamiana plants were grown in soil from seeds under controlled conditions (16 hr of light 
at 24°C and 8 hr of dark at 21°C) for 5-6 weeks prior to infiltration.  After infiltration, the plants were 
incubated for 6-14 days under the same controlled conditions used for pre-infiltration growth.  Plants 
were monitored for signs of WT TMV infection (mosaic patterns on leaves, curling of the upper leaves, 
and upper stem flexion) or necrotic lesions.   
Viral nanoparticle extraction, purification, and characterization 
The extraction process is outlined in Figure 8.  To extract the viral particles, infected leaves were 
homogenized in 4 volumes (w/v) of grind buffer (50 mM sodium acetate, 0.1% sodium metabisulfite, 




precipitate the virus, the resulting supernatant (i.e., green supernatant) was mixed with 40% PEG (v/v) 
to achieve a final concentration of 4 %, 5 M NaCl was added to achieve a final concentration of 0.68 M, 
and the solution was incubated on ice for 1 hr.  Following centrifugation (15,000 x g for 25 min at 4°C), 
the pellet (i.e., the PEG pellet) was resuspended in 50 mM phosphate buffer.  A clarification step was 
then performed by centrifuging the resuspended pellet (7,000 x g for 7 min at room temperature) and 
collecting the supernatant (i.e., the clarification supernatant).  This process repeated with leaves from 
non-infected plants, and these process samples served as negative controls.  Process samples were then 
analyzed by SDS-PAGE and western blot.   
 
 
Figure 8. Extraction of TMV from infected plant tissue. Infected plant tissue is homogenized in grind buffer and the filtered 
through cheesecloth to produce “green juice”.   The green juice is centrifuged at 8,000 x g for 25 min at 4°C, which separates 
the “green supernatant” from the “green pellet”.   PEG and NaCl are added to the green supernatant, followed by incubation on 
ice for 1 hr.  Following centrifugation (15,000 x g for 25 min at 4°C), the PEG pellet is resuspended in phosphate buffer then 
clarified by low-speed centrifugation (7,000 x g for 7 min at room temperature).  The boxes outlined in black indicate the 




Sucrose density gradient centrifugation 
Sucrose density gradient ultracentrifugation was used to further purify the TMV-GL and WT TMV 
viral nanoparticles following extraction with PEG-based on a protocol by Bruckman et al. 477.   Briefly, 
viral nanoparticles were loaded on a 10-40% sucrose gradient and ultracentrifuged at 96,000 x g for two 
hours at 4°C using a Beckman Coulter SW 28 rotor.  The light-scattering region (see Figure 14) was 
collected and diluted in 10 mM phosphate buffer and then ultracentrifuged at 27,000 rpm for 23 hours 
at 4°C using a Beckman Coulter SW 28 rotor.  The supernatant was discarded and the viral pellet 
resuspended in endotoxin-free PBS by placing it in the 4°C fridge for approximately 18 hours.  The 
resuspended pellet was centrifuged for 15 minutes at 7,500 x g, and the supernatant containing the 
purified viral nanoparticles was stored at 4°C.  Process samples were run on SDS-PAGE as previously 
described, and percent purity was calculated using AzureSpot software.    
SDS-PAGE and western blotting 
Laemmli sample buffer was added to the extraction process samples and heated at 95°C for 5 
min.  Proteins were separated on a 4-20% Tris-Glycine SDS-PAGE gel at 100 volts, followed by staining 
with Bio-Safe Coomassie (BioRad) or transferred to a nitrocellulose membrane for Western blot analysis.  
For western blotting, SDS-PAGE gels were transferred onto 0.2 µm nitrocellulose membrane (BioRad) for 
90 mins at 400 mAmps.  The membrane was blocked with 5% (w/v) nonfat dry milk (First Street) in TBS 
at room temperature for 1 hour then incubated with a primary antibody in blocking buffer overnight at 
4°C.  After washing with TBS and TBST, the membrane was incubated with goat anti-rabbit HRP-
conjugated secondary antibodies (BioRad) (1:3,000 dilution) for 1.5 hr at room temperature. After 
another round of washing, a chemiluminescent signal was generated by incubating the membrane for 5 
min with Clarity Western ECL Substrate (BioRad) and was documented using the Azure c500 (Azure 
Biosystems).  Three different primary antibodies were used for these western blots were: 1) a 1:2,000 




full-length recombinant envelope protein from the ZIKV strain BeH815744 (a Brazilian strain from the 
Asian lineage that includes the complete glycan loop) and was produced in mammalian cells (i.e. likely 
glycosylated at Asn154); 2) a 1:1,000 dilution of anti-ZIKV envelope protein polyclonal antibodies 
(Abiocode) raised in rabbits immunized with amino acids 140-180 from the MR766 strain (missing VNDT 
motif in the glycan loop) recombinantly expressed in E. coli, and 3) a 1:5,000 dilution of anti-DENV-2 
envelope protein polyclonal antibodies (Thermo Fisher Scientific) raised in rabbit immunized with amino 
acids 1-495 of the DENV type 2 envelope protein recombinantly expressed in E. coli.  The positive control 
for all three blots was recombinant full-length ZIKV envelope protein (eEnzyme) from strain a Brazilian 
strain (BeH815744) that was expressed in E. coli.  The Pierce™ BCA Protein Assay Kit (Thermo Scientific) 
was used to estimate the concentration of the TMV-GL viral nanoparticles, and these concentrations 
were used to calculate yield.  
Preparation of TMV-E and rE (Novici Biotech) 
Recombinant ZIKV envelope protein (ZIKV-E) (amino acids 291-698, GenBank accession no. 
AMK49164.2) with an N-terminal extensin secretory signal peptide from Nicotiana plumbaginifolia and a 
C-terminal InaD Pdz domain (amino acids 2-98, GenBank accession no. 1IHJ_A, cys53ala mutation) and 
6xHis purification tag were codon-optimized for expression in Nicotiana and cloned into a tobamovirus 
iBioLaunch vector (iBio Inc.).  ZIKV-E with the extensin secretory signal peptide and a C-terminal 6xHis 
purification tag; KDEL was also cloned into an iBioLaunch vector.  The plasmids were transformed into 
Rhizobium radiobacter strain GV3101 and transiently expressed in Nicotiana benthamiana by vacuum 
infiltration of GV3101 478.  5 or 6 days post-infiltration, plants were ground in 50mM CAPS 10.9, 500mM 
NaCl, 200mM Sucrose, 40mM Ascorbic Acid, 2mM PMSF.  The lysate was filtered through spun-bonded 
polypropylene fabric, centrifuged at 30,100 x g, acidified with 1 M NaOAc pH 4.5, centrifuged, 




then purified from the lysate by IMAC with Nickel-NTA agarose (Qiagen) or using a 1 ml HisTrap ™ HP 
(GE Healthcare), dialyzed into PBS, and concentrated with a 10 kDa cutoff spin concentrator. 
The TMV-EFCA dock-and-lock virus scaffold was cloned by adding the amino acid sequence 
“EFCA” from the NorpA protein to the C-terminus of the TMV coat protein in a TMV vector 5.  RNA was 
transcribed using the Ambion mMESSAGE mMACHINE kit (Invitrogen) and encapsidated with purified 
TMV U1 capsid protein 6.  The virus was then rub-inoculated onto N. benthamiana plants by manual 
abrasion with diatomaceous earth.  Leaf tissue was harvested about 12 days later, and the virus was 
purified by PEG precipitation 7.    
ZIKV-E-TMV VLPs were prepared using the “Dock-and-Lock” method 8 to covalently attach the 
ZIKV-E-InaD fusion protein to TMV-EFCA virus scaffold.  The VLP was then separated from unbound ZIKV-
E-InaD by precipitation of the VLP with 0.5 M NaCl/4% PEG.  The supernatant was removed, and the 
VLP resuspended in PBS.  Docking was confirmed by Coomassie-stained SDS-PAGE gels of both reduced 
and non-reduced samples (Figure 9).  
Immunization of mice and generation of hybridomas (USDA) 
SP2/0 mouse myeloma cells and all hybridoma cells were maintained in hybridoma medium 
(HM), consisting of Iscove's modified Dulbecco's Minimal Medium (Sigma #I-7633) containing NaHCO3 
(36 mM) and glutamine (2 mM)] supplemented with 10% fetal calf serum (cHM).  Hybridomas were 
selected following cell fusion using HAT selection medium prepared by adding Sigma 50 x stock HAT 
media supplement to 1x hypoxanthine (5 μM), aminopterin (0.2 μM), and thymidine (0.8 μM) to cHM. 
Macrophage conditioned medium (MφCM) was prepared as described in Sugasawara et al. 479.  A 






Figure 9. SDS-PAGE of ZIKV rE-InaD fusion protein docked to TMV-EFCA virus scaffold. ZIKV rE-InaD runs at approximately 58 
kDa (lanes 5 and 7).  When docked to a TMV coat protein, ZIKV rE-InaD runs at approximately 80 kDa (lane 3, band indicated by 
black arrow).  Under reducing conditions, docked rE-InaD runs as its constituent parts (i.e., rE-InaD at 58 kDa, and TMV-EFCA at 
20 kDa). Gel image kindly provided by Novici Biotech. Additional information about the “Dock-and-Lock” method can be found 
in chapter 2.  
Five groups of three-month-old female BALB/c mice (Simonsen Labs) were intraperitoneally 
immunized with 25 µg of antigen:  TMV-GL, TMV-E, rE, or a control (TMV or sterile PBS) and adjuvant 
(Sigma Adjuvant System, Sigma-Aldrich).  Boosters were given approximately every 3 weeks for 4 
rounds.  Sera were obtained and evaluated for reactivity to the various target antigen using a direct-
binding ELISA format.  Black Nunc Maxisorp 96-well flat-bottom plates were coated with antigen at 
30 μL/well of a 1.0 μg mL− 1 in 0.05 M sodium carbonate buffer, pH 9.6 overnight at 4 °C. The coating 
solution was aspirated and non-coated sites blocked by adding 300 μL well− 1 of 3% non-fat dry milk in 
Tris-buffered saline containing 0.05% Tween-20 (NFDM-TBST) and the plates were incubated for 1 h at 
37 °C.  The plates were then washed 3 times with Tris-buffered saline containing 0.05% Tween-20 
(TBST). Next, sera were added (30 μL well− 1) and the plates were incubated at 37 °C for 1 hr. Plates were 




(Sigma, St. Louis, Mo) was added and the plates incubated for 1 h at 37 °C.  The plates were then 
washed 3x with TBST.  Freshly prepared luminescence substrate (SuperSignal West Pico 
chemiluminescence) was added (30 μL/well) according to the manufacturer's recommendation.  The 
plates were incubated for 3 min at room temperature and luminescent counts recorded using the Victor 
3 (Perkin Elmer).  All protocols were approved by the Western Regional Research Center Institutional 
Animal Care and Use Committee (Protocol # 16-1). 
Mice that were positive for reactivity to antigen were immunized once more three days before 
the start of cell fusion.  Mice were euthanized, and their splenocytes were fused with SP2/0 myeloma 
cells using polyethylene glycol as previously described in 481.  Following cell fusion, the cells were 
suspended in 100 mL of HAT selection medium supplemented with 10% fetal calf serum and 10% 
MφCM, dispensed into ten, 96-well tissue culture plates, and incubated for 10 to 14 days at 37 °C in 5% 
CO2 before screening for antibody production.  
Supernatants from cell fusion plates were screened using a direct-binding ELISA. Clear Nunc 
Maxisorp microtiter plates were rinsed with distilled water and coated by incubating 100 μL/well of a 
1.0 μg /mL rE (ZIKV) in 0.05 M sodium carbonate buffer, pH 9.6 overnight at 4 °C.  The coating solution 
was aspirated and non-coated sites blocked by adding 300 μL well− 1 of 3% non-fat dry milk in Tris-
buffered saline containing 0.05% Tween-20 and the plates were incubated for 1 h at 37 °C.  The plates 
were then washed 3 times with Tris-buffered saline containing 0.05% Tween-20. Next, cell culture 
supernatants were added (100 μL per well) and the plates were incubated at 37 °C for 1 h.  Plates were 
again washed 3x and 100 μL well per well of a 1/1000 dilution of peroxidase-conjugated goat anti-mouse 
sera (Sigma) was added and the plates incubated for 1 h at 37 °C.  The plates were then washed 3x with 
TBST.  150 μL well per well of K-Blue enhanced substrate (TMB) (Neogen) was added to each of the 10-
96 well plates until color development was sufficient.  The signal was read at 650 nm on the VersaMax 




by limiting dilution (3x) with screening using direct ELISA 480.  The 26 hybridomas that were created are 
outlined in Table 8. 
Table 8. Hybridomas created from TMV-GL, TMV-E, and rE-vaccinated mice.  
 
Evaluation of serum antibody levels by ELISA (USDA) 
Mouse sera were analyzed for glycan loop-specific antibody responses by ELISA.  Briefly, 96-well 
plates were coated with antigen in carbonate buffer (0.03 M Na2CO3/0.07 M NaHCO3, pH 9.6), incubated 
overnight at 4°C, and then blocked with 5% BSA for 1 hour at room temperature.  Pooled or unpooled 
serially diluted mouse sera were added to the plates and then incubated overnight at 4°C.  Following 
three washes with PBS, the plates were incubated with HRP-conjugated goat anti-mouse IgG 
(1:2000, BioRad) for 1 hr at room temperature then washed three times with PBS.  OPD substrate 
(Sigma) was added, and the absorbance at 450nm was measured on a SpectraMax Plus plate reader 
(Molecular Devices).  The antibody endpoint titers were defined as the reciprocal of the highest serum 
dilution that gave a reading above the cutoff.  Cutoff values were determined for each dilution of the 
pooled adjuvant only serum as described in Frey et al. 482.  
Flow cytometry-based neutralization assays (LJIAI) 
A flow cytometry-based assay was used to measure the capacity of the mouse sera and the 




by de Alwis et al. 483.  Briefly, ZIKV and sera or hybridoma supernatants were incubated for 1 hour at 37 
°C, followed by addition to U937+ DC-SIGN cells and 2 hr of incubation at 37 °C.  Cells were washed 
twice with infection media, incubated for an additional 22 hr at 37 °C, then fixed and permeabilized. 
FITC-conjugated 2H2 was used to detect ZIKV, while a phycoerythrin-conjugated anti-CD209 antibody 
was used to assess DC-SIGN expression.  Percentage of infected cells was determined using flow 
cytometry, and Prism software (GraphPad Software, Inc.) was used to calculate and plot percent 
neutralization values against Log (1/dilution).  
Human serum samples 
Four human serum samples from ZIKV-positive patients were purchased from Antibody Systems, 
and their reciprocal 90% neutralization titers (NT90) were published by Lynch et al. 484.  Details of these 
samples are provided in Table 9. 
Table 9. Details of human serum samples from Columbian ZIKV patients. Days after onset of symptoms indicates the number of 
days that passed between the onset of symptoms of ZIKV and when the serum sample was taken.  ZIKV NT90 indicates 
reciprocal dilution at which the serum neutralized 90% of virions from ZIKV strain HF/PF/2013, which was isolated during the 
outbreak in French Polynesia.   Mild symptoms of ZIKV infection include fever, skin rash, joint pain, myalgia, ocular pain, 
cephalgia, and conjunctivitis. 
 
Dot blot and ELISA analysis of Z3L1 binding  
TMV-GL, unglycosylated rE (eEnzyme), or plant-glycosylated rE were diluted in TBS spotted onto 




milk in TBS, followed by incubation with the Z3L1 mAb diluted 1:1,000 in blocking buffer and incubated 
overnight at 4 °C.  The membranes were washed three times with TBST, followed by one wash with TBS.  
The blots were incubated for 1 hr at room temperature with 1:2,000 dilution of secondary antibody 
(goat anti-human IgG – peroxidase (Sigma)) followed by the addition of Clarity Western ECL Substrate 
(BioRad) and visualization of chemiluminescence using an Azure Biosystems C500 imager with an 
exposure time of five min.  
The binding of human mAb Z3L1 to unglycosylated GL, plant-glycosylated rE, and unglycosylated 
rE (eEnzyme) was analyzed by ELISA in triplicate wells.  Briefly, 96-well plates were coated with protein 
antigens diluted to 10 ng/µL in carbonate buffer, incubated overnight at 4 °C, and then blocked with 5% 
non-fat milk in TBS for 1 hr at room temperature.  Z3L1 diluted to 10 ng/µL in blocking buffer was added 
to the plates and then incubated at room temperature for 2 hr.  Following two washes with PBST and 
one wash with PBS, the plates were incubated with a 1:2,000 dilution of secondary antibody (goat anti-
human IgG – peroxidase (Sigma)) for 1 hour at room temperature then washed as above.  OPD substrate 
(Sigma) was added, and the absorbance at 450 nm was measured on a SpectraMax Plus plate reader 
(Molecular Devices).  The background was measured as above, except blocking buffer was used instead 
of antigen.  For the unglycosylated rE antigen, anti-ZIKV rE (eEnzyme) was used as a positive control with 
a goat anti-rabbit HRP-conjugated secondary antibody (BioRad).   
Dot blots with mouse sera, human sera, or hybridoma supernatants 
TMV-GL, WT TMV, or rE (E. coli) were diluted in TBS, spotted onto nitrocellulose membrane, and 
allowed to air-dry.  The membranes were blocked for 1 hour in 10% NF milk in TBS followed by 
incubation with a 1:500 dilution of human serum/ mouse serum/ hybridoma supernatant in blocking 
buffer overnight at 4°C.  The membranes were washed 3 times with TBST, followed by one wash with 
TBS and then incubated for 1 hr at room temperature with 1:2,000 dilution of secondary antibody (goat 




Clarity Western ECL Substrate (BioRad) and visualization of chemiluminescence using Azure 
imager.  ImageJ software was used to digitally quantify the mean inverted pixels of the signal and 
corrected by that of the background.  Normalized fold changes were subsequently calculated by dividing 
the corrected mean pixels of the signal of TMV-GL by that of TMV. 
RESULTS  
TMV-FL and TMV-GL were cloned into pTRBO 
 Constructs from Eurofins were successfully PCR amplified and then gel purified, cloning into 
pTRBO, and transformed into E. coli.  Colony PCR (Figure 10) and/or sequencing (Figure 11) were used to 
confirm the plasmid sequences were correct prior to transforming into Agrobacterium and then 

















Figure 11. Example of a sequence alignment to check the sequencing results mini-prepped plasmid DNA from a pTRBO-CP-GL 
colony.  Sequence 1 shows the sequencing results from, while sequence 2 shows the expected sequence of the TMV coat 
protein with the ZIKV glycan loop genetically fused to the 3’ end (indicated by the brown letters).  Sequences aligned using 
Serial Cloner software.   
 





Seq_1  1     ---------------------------------------------------CCTTCTCAG  9 
                                                                ||||||||| 
Seq_2  301   tcagttcgtgttcttgtcattaattaacggATGAGCTATTCCATAACAACACCTTCTCAG  360 
 
 
Seq_1  10    TTTGTCTTTCTCTCTTCTGCATGGGCAGATCCGATTGAGCTGATTAACCTCTGTACCAAT  69 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   TTTGTCTTTCTCTCTTCTGCATGGGCAGATCCGATTGAGCTGATTAACCTCTGTACCAAT  420 
 
 
Seq_1  70    GCCTTAGGCAATCAGTTCCAAACACAGCAAGCTAGAACAGTGGTACAAAGGCAATTCTCA  129 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   GCCTTAGGCAATCAGTTCCAAACACAGCAAGCTAGAACAGTGGTACAAAGGCAATTCTCA  480 
 
 
Seq_1  130   GAAGTGTGGAAACCTAGTCCACAAGTTACCGTTAGGTTTCCAGACTCAGACTTCAAGGTC  189 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAAGTGTGGAAACCTAGTCCACAAGTTACCGTTAGGTTTCCAGACTCAGACTTCAAGGTC  540 
 
 
Seq_1  190   TATAGGTACAATGCAGTTTTGGATCCCTTAGTTACTGCTCTTCTAGGGGCTTTTGATACT  249 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TATAGGTACAATGCAGTTTTGGATCCCTTAGTTACTGCTCTTCTAGGGGCTTTTGATACT  600 
 
 
Seq_1  250   CGAAACAGAATCATTGAAGTAGAGAATCAAGCCAATCCAACGACTGCAGAAACGCTTGAT  309 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   CGAAACAGAATCATTGAAGTAGAGAATCAAGCCAATCCAACGACTGCAGAAACGCTTGAT  660 
 
 
Seq_1  310   GCAACTAGAAGAGTTGATGATGCTACTGTTGCGATAAGATCAGCTATCAACAACTTGATA  369 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   GCAACTAGAAGAGTTGATGATGCTACTGTTGCGATAAGATCAGCTATCAACAACTTGATA  720 
 
 
Seq_1  370   GTAGAGTTGATTAGAGGTACAGGTTCATACAATCGTTCCTCCTTTGAAAGCTCTAGTGGA  429 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   GTAGAGTTGATTAGAGGTACAGGTTCATACAATCGTTCCTCCTTTGAAAGCTCTAGTGGA  780 
 
 
Seq_1  430   CTTGTGTGGACTTCTGGTCCTGCTACTGGAAGTCAGCATTCTGGCATGATTGTGAACGAC  489 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  781   CTTGTGTGGACTTCTGGTCCTGCTACTGGAAGTCAGCATTCTGGCATGATTGTGAACGAC  840 
 
 
Seq_1  490   ACAGGACACGAAACCGATGAGAATCGTGCCTAAGGTCCTGCAACTTGAGGTAGTCAAGAT  549 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  841   ACAGGACACGAAACCGATGAGAATCGTGCCTAAggtcctgcaacttgaggtagtcaagat  900 
 
 
Seq_1  550   GCATAATAAATAACGGATTGTGTCCGTAATCACACGTGGTGCGTACGATAACGCATAGTG  609 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  901   gcataataaataacggattgtgtccgtaatcacacgtggtgcgtacgataacgcatagtg  960 
 
 
Seq_1  610   TTTTTCCCTCCACTTAAATCGAAGGGTTGTGTCTTGGATCGCGCGGGTCAAATGTATATG  669 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  961   tttttccctccacttaaatcgaagggttgtgtcttggatcgcgcgggtcaaatgtatatg  1020 
 
 
Seq_1  670   GTTCATATACATCCGCAGGCACGTAATAAAGCGAGGGGTTCGAATCCCCCCGTTACCCCC  729 
             ||||||||||||||||||||||||||||||||||||||                       







Expression of ZIKV epitopes on TMV nanoparticles in Nicotiana benthamiana 
At 6 days post-infection (DPI), the plants infiltrated with TMV-FL formed necrotic lesions, and 
the leaves were harvested and frozen to prevent further tissue death (Figure 12b).  Following PEG-
precipitation, SDS-PAGE analysis revealed that the clarification pellet contained bands of approximately 
the right size, although the band seemed to have a molecular weight very similar to the wild-type TMV 
coat protein (Figure 13a).  To increase the concentration of TMV-FL and further remove some of the 
host-cell proteins, and an additional round of PEG-precipitation and clarification were performed. 
Subsequent western blot analysis demonstrated that polyclonal anti-ZIKV envelope protein antibodies 
did not recognize the TMV-FL construct (Figure 13c), suggesting that the FL epitope was not being 
displayed on TMV.  Despite multiple further attempts, expression of TMV-FL was not successful, as the 
coat proteins of the TMV-FL construct seemed to always revert to wild-type coat protein (data not 
shown). This could be because the fusion loop is hydrophobic 485,486, and thus, TMV doesn’t tolerate 
having it on a solvent-exposed surface.  FL also contains positively charged amino acids, which have 
been shown to alter the isoelectric point of the TMV coat protein to the point that stable viral particles 
are unable to form 199. 
At 14 DPI, the leaves of plants infiltrated with TMV-GL showed classical symptoms of TMV 
infections (i.e., mosaic patterns on the leaves and curling of the upper leaves) (Figure 12b), as compared 
to uninfected N. benthamiana (Figure 12a).  Following PEG-precipitation, SDS-PAGE analysis revealed 
that the majority of TMV-GL was found in the clarification supernatant and that it appeared to have a 
higher molecular weight than the wild-type TMV coat protein (Figure 13b).  Subsequent western blot 
analysis showed that the TMV-GL construct did indeed contain an epitope recognized by polyclonal anti-







Figure 12.  Viral nanoparticle production in Nicotiana benthamiana.  a) Uninfected N. benthamiana. b) N. benthamiana infected 






Figure 13. SDS-PAGE and western blot analysis of viral nanoparticle extraction from N. benthamiana plants.  a) Coomassie blue-
stained gel of TMV-FL extraction process samples.  TMV-FL coat proteins have an expected molecular weight of 18.9 kDa.  Wild 
type (WT) TMV coat proteins have an expected molecular weight of 17.6 kDa.  b) Coomassie blue-stained gel of TMV-GL 
extraction process samples. TMV-GL coat proteins have an expected molecular weight of 19.8 kDa. c) Western blot analysis of 
TMV-FL and TMV-GL using polyclonal anti-ZIKV envelope protein antibody.   The recombinant ZIKV envelope protein has an 




Purification of TMV-GL and WT TMV 
Sucrose gradient ultracentrifugation was used to further purify the TMV-GL PEG-precipitation 
clarification supernatant, as well as the wild-type TMV that would serve as a negative control when 
immunizing mice (Figure 14).  Figure 15 demonstrates the final products of this process:  viral 
nanoparticles free from any visible protein contaminants.  The TMV-GL sucrose-purified clarification 
supernatant showed two bands; the higher molecular weight band (approximately 23 kDa) corresponds 
with the expected molecular weight of the TMV coat protein plus the ZIKV glycan loop (20 kDa) and 
accounts for approximately 87% of the protein, and the smaller band at approximately 18 kDa 
corresponds with the estimated molecular weight of the TMV coat protein alone (17.6 kDa).  The 
sucrose-purified wild-type (WT) TMV was in the sucrose clarification supernatant, as was the majority of 
TMV-GL VNPs (Figure 15) as expected, and this was used for the subsequent animal studies.  Thus, both 
clarification supernatants were used in subsequent experiments in which human sera were screened for 
GL-binding antibodies and to determine if GL is capable of eliciting a neutralizing antibody response in 
mice.  Based on a BCA assay of the clarification supernatants, the calculated yield of purified TMV-GL 
viral particles was approximately 0.42 mg/g of leaf tissue, and the yield of WT TMV was approximately 






Figure 14. Purification of TMV nanoparticles by sucrose density gradient ultracentrifugation. a) Blue arrow indicates the light-
scattering region of an ultracentrifuged sucrose density gradient that contains WT TMV.  b) Viral pellet from the 
ultracentrifugation of WT TMV.  
 
 
Figure 15. SDS-PAGE of sucrose density gradient purified TMV-GL and wild-type TMV.  Coomassie blue-stained gel showing 




Binding characteristics of commercial anti-E antibodies to the unglycosylated GL epitope 
To investigate whether a commercially available polyclonal Ab raised against E of a Brazilian 
strain of ZIKV recognized unglycosylated GL displayed on TMV, we performed Western blot analysis. The 
E protein used as a positive control in this experiment was a 55-kDa full-length recombinant E from ZIKV 
strain BeH815744 expressed in Escherichia coli, and, therefore, was unglycosylated. Rabbit polyclonal 
antibodies raised against a glycosylated ZIKV E protein bound to TMV-GL and to E, but did not bind to 
the unmodified TMV (Figure 16a).  This data demonstrates that antibodies raised against glycosylated E 
were able to recognize unglycosylated GL displayed on TMV.     
 
Figure 16. Characterization of plant-expressed TMV-GL by western blot analysis. TMV-GL, TMV, and ZIKV envelope protein 
recombinantly expressed in E. coli were separated on a 4-20% SDS-PAGE gel under reducing conditions and then blotted onto a 
nitrocellulose membrane.  The membrane was then incubated with polyclonal anti-ZIKV envelope protein antibodies (a), 
polyclonal anti-ZIKV (strain MR766) envelope protein antibodies (b), or polyclonal anti-DENV-2 envelope protein antibody (c).   
 
The Uganda MR766 strain of ZIKV does not contain N154 and three of the surrounding amino 
acids (i.e. VNDT), and therefore, is not glycosylated (Figure 17).  A rabbit polyclonal Ab raised against 




BeH815744 but did not react with TMV-GL (Figure 16b).  This suggests that antibodies raised against the 
E protein of the Uganda MR766 strain, as well as antibodies raised against other strains of ZIKV that lack 
the VNDT amino acid motif in the GL region, would not recognize the GL region of E proteins from the 
majority of ZIKV strains from the Asian lineage, which includes the strains responsible for recent 
outbreaks.  
While there is a relatively high degree of homology between the ZIKV E protein and the E 
proteins of other flaviviruses, there is poor homology in the GL region (Figure 17).  Thus, we theorized 
that antibodies raised against other flavivirus E proteins would not bind to TMV-GL, but would be able to 
bind to the full-length E protein.  We tested the ability of an anti-DENV-2 E polyclonal antibody raised in 
rabbits immunized with full-length DENV-2 E for its ability to bind to TMV-GL and the previously-
mentioned recombinant ZIKV E. The anti-DENV-2 E antibody bound to the recombinant ZIKV E protein 
(Figure 16c), which shows that there is indeed significant homology between the DENV-2 and ZIKV 
envelope proteins.  The anti-DENV-2 antibody did not bind to TMV-GL, suggesting that the glycan loop 
region is unique to Zika and does not cross-react with DENV antibodies.     
 
Figure 17. Sequence alignment of the glycan loop regions of various pathogenic flaviviruses, including the Asian (H/PF/2013) 
and African (MR766) strains of ZIKV. The numbers at the top indicate the position of the amino acids in the ZIKV envelope 
protein reference sequence (i.e., glycine (G) is at position 145 within the ZIKV (Asian strain) envelope protein amino acid 




Collectively, these data demonstrate that commercially available antibodies raised against 
glycosylated recombinant E protein from a Brazilian strain of ZIKV are capable of binding to 
unglycosylated GL but that the VDNT amino acid motif is likely an important component of the immune 
response to this region.  If antibodies to the GL region are an essential part of the immune response to 
ZIKV amino acids variations in GL region of ZIKV strains would elicit strain-specific antibodies that might 
be incapable of recognizing other strains of ZIKV.  Furthermore, DENV-2, which is glycosylated at N153, 
but contains a GNDT amino acid motif, is not capable of binding to the ZIKV GL (Figure 15d).  This data 
prompted us to investigate whether ZIKV infection leads to the production of antibodies capable of 
recognizing unglycosylated GL.  
To confirm that host cell proteins (i.e. proteins from N. benthamiana) were not responsible for 
the binding of the anti-ZIKV envelope protein antibodies to TMV-GL (Figure 16a), the viral extraction 
process was performed on uninfected plant material.  Samples from the final stage of the extraction 
process were analyzed by Western blot using the aforementioned anti-ZIKV envelope protein antibody 
(Brazilian).  The ZIKV E antibody does not bind to N. benthamiana proteins in the extraction process 
samples, but it was reconfirmed that it does bind to both ZIKV rE and the TMV-GL construct (Figure 18).   
 
Figure 18. Western blot analysis of extracts from uninfected N. benthamiana.  Extraction process samples from uninfected N. 
benthamiana plants were separated on a 4-20% SDS-PAGE gel under reducing conditions, blotted onto a nitrocellulose 
membrane, probed with a polyclonal anti-ZIKV envelope protein antibody (Brazilian strain), and visualized using a 




To our knowledge, Z3L1 is the only reported ZIKV-neutralizing human antibody with a footprint 
on monomeric E that includes contacts within GL (i.e., T156, H158, E159) 242.  The binding of Z3L1 to 
unglycosylated GL displayed on TMV, monomeric unglycosylated rE, and plant-glycosylated rE was 
analyzed via dot blot and ELISA.  Z3L1 did not bind to unglycosylated GL, plant-glycosylated rE, or 
monomeric unglycosylated rE in the dot blots (Figure 18a).  The ELISA showed similar results: Z3L1 did 
not bind to unglycosylated GL, plant-glycosylated rE, or monomeric unglycosylated rE to any significant 
degree above background levels (Figure 18b), even though Wang et al. showed that Z3L1 does bind to 
monomeric unglycosylated rE 242.  Thus, the three contacts within the GL region do not seem to be 
sufficient for Z3L1 to bind to unglycosylated GL on TMV.   
 
Figure 19. Binding characterization of Z3L1 by dot blot and ELISA.  a) TMV-GL, ZIKV rE made in N. benthamiana plants, or E. coli-
made ZIKV rE were dotted onto nitrocellulose, blocked, and then incubated with the human anti-ZIKV mAb Z3L1.  A peroxidase-
conjugated anti-human IgG secondary antibody and a chemiluminescent substrate were then used to detect any Z3L1 binding.  
b) TMV, TMV-GL, plant-made ZIKV rE and E. coli-made ZIKV rE were used to coat a 96-well plate.  The Z3L1 mAb or an anti-ZIKV 
rE serum (C+) were added, followed by incubation with HRP-conjugated secondary antibodies and addition of OPD substrate.  
The data depicted are the mean absorbance at 450 nm + SD of triplicate wells. The labels on the x-axis indicate the antigen that 
was plated. C- indicates that blocking buffer was used to coat the wells instead of an antigen, thus measuring the background 
noise from Z3L1 antibody binding directly to the blocked plate.    C+ indicates the use of an anti-ZIKV rE antibody as a positive 




IgM and IgG antibodies in the sera of ZIKV patients react to TMV-GL 
In a recent study, sera from fifty-one Zika-infected individuals from Colombia were analyzed for 
their ability to neutralize ZIKV in vitro 487.  We selected four serum samples from this group of individuals 
based on the ability of the serum to neutralize 90% of Zika strain H/PF/2013 viral particles at low 
concentrations (i.e., high reciprocal neutralizing titers (Table 9).  All four patients exhibited clinical 
symptoms of ZIKV infection, ZIKV was serologically confirmed, and serum samples were collected 14-51 
days after the onset of symptoms 487.  IgMs develop as an immediate response to viruses, but they 
typically disappear within 2-3 weeks of production, by which time IgGs have developed (although ZIKV 
infections have been known to cause prolonged IgM responses of up to 4 months 488).  Since the serum 
samples were collected at different time points after the onset of symptoms, we tested for both IgM 
and IgG antibodies that recognize unglycosylated GL.  Using dot blots, we determined that sera from 
patients ARSZGB16031 and ARSZ16467 contained IgM and IgG antibodies that bind to unglycosylated GL 
at levels higher than antibodies recognizing TMV (Figure 20 a, c).  The presence of antibodies recognizing 
TMV could be due to prior exposure to TMV 185 or non-specific binding.  Moreover, while all four serum 
samples appear to have similar levels of anti-rE IgM and IgG antibodies (Figure 20b), GL-binding IgMs 
constitute a small but significant portion of the total anti-rE IgM response, and IgGs recognizing 
unglycosylated GL represent an even smaller fraction of total anti-E IgG antibodies.  Since these data 
show that natural ZIKV infections elicit GL-specific antibodies in some patients, we investigated whether 
some of these antibodies bind to monomeric or dimeric E proteins and whether those antibodies are 
neutralizing.   
TMV-GL is immunogenic in mice 
While Wang et al. demonstrated that NAbs that recognize monomeric E and GL exist 242, we 
investigated whether we could find more of such antibodies.  Immunocompetent female BALB/c mice 




adjuvant only.  Mice were boosted approximately every three weeks thereafter, with a final boost given 
3 days prior to final bleeds and harvesting of spleens for cells fusions. The route of administration and 
the schedule of the immunization was comparable to previously published studies 489.  TMV-GL was used 
to determine if the unglycosylated GL was immunogenic.  Glycosylated TMV-E and rE were included to 
investigate whether any of the antibodies generated in response to glycosylated rE and capable of 
binding to unglycosylated GL.  Soluble rE that lacks the transmembrane region has been shown to be 
monomeric under physiological conditions and to crystallize as a dimer 242,250,368.  To further ensure the 
monomeric state of rE, a TMV-E construct was produced, where rE was displayed as a monomer on the 
surface TMV.  Also, one group of mice received wild-type TMV in order to control for and exclude any 





Figure 20. Dot blot analysis of sera from ZIKV-infected patients. a) Purified antigen (either TMV or TMV-GL) was spotted onto 
each square of nitrocellulose, dried, blocked, and then incubated with a 1:500 dilution of the indicated human serum in 
blocking buffer.  After washing, antibody bound to the membrane was detected using horseradish-peroxidase-conjugated 
secondary antibodies and Clarity Western Substrate.  b) Dot blot analysis of human sera to detect IgM and IgG responses to 
ZIKV E recombinantly expressed in plants.  c)  Digital quantification of the magnitude of dot blot assays using ImageJ software. 
The y-axis represents the mean pixel count ratio of the TMV-GL signal divided by the TMV signal.   
While immunized mice possessed detectable levels of IgM antibodies (Figure 21b), we proceeded to 




IgG responses of individual mice by ELISA and determined the endpoint titers (Figure 22a).  Endpoint 
titers were defined as the reciprocal serum dilution at which the absorbance at 450 nm (A450) was 
higher than the A450 signal of the pooled serum of the control mice (i.e., those injected with PBS + 
adjuvant).  We observed that mice immunized with TMV-GL produced the highest levels of IgG against 
TMV-GL.  Importantly, the serum of mice immunized with rE reacted with TMV-GL, which strongly 
suggests that the immune response to monomeric glycosylated E includes antibodies that recognize GL 
independently of the glycan.  Similarly, serum from mice immunized with either TMV-E or TMV reacted 
with TMV-GL, likely because antibodies recognize either the TMV or GL portions of the construct.  These 
data show that unglycosylated GL is immunogenic in mice and that some of the antibodies raised against 
monomeric glycosylated E recognize GL in a glycan-independent manner.  Pooled sera from each group 
of mice were also analyzed by ELISA to determine the relative antigenicity and immunogenicity of each 
construct (Figure 22b).  All four proteins were antigenic, and, as shown in red, TMV, TMV-GL, and the 
plant-made rE were also immunogenic.  We next looked at the ability of the mouse sera to inhibit ZIKV 
infection in cellular assays.   
 
Figure 21. Detection of IgM antibodies in mouse sera. Pooled sera from each of the 5 groups of immunized mice (TMV, TMV-GL, 
TMV-E, rE, and adjuvant only) was dotted onto nitrocellulose followed by incubation with a goat anti-mouse IgM HRP-





Figure 22. ELISA endpoint titers using sera from immunized mice. Balb/c mice were immunized with five doses TMV, TMV-GL, 
rE, or TMV-E. Assay cutoffs were calculated as described by Frey et al. 482 using pooled adjuvant-only sera.  a) Sera from each 
mouse was serially diluted and endpoint titers against TMV-GL were determined by ELISA.  Individual serum samples were 
assayed in 5 wells and the average A450 of these wells was then used to determine the endpoint titer.   Each dot on the graph 
represents the endpoint titer of the serum from one mouse and the bars indicate the average endpoint titer for each group.  b) 
Pooled sera from each group of mice were serially diluted and endpoint titers against TMV, TMV-GL, plant-made rE, and E. coli-
made rE were determined by ELISA. The numbers shown are the average endpoint titer from three sets of ELISAs.  The endpoint 
titers in red represent immunogenicity, as the plated antigen was the same as the antigen used to immunize the mice in that 
group.  * indicates constructs that were presumably glycosylated.  
Sera from immunized mice neutralize ZIKV in vitro 
Flow cytometry-based neutralization assays were performed to determine if sera from 
immunized mice could protect U937+DC-SIGN cells against ZIKV infection (strain SD001490).  As shown in 
Figure 23, sera from mice immunized with TMV + adjuvant or adjuvant alone provided no protection.  In 




and TMV-E sera neutralized 94%.  However, 50% neutralization is required for serum to be considered 
protective, and only the TMV-E and rE constructs met this requirement.  These data show that 
unglycosylated GL in the absence of other E regions is not sufficient to generate a neutralizing antibody 
response against ZIKV, but that rE is sufficient.  This is not surprising, as the ability of rE-based vaccine 
candidates to elicit ZIKV-neutralizing antibodies has been demonstrated by other groups.   
 
Figure 23. Analysis of mouse sera using a flow cytometry-based ZIKV neutralization assay.  Individual serum samples from five 
groups of immunized mice were assessed for their ability to neutralize ZIKV (strain SD001) using a U937 DC-SIGN flow 
cytometry-based neutralization assay.  The sera were serially diluted two-fold starting at a 50x dilution.  Each point represents 
the mean percent neutralization of the three mice in the group, and the error bars depict the standard deviations. 
ZIKV-neutralizing monoclonal antibodies bind to unglycosylated glycan loop 
To determine whether any of the NAbs from TMV-E and rE immunized mice were directed 
towards GL, monoclonal antibodies (mAbs) were made from mice immunized with TMV-E and rE.  
Hybridomas were also produced from a TMV-GL immunized mouse.  All hybridoma supernatants were 
screened for mAbs capable of binding to plant-produced glycosylated rE, and the 26 clones that bound 
to rE were cultured further (Table 8).  As with the mouse sera, the ability of the mAb-containing 
hybridoma supernatants to neutralize ZIKV was examined using a flow-cytometry based neutralization 
assay.  Four out of the six hybridoma supernatants from a TMV-E immunized mouse moderately 




immunized mouse strongly neutralized the virus while one (#24) was moderately neutralizing (Figure 
24b).  None of the TMV-GL hybridoma supernatants were neutralizing (Figure 24c). 
 
Figure 24. Neutralization of ZIKV by monoclonal-antibody containing hybridoma supernatants. Hybridomas were created from 
TMV-GL, TMV-E, and rE-immunized mice. Hybridoma supernatants were assessed for their ability to neutralize ZIKV (strain 
SD001) using a U937 DC-SIGN flow cytometry-based neutralization assay.  The supernatants were serially diluted two-fold 
starting at a 10x dilution. a) Neutralizing hybridoma supernatants from a TMV-E -immunized mouse.  b) Neutralizing hybridoma 
supernatants from an rE-immunized mouse. c) Non-neutralizing hybridoma supernatants from a TMV-GL immunized mouse 
(#1, 2, 4-6, 8, 9, 13, 14, and 16-20), a TMV-E immunized mouse (#3 and 15), and a control hybridoma supernatant raised from a 
mouse immunized with a non-specific antigen (#21).   
The ten hybridoma supernatants that contain ZIKV-neutralizing mAbs were then analyzed via 
dot blot for their ability to bind to unglycosylated TMV-GL.  All four of the neutralizing mAbs from TMV-E 
bound to the unglycosylated glycan loop (Figure 25a), while none of the neutralizing mAbs from rE 
bound to the unglycosylated glycan loop (Figure 25b).  Additional immunoblotting revealed that the GL-




and TBEV), and preferentially bound to unglycosylated rE (expressed in E. coli) over plant-glycosylated rE 
(Figure 26a).  In contrast, mAb #26 cross-reacted with the DENV-2 recombinant envelope protein and 
preferentially bound to plant-glycosylated ZIKV rE compared to unglycosylated rE expressed in E. coli 
(Figure 26b).   
 
Figure 25. ZIKV-neutralizing mAbs bind to the glycan loop. TMV-GL was spotted onto squares of nitrocellulose, blocked, and 
then incubated with diluted hybridoma culture supernatants from either a TMV-E immunized mouse (a) or an rE immunized 
mouse (b), followed by incubation with a goat anti-mouse IgG HRP-conjugated secondary antibody and detection using Clarity 
Western Substrate.   
 
 
Figure 26. Further characterization of ZIKV-neutralizing mAbs. The indicated antigens were spotted onto squares of 
nitrocellulose, blocked, and then incubated with either hybridoma culture supernatant #12, from a TMV-E immunized mouse 
(a), or #26, from a rE-immunized mouse (b), followed by incubation with a goat anti-mouse IgG HRP-conjugated secondary 





Recent epidemics revealed that the supposedly-innocuous Zika virus can cause serious 
neurological and developmental complications and led the WHO to declare ZIKV a Public Health 
Emergency of International Concern in 2016.  The scientific community responded vigorously, and 
hundreds of monoclonal antibodies, antivirals, diagnostics, and vaccines are currently being developed.  
Because ZIKV induces only mild symptoms in the majority of infected patients, the most pressing need is 
for a vaccine that could be given to pregnant women and women of childbearing age during outbreaks 
to mitigate the threat of CZS.  However, to prevent endemic transmission of ZIKV, mass vaccination 
campaigns would be necessary.   
Given that an estimated 2 billion people are currently at risk of developing ZIKV, the ideal 
vaccine candidate would be affordable.  Additionally, antibodies elicited by a prior flavivirus infection or 
vaccine can cross-react with ZIKV, or vice versa, which would hypothetically lead to antibody-dependent 
enhancement (ADE) of disease.  Several studies have attempted to assess the risk of ADE, particularly 
between ZIKV and DENV due to their antigenic similarity, but whether or not ADE might actually occur 
between ZIKV and DENV remains to be seen.   The WHO recently summarized the ideal characteristics of 
a ZIKV vaccine as follows: “high-quality, safe and effective ZIKV vaccines that prevent serious ZIKV-
associated clinical complications, and ensure availability and affordability for use in countries were ZIKV 
circulates” 269.  
A variety of candidate ZIKV vaccines are currently in clinical trials including inactivated virus, 
attenuated virus, nucleic acid vaccines, and recombinant viral vectors.  Despite the different vaccine 
platforms being utilized, all of these vaccines have one common characteristic: they all contain the 
envelope protein (E).  Previous studies have highlighted some of the unique structural features of ZIKV E 
289,290, including the fusion loop and glycan loop regions.  Functional epitopes with high sequence 




developing a vaccine or immunotherapies for ZIKV, it is important to utilize such epitopes.  With this in 
mind, we created two TMV-based viral nanoparticle vaccines with ZIKV envelope protein epitopes: one 
displaying the fusion loop (FL), the other displaying the glycan loop (GL).   
Fusion loop construct 
The fusion loop mediates the fusion of ZIKV with the host cell’s endosomal membrane, which 
allows the virus to enter the cell.  Studies have confirmed that FL is an immunodominant epitope 
capable of eliciting neutralizing antibodies and is highly conserved across flaviviruses.  Thus, we sought 
to create a TMV-FL vaccine candidate that could potentially be used as a universal flavivirus vaccine.  
However, the TMV-FL construct seemed to cause necrotic lesion to form on the leaves of the 
agroinfiltrated N. benthamiana, which resembled those seen during the hypersensitive response in 
TMV-resistant tobacco species 491.  In tobacco plants that contain the N gene, the hypersensitive 
response causes cell death at the site of infection, which prevents viral particles from infecting the rest 
of the plant 492.  While the process of agroinfiltration has been shown to lead to this type of 
hypersensitive response in some plant species 493, the fact that necrotic lesions did not appear in the 
TMV-GL plants that were agroinfiltrated concurrently suggests that it was the construct itself rather 
than agroinfiltration.  Necrotic lesions limited the yield of TMV-FL, but another issue arose with this 
construct as well.  Most, if not all, of the TMV-FL VNPs seemed to revert to wild type TMV, indicating 
that the TMV particles were not able to correctly assemble with ZIKV FL transcriptionally fused to the 
TMV coat protein, causing the FL sequence to be “kicked out” of the viral genome.  This is likely due to 
the hydrophobic nature of FL and how they change the isoelectric point of the TMV coat protein 183.  
Furthermore, due to their high thermal stability 290, ZIKV virions purportedly undergo less viral breathing 
than other flaviviruses, meaning that that FL might be less accessible on ZIKV and therefore a poor 
epitope.  Nevertheless, FL-targeting antibodies have been shown to neutralize ZIKV and protect animals 




Glycan loop construct 
With the risk of ADE in mind, we chose a region of the ZIKV envelope protein that showed little 
homology to other flaviviruses: the glycan loop.  While the exact biological function of the ZIKV GL 
remains to be determined, it is thought that the glycosylation on N154 plays a role in assembly, 
infectivity, vector competence, and neuroinvasion.  Unlike the TMV-FL construct, our TMV-GL construct 
assembled properly and was expressed at high levels in N. benthamiana.  Subsequent western blot 
analysis demonstrated that anti-ZIKV E antibodies recognize the unglycosylated GL on TMV, while DENV-
2 antibodies do not.  Furthermore, IgM antibodies in convalescent sera from patients ARSZGB16031 and 
ARSZ16467 bound to GL displayed on TMV.  Blood samples were collected from these patients 30 and 
37 days after the onset of ZIKV symptoms, respectively, which fits with the known pattern of the IgM 
response peaking earlier in infection.  While the primary effector function of IgM is activating the 
complement system, IgMs have also been shown to neutralize ZIKV, especially during the early stages of 
an infection 328.  Sera from the same patients (i.e., ARSZGB16031 and ARSZ16467) also showed positive 
results on IgG dot blots against TMV-GL.  However, immune responses are influenced by a variety of 
host and pathogen-specific factors 376, and antibodies are not always produced against the same 
epitopes, which may explain why patients ARSZ16308 and ARSZGB16015 showed no IgM or IgG 
response to GL.   
The four human sera analyzed for their ability to bind to GL were selected primarily based on 
their high neutralizing titers that inhibit 90% of the virus NT90 titers.  Despite these high NT90 titers, all 
four of these donors experienced clinical symptoms of ZIKV infection, ranging from flu-like symptoms to 
Guillain-Barré syndrome.  This suggests that in vitro neutralization might not necessarily be a good 
predictor of in vivo neutralization and that by utilizing sera from patients exhibiting ZIKV symptoms, we 
might have unintentionally tested sera with poor in vivo neutralization.  All 51 of the ZIKV-positive serum 




infection, so serum samples for asymptomatic ZIKV-infected donors were not available 487.  Thus, the 
presence of GL-binding antibodies in the sera of some patients could reflect exposure to ZIKV instead of 
functional protection.  
TMV-GL as a vaccine candidate 
The majority of vaccines effect protection by inducing antibodies that prevent viremia and/or 
prevent viruses from reaching their target organs, and the laboratory measurement that most 
frequently correlated with vaccine-induced protection is antibody titer.  In the vaccine industry, 
neutralizing antibody titers, measured via plaque-reduction neutralization tests or other types of viral 
neutralization assays, are often used as surrogate markers of seroprotection.  Vaccine-induced 
production of neutralizing antibodies has been shown to correlate well with protection for vaccines 
against YFV and WNV 495,496, but no such correlate of protection has been established for ZIKV.  For 
licensed flavivirus vaccines, a neutralization titer of 1:10 (i.e., at a dilution of 1:10 or greater, the serum 
is capable of neutralizing at least 50% of the virus) has been established as a surrogate for protective 
immunity 497,498.  However, several studies have suggested that higher levels of neutralizing antibodies 
may be required to protect against ZIKV infection and have suggested neutralization titers of 1:50 or 
1:100 may be a more appropriate surrogate marker for ZIKV protection 69,412,413,499.  A neutralizing titer 
(NT50) of 100 has been shown to correlate with protection against viremia in mice and non-human 
primates challenged with ZIKV 413,465,500,501, but neutralizing titers may vary based on assay type, virus 
strain, cell type, etc.  Even when the same assay type is used, neutralization titers may not be able to be 
directly compared to one another.  For example, flow-based cytometry neutralization assay can have 
high inter-assay variability, especially with samples tested on different days 502.  Thus, while the TMV-E 
and rE constructs did elicit neutralizing antibodies based on what has been seen in other studies (i.e., an 
NT50 of 100), we won’t know if our constructs, including TMV-GL, truly protect against viremia until we 




Although an immune correlate of protection has not been established for ZIKV, data from 
neutralization assay should still be considered when determining the efficacy of a vaccine.  
Neutralization assays revealed that TMV-GL was unable to elicit neutralizing antibodies in mice, leading 
us to suspect that either GL antibodies were poorly neutralizing in general, or that our TMV-GL construct 
was not ideal.  Poorly neutralizing antibodies are thought to be elicited, at least in part, by epitopes 
infrequently displayed on the surface of mature virions 293.  However, cryo-electron microscopy 
structural studies suggest that GL is a prominent feature of the ZIKV surface 289,290.  As far as our TMV-GL 
construct not being ideal, there were three potential issues: 1) conformationally, GL was not displayed 
correctly on TMV, 2) the GL epitope we chose was missing adjacent amino acids critical for the induction 
of neutralizing antibodies, or 3) TMV proteins are not glycosylated, and the N154 glycosylation on GL 
was necessary.  In an attempt to address all three of these issues, the glycosylated ZIKV E was 
recombinantly expressed in N. benthamiana, and used either or its own (i.e., rE) or docked to TMV (i.e., 
TMV-E) to immunize mice.   Monoclonal antibody-secreting hybridomas were then made from the 
spleens of the immunized mice and then were screened for their ability to bind to rE and neutralize ZIKV 
in vitro.  Out of the ten neutralizing mAbs, four bound to TMV-GL, demonstrating that neutralizing GL-
binding mAbs are capable of recognizing the GL epitope we displayed on TMV and bind in the presence 
or absence of glycosylation at N154.  Thus, we suspect that our TMV-GL construct failed to elicit 
neutralizing antibodies because the epitope we chose was incomplete.  Epitope mapping studies using 
the GL-binding mAbs we discovered would help us determine which critical amino acids are missing in 
our TMV-GL constructs and hopefully lead to a redesigned GL-based construct capable of eliciting a 
neutralizing antibody response.  
Antibody isotypes and T cell epitopes 
To develop a safe and effective ZIKV vaccine, understanding the mechanisms of antibody-




antibody isotype produced.  IgM-mediated phagocytic clearance and destruction of viruses occur in the 
early stages of the adaptive immune response while the IgG response is still developing, and several 
studies have indicated that the IgM response is critical for full protection against ZIKV 341, JEV 503, and 
other viral infections 504-506.  Clusters of specially-glycosylated IgG antibodies are also able to recruit 
complement, but the main protective role of IgGs lies in their long-term ability to neutralize viruses.  
Interestingly, in addition to enhancing phagocytosis, activating complement, and priming the adaptive 
immune response, IgMs have also been shown to neutralize viruses 506-508.  Furthermore, in one study, 
ZIKV-specific IgM antibodies cross-reacted weakly with DENV, while IgG antibodies strongly cross-
reacted with DENV 361.  Since both IgM and IgG seem to play critical roles in antibody-mediated 
protection against ZIKV, vaccines may need to effectively induce both isotypes.  
Consistent with results from Hansen et al., we observed that peptides within the GL region were 
recognized by IgM antibodies sera collected within 30 days of the onset of ZIKV symptoms 362.  Sera 
ARSZGB16015 and ARSZGB16031 were collected in this period, and ARSZGB16031 showed positive 
results on the IgM dot blot (Figure 20a).  An IgM response to GL was also noted for ARSZ16467, and 
while this serum was taken at 37 days, extended IgM responses have been observed with ZIKV infections 
360,361.   Although IgMs are typically less neutralizing than IgGs, and the relative contribution of IgMs and 
IgGs to neutralization varies by individual 507, IgMs may play an essential role in neutralization early in 
the course of viral infections.  Exploring the contribution of IgMs to protection from infection in a 
murine WNV model, Diamond et al. demonstrated that the delayed development of neutralizing anti-
WNV IgMs is likely to be an independent risk factor for morbidity and mortality (i.e., severe WNV 
infection) 506.  This suggests that vaccine strategies capable of inducing an IgM response could be utilized 
for both pre- and post-exposure prophylaxis.   
In testing the four samples from ZIKV-infected patients, we observed that there was a marked 




related to the different secondary antibodies that were used or the inherent differences between IgMs 
and IgGs, it might also be a characteristic of the GL epitope.  Repetitive surface proteins, such as GL 
displayed on TMV, efficiently crosslink B cell receptors and trigger them to proliferate and produce IgM.  
However, only a portion of early B cells undergo class-switching and become long-lived memory B cells 
that produce IgG 509.  Class switching is induced by various stimuli, including signaling by multiple 
cytokines (e.g., IL-10 and IFN-ɣ) 510, the presence of CD4+  T cells 511, and the affinity of early primary IgM 
512.  CD4+ T cells promote affinity maturation and the development of memory B cells.  These CD4+ 
helper T cells are activated by APCs that present MHCII peptides from the proteolytic processing of viral 
structural proteins.  However, only certain peptides induce this T cell response, and the factors that 
influence which epitopes are immunodominant are not wholly understood 513.   
Cell-mediated immune responses play an integral role in controlling and preventing intracellular 
infections, and both CD8+ and CD4+ T cells have been shown to play important roles in protection against 
ZIKV 321-323,328,514-516.  Although we did not test the T cell responses of the mice we immunized, previous 
studies in humans or transgenic mice expressing human HLA proteins have shown that multiple T cell 
epitopes lie within, or close to, the GL region of the ZIKV envelope protein 513,516-519.  For example, 
Reynolds et al. mapped immunodominant CD4+ T cell ZIKV epitopes in transgenic mice and showed that 
p14, a peptide that corresponds to amino acids 131-150 in the E protein, is a positive epitope in mice 
with HLA-DR4 and HLA-DR1.  In fact, p14 bound strongly or moderately to almost all the HLA-class II 
molecules tested and no cross-reactive T cell epitope recognition was seen with the other flaviviruses 
tested (WNV, YFV, and DENV1-4). 517.  An additional study by Koblischke et al. analyzed the CD4+ T cell 
response of 13 ZIKV patients and identified five peptides entirely or partially composed of GL residues as 
CD4+ T cell epitopes.   Although none of these peptides was considered “immunodominant” as only 10% 
of the patients recognized each peptide (rather than the 20% recognition that was deemed to be 




The importance of vaccine-induced T cell responses was recently demonstrated by the low 
efficacy of Dengvaxia, a tetravalent, live-attenuated DENV vaccine.  It has been theorized that the low 
efficacy may be due to the inability of Dengvaxia to stimulate a DENV-specific T cell response, as it 
contains an NS protein from YFV rather than a DENV NS protein 520.  Along with our observations that 
more IgM antibodies in human sera bind to TMV-GL than IgG antibodies, these data suggest that if our 
GL construct contains a CD4+ T cell epitope, this epitope may not be sufficient to effectively induce IgM 
to IgG class-switching.  Furthermore, because the TMV-E construct was able to induce neutralizing, GL-
binding mAbs and the TMV-GL constructs did not, perhaps only a portion of the GL immunodominant 
CD4+ T cell epitope was contained in our TMV-GL construct.  Thus, to further develop TMV-GL as a 
vaccine candidate, T cell responses should be evaluated for all three constructs, and if TMV-GL does not 
contain an immunodominant CD4+ T cell epitope, then a new iteration of TMV-GL should be created.   
Viral nanoparticle vaccines 
TMV nanoparticles were chosen to display the ZIKV glycan loop epitope due to their ability to 
present multiple copies of a foreign epitope on its surface, its favorable safety profile, and the 
inexpensive production process.  However, like other carrier molecules, antibody responses can also be 
induced to the TMV scaffold itself.  It is unclear whether or not this would a negative impact on the 
immunogenicity of the foreign epitope being displayed, and the presence of carrier-specific antibodies in 
populations with prior exposure to TMV (e.g., from smoking or previous TMV-based vaccines) may 
preclude the use of a TMV-based ZIKV vaccine 185.  However, studies have shown that pre-existing 
immunity to TMV does not lead to loss of immune activation from subsequent injection with the same 
or different TMV VNPs, and, in the case of booster shots, that this occurs even when levels of anti-TMV 
antibodies are higher than the level of antibodies to the epitope 193.   
Aside from producing an effective vaccine candidate, this project also aimed to create a vaccine 




serum neutralization assay (Figure 23), the rE and TMV-E constructs are better at inducing ZIKV-
neutralizing antibodies and could, therefore, be considered better candidate vaccines than TMV-GL.  
However, the sheer number of people at risk for contracting ZIKV necessitates the use of a platform that 
can produce affordable vaccines at a large scale, and both of these vaccine candidates require the 
production and purification of a recombinant protein, which increases the cost of manufacturing 
significantly.  Furthermore, many envelope protein-based vaccines are already in clinical trials, which 
would make further development of the rE and TMV-E constructs redundant, and because the 
geographical distribution of ZIKV and DENV overlap, minimizing the risk of ADE is an important 
consideration.  Thus, in addition to increased production costs, neither the rE or TMV-E constructs 
presented here address the issue of ADE.  While TMV-GL was designed with the ADE risk in mind, further 
in vitro and in vivo tests would be required to determine if TMV-GL induces antibodies that could lead to 
ADE.  
Monoclonal antibodies 
The glycosylation site at N154 is a conserved feature of flaviviruses that may be important for 
infectivity and viral assembly 422,521,522, but the extended loop surrounding it is unique to neuroinvasive 
flaviviruses (i.e., WNV, JEV, and ZIKV).  The extended ZIKV GL shares minimal sequence identity with the 
WNV and JEV, making it a promising antigen for eliciting ZIKV-specific antibody response.  Furthermore, 
computational approaches have predicted multiple B cell epitopes in the GL region 400,523, and  Xu et al. 
showed that the GL region of ZIKV has low sequence identity to other flaviviruses and high surface 
accessibility 523.  We sought to explore the antibody-mediated immune response to the ZIKV-specific 
glycan loop. 
To focus exclusively on the GL region without the rest of the E protein, we utilized TMV viral 
nanoparticles to display unglycosylated GL from a Brazilian strain of ZIKV.  We confirmed that antibodies 




antibodies raised against the GL region of the Uganda MR766 strain of ZIKV recognized rE, they did not 
recognize the GL portion of our construct.  The Uganda MR766 strain lacks the GL “VNDT motif” and is 
therefore unglycosylated.  However, rather than being a natural mutation, this deletion is thought to be 
the result of the virus adapting to mouse brain cells, as this strain was passaged over 150 times in brains 
of suckling mice 209,268,453.  Thus, our MR766 western blot data suggests that to elicit antibodies capable 
of binding to the GL region, the antigen must contain the VNDT motif.   And, because the majority of 
ZIKV strains associated with the recent outbreaks contain the VNDT motif 426, antibodies to this region 
are particularly relevant.  The inability of the anti-DENV-2 envelope protein antibody to bind to our 
unglycosylated GL construct confirms that the GL region is unique to ZIKV, even though the DENV-2 
antibodies cross-reacted with the full ZIKV E protein. 
Although we confirmed that antibodies raised against recombinant ZIKV envelope protein 
recognized our TMV-displayed GL, rE likely presents a slightly different antigenic landscape than the 
natural Zika virus.  Thus, our next step was to determine if antibodies from individuals naturally infected 
with ZIKV bound to GL.  Consistent with observations made by Hansen et al. 362, we observed that IgM 
antibodies in convalescent sera bound the best to the GL region.  Serum samples from two patients, 
ARSZGB16031 and ARSZ16467, showed IgM binding to GL, and these samples were collected from these 
patients 30 and 37 days after the onset of ZIKV symptoms, respectively.  Although the IgM response 
typically peaks about one week after infection and disappear within 2-3 weeks, IgM antibodies can 
persist for 12 weeks or more after ZIKV infection 360,361.  Serum samples ARSZGB16031 and ARSZ16467 
also showed positive results on the IgG dot blots against GL, suggesting that at least some class 
switching from IgM to IgG did occur.  Because serum sample ARSZ16308 was collected 51 days after the 
onset of symptoms, the negative results seen for IgM and IgG against GL could be due to the natural 
disappearance of IgM coupled with no class-switching to IgG.  However, this is unlikely as there was still 




ARSZGB16031 and ARSZ16467.  The negative results from the ARSZGB16015 dots blots could be 
attributed to the time at which the sample was taken, but, again, the rE blots show that both an IgM and 
IgG response to ZIKV was present.  Thus, the negative results are more likely due to the fact that 
immune responses vary by individual and antibodies are not always produced against the same 
epitopes.  Taken together, these data suggest that natural ZIKV infection can elicit an antibody response 
to the GL region, but that the response varies by individual.   It should also be noted that despite having 
high NT90 titers, all four serum donors experienced clinical symptoms of ZIKV infection, ranging from flu-
like symptoms to Guillain-Barré syndrome.  This suggests that in vitro neutralization might not 
necessarily be a good predictor of in vivo neutralization and that by utilizing sera from patients 
exhibiting ZIKV symptoms, we might have unintentionally tested sera with poor in vivo neutralization. All 
51 of the ZIKV-positive serum donors described in Lynch et al. were referred to the study because they 
manifested clinical symptoms of ZIKV infection, so serum samples for asymptomatic ZIKV-infected 
donors were not available 487.     
In this study, we immunized mice with rE and TMV-E and isolated NAbs that either recognize 
unglycosylated GL or require glycan for their efficient binding to monomeric E.  Based on the existing 
nomenclature of EDE mAbs, our group proposes a new classification for Abs that bind to E monomer 
epitopes (EME).  We consider NAbs 22-27 EME1 because they bind to envelope protein monomers 
better in the presence of glycosylation at N154 (Figure 26b).  On the other hand, NAbs 7, 10, 11, and 12 
are EME2 because they bind to E monomers regardless of the presence or absence of glycosylation at 
N154, although plant-glycosylation does seem to decrease their binding somewhat (Figure 26a) and rE 
with mammalian glycosylation was not available for testing.  Given their binding characteristics, it seems 
likely that the group of NAbs that we are calling EME1 are clonal, and the same is true of the EME2 
NAbs.  Sequencing the variable regions of these NAbs would allow us to determine how many ZIKV-




Numerous ZIKV-neutralizing mAbs that bind to envelope protein epitopes have been described 
242-244,251,332,333,524, including several EDE NAbs isolated from DENV patients 250,370,375,407, as well as both 
EDE and EME NAbs from ZIKV-infected patients and mice.  Of the many EME NAbs described thus far in 
the literature, only one has been shown to have contacts within the GL region: Z3L1 242.  Because Z3L1 
was commercially available, the ability of Z3L1 to recognize TMV-GL was tested, and the results 
suggested that the 3 contacts that Z3L1 makes within the GL region are not sufficient for Z3L1 to bind to 
unglycosylated GL on TMV (Figure 18).  Furthermore, although Wang et al. suggest that Z3L1 binds to 
unglycosylated monomeric rE, we were unable to confirm this, as Z3L1 did not bind to unglycosylated 
monomeric rE in a dot blot or ELISA (Figure 18).  These data suggest that our EME2 NAbs likely have 
more than three contact points in the GL region and that these NAbs are currently the only known GL-
binding EME NAbs.  Of course, validating these claims would require further work, including epitope 
mapping studies.   
Monoclonal antibodies that bind to the E protein neutralize ZIKV by blocking attachment factors, 
obstructing binding to entry receptors, or hindering the membrane fusion process.  Many cellular 
receptors, including AXL, Tryo3, DC-SIGN and TIM-1 279, have been implicated in ZIKV binding and entry.  
Lectin-type receptors, including DC-SIGN, recognize viral glycoproteins, so any glycans present on the 
ZIKV E-protein could play a role in viral entry 366,372.  The fact that the N154 glycosylation site remains 
highly conserved among flaviviruses suggests it has a vital function, such as a binding site for viral entry.  
However, ZIKV particles lacking the E protein glycan were capable of infecting Raji cells expressing the 
lectin DC-SIGN, so the prM glycan on partially mature particles may also be able to facilitate entry 424.  
Additional studies demonstrate that ZIKV utilizes different host cell receptors in different tissues 274, and 
each receptor could bind to a different part of the E and/or prM proteins. 
Consequently, an antibody that blocks a single binding site may only neutralize ZIKV in specific 




locking the envelope protein in its dimeric conformation, which prevents membrane fusion.  By their 
nature, EME mAbs cannot lock envelope dimers, but they may still impede the fusion process by 
sterically hindering the change from the dimeric form to the trimeric form during membrane fusion.  GL 
has been shown to at least partially cover the FL on ZIKV 289 and blocks neutralization by FL-binding 
mAbs 424,  so EME1 could hinder fusion by blocking FL and preventing membrane fusion.      
For DENV, strongly neutralizing antibodies frequently target quaternary E epitopes, rather than 
those displayed on E monomers 365,525,526.  Given that DENV and ZIKV are structurally similar, it has been 
hypothesized that the same is likely true for ZIKV.  Recently, Collins et al. observed that the 
neutralization capacity of sera from ZIKV-infected donors can primarily be attributed to antibodies that 
target quaternary E epitopes 376.  However, they do concede that in 2 out of the 4 serum samples they 
tested, antibodies to “simple” epitopes also contributed to neutralization.  Other studies have also 
shown that antibodies targeting recombinant monomeric E protein epitopes are neutralizing 
242,243,251,332,527, and some of the most potently neutralizing ZIKV mAbs bind to E monomers (Table 3). 
Nevertheless, to be protective in vivo, neutralizing antibodies must recognize epitopes on 
oligomeric ZIKV E proteins in their native state, and these epitopes are often conformational and 
quaternary 528.  By immunizing mice with monomeric ZIKV E protein, we may have inadvertently selected 
for moderately or poorly neutralizing antibodies.  Determining how effective the EME1 and EME2 mAbs 
are at neutralizing ZIKV will require additional culturing of the hybridomas, purification and 
quantification of the mAbs, and another round of neutralization assays.  The IC50 or FRNT50 
concentrations could then be compared to other mAbs, such as those found in Table 3, to determine 
their relative ability to neutralize ZIKV.   Further in vitro assays and/or in vivo studies could also help 





Therapeutic antibodies, in the form of pooled sera or recombinant mAbs, can be used to 
prevent or treat infectious diseases, and post-exposure passive immunotherapy has been shown to 
prevent congenital disabilities caused by cytomegalovirus 529 and the rubella virus 530.  Thus, as an 
alternative to vaccination, administering ZIKV-neutralizing mAbs to pregnant women may prevent 
congenital Zika syndrome (CSZ) 333. Passive immunotherapy still carries the risk of ADE if the 
concentration of antibodies is sub-neutralizing or the antibodies cross-react with other flaviviruses.  To 
avoid ADE, a therapeutic ZIKV mAb would have to be given at the proper dose and be ZIKV-specific.  The 
latter of these requirements could be filled by our GL-binding mAbs (EME2).  Alternatively, or perhaps 
additionally, ADE could be avoided by LALA mutations (i.e., mutating the Fc portion of the antibody to 
abolish its Fc activities) 531.  However, ablating the Fc-mediated effector functions of a ZIKV therapeutic 
mAb may make it less effective, as this would abrogate its cellular and complement-mediated immune 
functions 532, but the mAb would still retain its ability to neutralize ZIKV.  The passive immunotherapy 
approach to ZIKV poses more problems than just the risk of ADE.   For one, ZIKV has a short incubation 
period, so treatments utilizing immune sera or mAbs would only be effective if given within a narrow 
window of time.  Second, because many ZIKV-endemic regions are in low-income countries, the 
availability and cost of immunotherapeutics could prove prohibitive.  For example, even using local 
manufacturers to produce biosimilars, therapeutic mAbs are predicted to cost at least $500 per dose 533.  
In conclusion, with further testing and optimization, our EME2 mAbs could potentially be used as a 
therapeutic.  However, due to the high cost of mAb production, it is unlikely that such a therapeutic 
would be available to those who need it most. 
Diagnostics 
There is a moderate, but significant, degree of homology between flavivirus envelope proteins 




areas as ZIKV outbreaks, which makes serological differentiation difficult 362 and also introduces the 
possibility of antibody-dependent enhancement (ADE) of disease 242.  Our results indicate that GL may 
be an important part of the ZIKV-specific adaptive immune response and that DENV2 antibodies cannot 
bind to this region.  The high sequence conservation of the envelope protein across ZIKV  strains (94% or 
greater 251) holds a promise that an antibody specific to the ZIKV envelope protein would likely work for 
the majority of ZIKV serotypes. 
Furthermore, most of the recent ZIKV outbreaks, in which CZS and GBS were seen, have been 
attributed to the Asian lineage of ZIKV 437,438, in which there is only a 2% variation in the amino acid 
sequences of the E protein 366.  An analysis of the protein evolution of ZIKV by Ramaiah et al. 
demonstrated that the GL region contains 2 of the 3 negatively-selected amino acid sites in the E protein 
so any substitutions in this area may prevent ZIKV from replicating 439.  Together with evidence 
presented by Faye et al. that acquisition of the N154 glycosylation site is a recurrent event in the history 
of ZIKV 430 and the theory that the N154 was only lost because of serial passage in mice, these data 
suggest that the residues of the GL region are less likely to change than other areas of the E protein.  
Our results suggest that GL plays an important part in the B cell response to ZIKV and that DENV2 
antibodies cannot bind to this region.  Thus, the TMV-GL VNPs could potentially be used to create a 
ZIKV-specific diagnostic that detects GL-binding antibodies in human serum samples.  Alternatively, the 
GL-binding EME2 mAb could be used to detect Zika virions in various types of human samples.   
CONCLUSION 
 Vaccine-induced antibody-dependent enhancement of disease is a very real possibility when it 
comes to flavivirus vaccines, particularly in areas where ZIKV and DENV co-circulate.  Developing a safe 
and effective ZIKV vaccine may, therefore, necessitate the use of ZIKV-specific antigens, and we 




against other flaviviruses.  Subsequently, we created TMV viral nanoparticles displaying the ZIKV glycan 
loop and discovered that sera from ZIKV-infected patients contain antibodies to the GL region.  TMV-GL 
also proved to be highly immunogenic in mice, but neutralization assays demonstrated that this 
response was not neutralizing. To better elucidate the role the GL plays in the ZIKV immune response, 
we immunized mice with TMV-E, and rE and analyzed their immune response.  Both constructs induced 
a neutralizing immune response, and the subsequent creation of mAb-expressing hybridomas led to the 
discovery of 10 NAbs that were categorized into two groups: EME1 and EME2. 
Interestingly, the EME2 group of NAbs recognized the glycan loop region displayed on TMV-GL, 
suggesting that the glycan loop region does contain a neutralizing epitope, but that our TMV-GL 
construct may not include the entire epitope.  Thus, with modifications, our TMV-GL constructs could 
prove to be a safe, effective, and economical ZIKV vaccine candidate.  The discovery of GL-binding NAbs 
also has significant implications for the development of ZIKV therapeutics and diagnostics, as ZIKV-
specific antibodies could prove useful in both of these fields.  Although further studies are needed, our 
data suggest that EME2 Nabs do not bind to other flaviviruses, which may prove advantageous for both 
therapeutic and diagnostic applications.  Thus, future work on this project can include modifying and 
retesting the TMV-GL vaccine candidate, or further characterization and development of the EME2 NAbs 




CHAPTER TWO: ANTHRAX 
INTRODUCTION 
Bacillus anthracis, the causative agent of anthrax, is a toxin-producing, Gram-positive bacterium.  
Spores, the dormant form of the bacteria, naturally dwell in soil and can be found across the world 534.  
Primarily a zoonotic disease, domestic and wild animals become infected when they ingest anthrax 
spores while grazing 535.  Humans can then be infected when they come into contact with infected 
animals or animal products.  Once inside the body, anthrax spores germinate into their vegetative form 
and start producing toxins.  These toxins act synergistically to cause tissue necrosis and edema, and can 
ultimately lead to cardiopulmonary shock and meningitis, which are lethal if left untreated 535. Naturally 
occurring cases of anthrax in humans are extremely rare; in the U.S., only a few cases are reported every 
year 536.   Globally, an estimated 1,000-2,000 people die per year as a result of anthrax infections 537. 
The U.S. government has classified B. anthracis as a Category A Priority Pathogen because 
anthrax spores can be easily acquired and dispersed, which can lead to mass casualties 538,539.  Inhaling 
as little at 0.01 micrograms of spores can lead to inhalational anthrax, the most severe type of anthrax 
infection 540.  Symptoms of inhalational anthrax, such a fever and muscle aches, manifest within 1-7 days 
of exposure, and over 92% of untreated patients die within 48 hours of the onset of symptoms 535.  
Exposure to spores can also lead to cutaneous or gastrointestinal anthrax, but the untreated mortality 
rates, 20% and 25-60%, respectively, are much lower than the inhalational form 541.  Recently, injectional 
anthrax has been observed among heroin users in Europe, and studies have shown that Bacillus species 
are frequent contaminants of heroin in the United States 541. 
Anthrax infections are primarily treated with oral antibiotics, and in the case of cutaneous or 
injectional anthrax may include surgical debridement and/or adjunctive glucocorticoid therapy 542.  Due 
to the high mortality rates associated with inhalational anthrax, the existing standard of care for 




Antibiotics, such as ciprofloxacin or levofloxacin, block bacterial growth, while an antitoxin, such as 
raxibacumab, counteracts the effects of the toxins.  However, there are situations in which the standard 
of care cannot be followed.  For example, patients could be allergic to ciprofloxacin or have other 
contraindications to first-line treatments.  Additionally, the Department of Homeland Security 
announced that antibiotic-resistant strains of anthrax pose a genuine threat to society 543,544.  Multiple 
studies have been published on antibiotic- and antitoxin-resistant strains of anthrax and terrorist could 
easily create multi-drug resistant weaponized strain, as this “involves relatively straightforward 
methodology that does not require a high level of microbiologic knowledge” 544-547.  Delaying treatment, 
even for a few hours, to test for drug resistance could significantly reduce survival, and in the event of a 
large-scale attack, this delay could lead to thousands of deaths 548.   
 
BACKGROUND 
Anthrax virulence factors and their biological effects 
The virulence genes of B. anthracis are located on two plasmids, pXO1 and pXO2.  The pXO1 
plasmid encodes for toxins, while pXO2 encodes for the biosynthetic machinery that produces the 
bacterium’s poly-ɣ-D-glutamyl (PGA) capsule, which allows the bacilli to avoid phagocytosis and the 
complement system 549.  Anthrax bacterium produce and secrete a tripartite AB toxin composed of a 
receptor-binding subunit, protective antigen (PA), and two enzymatic subunits, lethal factor (LF) and 
edema factor (EF) 550.  As outlined in, these subunits work together to gain entry into host cells where 
they exert their toxic effects (Figure 27).  PA is an 83-kDa protein that binds to host-cell receptors and is 
processed by furin-like proteases into its 63-kDa form (PA63).  This process exposes the EF and LF binding 
sites as well as a heptamerization site.  Subsequently, multiple PA63 proteins form a heptamer, which 





Figure 27. Cellular entry of anthrax toxins; PA83 or PA63 binds to cell surface receptors CMG2 and TEM8. PA83 undergoes 
cleavage by cellular furin releasing the 20 kDa fragment (PA20). PA63 monomers bound to cellular receptors form an oligomer 
that is capable of binding to three LF or EF molecules. Endocytosis of the PA63 oligomer bound to LF or EF and acidification of 
the endosome result in translocation of LF or EF to the cytosol.  LF cleaves and inactivates MAPKKs and Nlrp1, which causes cell 
death, while EF increases intracellular cAMP levels, leading to edema.  Adapted from McComb et al. 552.  Reproduced with 
permission. 
The combination of LF and PA is called lethal toxin (LT), while the combination of EF and PA is 
called edema toxin (ET).  After endocytosis, the PA heptamer forms a pore in the endosomal membrane 
allowing EF and LF to escape into the cytoplasm 553.  LF, a zinc metalloproteinase, cleaves and inactivates 
members of the MAP kinase kinase family (MAPKK), which causes apoptosis 554.   LF has also been shown 
to cleave NOD-like receptor protein 1 (Nlrp1) on macrophages, which increases their sensitivity to LF-
mediated apoptosis 555.   In animal models, administering LT alone was toxic and led to hypoxic liver 
failure 556-558.  EF, a calmodulin-dependent adenylate cyclase, converts ATP molecules to cAMP, and the 




In addition to the two major virulence factors (i.e., toxins and PGA), B. anthracis produces a 
variety of proteases that degrade host tissues.  Metalloproteases secreted by B. anthracis have been 
shown to digest casein and gelatin in vitro and cause hemorrhage in vivo 561.  In addition, these 
proteases degrade components of the extracellular matrix, such as fibronectin, laminin, and collagen, 
which leads to tissue damage 562.   It has also been suggested that the proteases may use host plasmin 
for fibrinolysis and invasion.  B. anthracis also expresses anthrolysin O, a cholesterol-binding pore-
forming toxin, and anthrolysin B, a sphingomyelienase, which have been shown to have hemolytic 
effects 563,564.  Thus, vegetative bacilli coated in PGA escape the innate immune response and propagate, 
the virulence factors they secrete accumulate in the blood leading to vascular permeability and 
decreased function of target organs (e.g., heart, spleen, kidney, and brain).  Although both septicemia 
and toxemia contribute to the pathological features of anthrax, the exotoxins produced by the bacilli are 
ultimately responsible for anthrax-related mortality in humans 565,566.  Fatal outcomes of anthrax 
toxemia include hypotension, tachycardia, hemoconcentration, coagulopathy, anoxia, cardiac failure, 
and meningitis 567.  
Immune response to B. anthracis 
Because cases of anthrax infection are rare, limited data on the human immune response to B. 
anthracis are available 568.  The majority of the available data comes from animal models, in vitro assays, 
studies of vaccinees, or experiments using other members of the Bacillaceae family, none of which 
accurately or fully recapitulate anthrax in humans.  In addition, the immune response may vary based on 
the mode of infection (i.e., cutaneous, gastrointestinal, inhalation, or injectional).  The following 
paragraphs summarize what is known about the innate and adaptive immune response to B. anthracis 
infections.  
Infections are initiated when spores enter the host via the epidermis, the gastrointestinal tract, 




spores by phagocytes is not entirely understood, several groups have demonstrated that spores can 
activate the classical complement pathway and then undergo CR3-mediated phagocytosis by 
macrophages, dendritic cells, and epithelial cells 569-571.  The fate of phagocytosed spores is also unclear.  
Some studies suggest that once inside these phagocytes, the spores germinate and are subsequently 
killed in the phagolysosomes 572-574.  Other studies suggest that B. anthracis can hijack the phagocytes 
and use them to disseminate locally or throughout the entire body 575-577.  In the case of inhalational 
anthrax, B. anthracis bacilli can escape from the lysosomes of alveolar macrophages and replicate 
intracellularly, followed by cell lysis and the release of vegetative bacilli into the extracellular 
environment where they spread throughout the lymphatic system 576.  These two opposing observations 
might both be accurate though, as a study by Ross et al. demonstrated that in a guinea pig model of 
inhalation anthrax, some phagocytosed spores are digested and killed, while others germinate and are 
released into the lymphatic system 578.  Dendritic cells can also internalize spores through coiling 
phagocytosis, but their internal environment is thought to be even more conducive to vegetative growth 
and subsequent spread through the lymphatic system than that of macrophages 579-581.   
Spores and vegetative B. anthracis also activate MyD88-dependent receptors, which triggers the 
production of inflammatory cytokines 582,583.  One of these cytokines, IL-12, activates natural killer cells 
(NK cells) to produce IFN-ɣ and cytotoxic granule proteins, which have antibacterial activity.  Murine and 
human NK cells have been shown to mediate the killing of intracellular and extracellular B. anthracis 584. 
As part of the early innate immune response, neutrophils are also recruited to the site of infection 
where they can engulf and kill bacterial pathogens.  Unlike dendritic cells, and possibly macrophages, 
neutrophils are capable of efficiently killing B. anthracis 585,586.  A study by Mayer-Scholl et al. 
demonstrated that human neutrophils engulf anthrax spores, induce them to germinate, and then kill 
the vegetative bacteria using α-defensins 587.  However, it was noted that this response likely only 




anthrax infection 587,588.  This may also at least partially explain why inhalational anthrax infections do 
not resolve on their own like cutaneous anthrax infections.   
B. anthracis possesses a unique cell wall structure that includes a thick layer of DAP-type 
peptidoglycan, a proteinaceous S-layer, and a poly-γ-D-glutamic acid capsule 589.  In the case of 
extracellular vegetative cells, the PGA capsule is thought to protect the bacterium from phagocytosis so 
that the bacilli can survive in the host as an extracellular pathogen 535.  Even though the peptidoglycan 
layer of the cell wall is shielded from the immune system by the PGA capsule of B. anthracis, studies 
have shown that peptidoglycan is shed by Bacillus species during the logarithmic growth phase and is 
thus bioavailable to the host 590,591.  Although the extracellular receptor that recognizes peptidoglycan 
from B. anthracis is unknown, Iyer et al. demonstrated that the peptidoglycan is internalized and 
degraded, and can thereby trigger the production of proinflammatory cytokines and chemokines 590.  
Additionally, intracellular NOD2 receptors have been shown to recognize degraded B. anthracis 
peptidoglycans and induce caspase-1-mediated secretion of IL-1β and activate NF-κB signaling, which 
drives the innate inflammatory response 592,593.  Disseminated infections and the subsequent systemic 
proinflammatory response can lead to sepsis and death 590,594,595.   
Bacterial infections are also kept in check by the adaptive immune system.  The cellular immune 
response to bacterial agents includes CD8+ T cells recognizing and destroying host cells infected with 
intracellular bacteria, Th1 cells secreting IFN-ɣ and other cytokines that contribute to antimicrobial 
defenses, and Th2 cells regulating the humoral immune response.  As for the humoral response, 
antibodies can neutralize extracellular bacteria, and antibody effector functions can lead to opsonization 
of bacteria or antibody-dependent cell-mediated cytotoxicity.  Because B. anthracis bacilli are 
encapsulated by polysaccharides, they do not tend to elicit a robust adaptive immune response. The 
capsular polysaccharides of B. anthracis, PGA, can elicit a T cell-independent humoral response, but 




maturation and isotype switching do not occur 596,597.  PGA is resistant to proteolysis in antigen-
presenting cells, making it a weak antigen 598.  Thus, most of the protective adaptive immune response 
to B. anthracis appears to be directed against peptide antigens found on EF, LF, and PA.  Laws et al. 
demonstrated that natural anthrax infections lead to the production of PA-, LF-, and EF-specific IFN-ɣ 
production by T cells, as well as an antibody response to PA and LF 599.  LF and EF antibodies do not 
provide robust protection against infection, but antibodies to LF may contribute to toxin neutralization 
600.  In contrast, multiple studies using a variety of animal models have shown that anti-PA antibodies 
are sufficient to protect against infection 601-605.  Additionally, Quinn et al. established that inhalational 
anthrax in humans leads to the production of anti-PA IgGs and PA-specific IgG memory B cells and that 
there is a strong positive correlation between serum levels of anti-PA IgG and in vitro serum antitoxin 
activity 568.  
Interestingly, the toxins secreted by vegetative bacilli interact with components of both the 
innate and adaptive immune system.  At the site of infection, low levels of germination allow for the 
production of toxins that subvert the innate immune response, primarily by effecting phagocytes.  This 
includes inhibiting macrophage activation, promoting apoptosis of macrophages and DCs, suppressing 
NK cell expression of IFN-γ, delaying apoptosis, inducing migration of monocytes, altering cytokine 
production in human monocytes, and inhibiting the phagocytic activity of human neutrophils 584,606-609.  
The subsequent impairment of proinflammatory activities and reduced recruitment of phagocytes from 
the bloodstream lead to delayed bacterial clearance 607.  Toxins produced by vegetative bacteria that 
make it to the regional lymph nodes can also suppress the adaptive immune response.  This includes 
impairing DC maturation and function, blocking T cell activation and proliferation, and inhibiting B cell 
proliferation and antibody production 610-612.  These effects are exerted at different stages of infection, 
creating an environment that allows B. anthracis to effectively establish an infection and propagate 




macrophages, but EF delays their cell death and promotes their migration to lymph nodes so that the 
bacteria can disseminate through the bloodstream to various organs and tissues 567.  During the second 
phase of anthrax, i.e., the fulminant stage, LT and ET disrupt vascular tissues to allow bacteria to 
disseminate throughout organs.   
The immunosuppressive effects of LT and ET are not absolute.  For instance, in an aerosolized 
spore infection model, Pickering et al. showed that mice are capable of producing proinflammatory 
cytokines following an anthrax infection 613.  In other studies, it has been demonstrated that anthrax 
survivors mount potent adaptive immune responses 568,599,614.  However, in cases where large amounts 
of spores enter the body, such as in inhalational anthrax, patients were given antibiotics, which likely 
helped keep the vegetative bacteria in check in the absence of an inefficient innate immune response.  
Without antibiotics and an efficient innate immune response, anthrax bacilli multiply unchecked and 
disseminate into the blood where they produce increased levels of toxins before an adaptive immune 
response can be mounted.  Thus, without treatment, inhalational anthrax victims typically die within a 
week or two from toxemia, and even with treatment death can occur within a few days if a large 
number of spores are inhaled 615-617.   
Anthrax vaccines 
In 1881, Pasteur created an anthrax vaccine for cattle by using a heat-attenuated strain of B. 
anthracis, even today live-spore vaccines based on the attenuated strains of B. anthracis are still used in 
China, Russia, and in veterinary medicine 565.  Currently, there is only one anthrax vaccine licensed in the 
United States, anthrax vaccine adsorbed (AVA), also known as BioThrax ®.  Developed in the 1950s and 
licensed in the 1970s, AVA is a subunit vaccine composed of a partially-purified anthrax PA toxin from an 
avirulent, non-encapsidated strain of B. anthracis 618.  Various characteristics make AVA a suboptimal 
vaccine. These include undefined components, high production expenses, lot-to-lot variability, a 




the fact that it contains cellular elements, which can lead to local and systemic reactions 534,605,619,620.  
AVA is prepared by adsorbing filtered culture supernatants from an attenuated strain of B. anthracis to 
an alhydrogel adjuvant 621.  Although PA is the principal antigen component of AVA, it also contains EF, 
LF, and other cellular impurities, which can contribute to side effects.   Furthermore, AVA is 
administered as a series of 6 doses: subcutaneous injections are given at 0, 2, and 4 weeks, followed by 
boosters at 12 months and 18, and annual boosters are required to maintain protection 621.  In 1997, 
U.S. Secretary of Defense William Cohen mandated that all active military personnel be vaccinated 
against anthrax 622.   In accordance with this order, BioThrax ® has been administered to millions of 
military personnel.  However, numerous articles have questioned the safety, practicality, and long-term 
efficacy of the AVA vaccine 621-623, and it has not been approved as a pre-exposure prophylactic for the 
general public 624.   
Following the terrorist attacks of September 11, 2001, anonymous letters containing anthrax 
spores were sent to congressional offices and media companies.  This led to 21 confirmed or suspected 
cases of anthrax, including 5 deaths from inhalational anthrax, and more than 10,000 people were given 
oral antibiotics for post-exposure prophylaxis 625.  Laboratory tests, treatments, decontamination, and 
the ensuing investigations by the FBI and CDC, as well as state and local authorities,  is estimated to 
have cost billions of dollars 625.  Since this attack there has been increasing concern about anthrax spores 
being used was as a weapon of bioterrorism against the general population 619, and it is suspected that 
biological weapons programs in Iraq and Russia have developed technology capable of releasing large 
amounts of aerosolized spores on urban populations 626,627.  Responding to such widespread exposure 
would be problematic: local hospitals do not have the resources or infrastructure to provide intravenous 
antibiotics and antitoxins to thousands of people simultaneously 628, so only those with confirmed cases 
of anthrax get these treatments, and many suspected exposure cases would only receive oral 




exposed to anthrax adhered to the recommended oral antibiotic regimen 629.  Therefore, the CDC now 
recommends that post-exposure prophylactic treatment include the administration of an anthrax 
vaccine 629.  Following this recommendation will require the development of a safe and efficacious 
anthrax vaccine, and such a vaccine would constitute a cost-effective means of countering the threat of 
weaponized anthrax spores 565.   
Previous studies have established that protective immunity against anthrax is primarily 
mediated by antibodies that bind to PA 603,630-632.  To address the safety issues and lot-to-lot variability of 
AVA, several candidate anthrax vaccines contain recombinant PA (rPA) 633,634.  Candidate rPA vaccines 
formulated with an alum adjuvant were shown to induce levels of neutralizing antibodies comparable to 
AVA and also required annual boosters to maintain protective immunity 552,635,636.  To elicit a longer-
lasting immune response and reduce the number immunizations needed, alternative adjuvants and 
carrier proteins have also been used to create new candidate rPA vaccines 637-640.  Although several of 
these rPA-based vaccines have made it into clinical trials, none have yet obtained licensure from the FDA 
641-645.  The aim of this project was to develop an improved anthrax vaccine candidate using TMV 
nanoparticles.    
Translational fusions to TMV coat protein 
As discussed in the previous chapter, neutralizing antibodies primarily recognize conformational 
epitopes and inducing neutralizing antibodies may, therefore, require conformational antigens.  Many 
neutralizing PA epitopes are known, including two linear epitopes in domain 4 that block the ability of 
PA to bind to receptors 646,647.  Genetically fusing foreign peptides to the TMV coat protein tends to be 
the easiest and least expensive method of creating VNP vaccine candidates, but this approach is typically 
limited to smaller epitopes.  Previous work by McComb et al. demonstrated that vaccines produced by 
genetically fusing small, linear PA epitopes to the TMV coat protein failed to protect mice challenged 




epitopes were displayed simultaneously, either by creating multiple monovalent VNPs and combining 
them or by increasing the size of the translational fusion so that multiple linear epitopes are displayed 
on a single TMV particle.  Thus, PA domains might serve as better antigens.  
PA domains 
As outlined in Figure 27, PA is an 83-kDa protein that binds to host cellular receptors and 
facilitates the cellular internalization of EF and LF.  PA consists of four domains, each contributing to its 
role in facilitating the cellular internalization of EF and LF (Table 10).  Mutational analysis and crystal 
structure mapping have revealed residues in all four domains that are essential for PA function 552,649,650.  
Additionally, Crowe et al. used sera from AVA-vaccinees to map the PA domains that contained 
neutralizing epitopes and found thirteen antigenic regions that spanned all four domains 651.  Based on 
this evidence, we included PAD1, PAD1’, PAD2, PAD3, and PAD4 in this work.  
Table 10. PA domains and their function(s). 
Domain Amino Acids 652 Function 
1 
PA20 1-167 Furin cleavage site653,654 
1’ 168-258 
Hepatmerization 652 
LF & EF binding sites 654,655 
2 259-487 
Heptamerization 652 
Membrane insertion / Pore formation 656,657 
LF & EF translocation 658 
3 488-595 Heptamerization 659  
4 596-735 Binding to cellular receptor 660-662 
The Dock-and-Lock system 
VNPs created by genetically fusing foreign epitopes to the coat protein of TMV have several 
limitations.  First, the biophysical properties of certain epitopes elicit necrotic lesions, leading to reduced 
yields or reversion to wild-type TMV, as was the case for the fusion loop epitope of ZIKV.  Second, while 




approximately 20 amino acids can be genetically fused to the TMV coat protein without affecting viral 
replication and assembly 183 (although some groups have been able to display larger proteins with the 
use of a linker peptide 663).  These limitations were addressed using an alternative approach that 
involves expressing and purifying the TMV scaffold and heterologous protein antigen separately, then 
conjugating the antigen to the surface of TMV.   
The Dock-and-Lock system allows large protein antigens to be covalently attached to the TMV 
nanoparticles.  This system utilizes two components of the Drosophila phototransduction system: 1) the 
C-terminal residues of the NorpA protein (EFCA) added to the C-terminus of the TMV coat protein, and 
2) the PDZ1 domain of InaD translationally fused to the C-terminus of a recombinant protein antigen 
(hereafter referred to as an InaD fusion protein) 664,665.  The EFCA sequence and the InaD domain both 
contain cysteine residues with free thiol groups that can form a disulfide bond, which allows multiple 
copies of the fusion protein to be covalently attached to the surface of TMV.  TMV VNPs displaying PA 
domains were created by expressing and purifying PAD-InaD fusion proteins and TMV-EFCA separately,  
followed by conjugation.   
MATERIALS AND METHODS 
Generation of TMV-EFCA 
Purified TMV viral particles with an EFCA sequence genetically fused to the C-terminus of the 
coat protein (TMV-EFCA) was kindly provided by Novici Biotech.  To create a working stock of TMV-EFCA, 
the leaves of N. benthamiana plants were first dusted with diatomaceous earth (Celite® 545, Acros 
Organics).  The TMV-EFCA sample provided by Novici was diluted in PBS, 5 µL of the suspension was 
pipetted onto the dusted leaves, and the leaves were rub-inoculated with sterile cotton swabs.  Infected 




TMV-EFCA particles were analyzed by SDS-PAGE and used in docking reactions to confirm the presence 
of the EFCA amino acids to the C-terminus of the coat protein.   
Cloning, expression, and purification of PA domain fusion proteins in Nicotiana benthamiana 
DL24, a TMV launch vector provided by Novici Biotech containing InaD (amino acids 2-
98, GenBank accession no. 1IHJ_A, cys53ala mutation) was digested using PacI and XhoI to remove the 
InaD insert and prepare the vector for HiFi assembly.  InaD with a C-terminal poly-histidine affinity 
purification tag (6xHis) was PCR amplified from the DL24 vector using primers with the appropriate PAD 
and DL24 overhangs.  The PA domains were PCR amplified from vectors created by Ryan McComb using 
primers with the appropriate InaD and DL24 overhangs.  The PCR products were analyzed on agarose 
gels and then purified using the Wizard ® SV Gel and PCR Clean-Up System (Promega).  Digested DL24, 
PCR-amplified PA domain, and PCR-amplified InaD were then assembled and transformed into 5-α 
competent E. coli using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England Biolabs).  Plasmids 
were extracted from E. coli cultures using a Zymo Plasmid Miniprep Kit (Zymo Research), and sequences 
were confirmed by PCR and sequencing.  The plasmids were then transformed into electro-competent 
Agrobacterium tumefaciens (strain GV3101), grown in L-MESA and then AIM, followed by vacuum 
infiltration into N. benthamiana.  To isolate the fusion proteins, agroinfected leaves were homogenized 
in grind buffer (100 mM Tris, 2 mM PMSF, 5 mM imidazole, 500 mM NaCl, 0.005% BME, pH 8) using a 
mortar and pestle.  The lysate was then strained through cheesecloth, centrifuged at 14 k x g for 15 min 
at 4°C, followed by re-centrifuging the supernatant at 14 k x g for 1 hr at 4°C.  The lysate supernatant 
was filtered through 0.22 µm vaccine filter (Corning), purified on a HisTrap™ HP column (GE Healthcare) 




Expression of PA domain fusion proteins in Escherichia coli 
Cloning and production in Escherichia coli   
The nucleic acid sequences for each PA domain fusion protein were codon-optimized for 
expression in E. coli using GENEius (Eurofins Genomics) and then ordered as GeneStrands from Eurofins 
Genomics.  The GeneStrands were designed to include a PA domain, a C-terminal InaD PDZ domain 
(amino acids 2-98, GenBank accession no. 1IHJ_A, cys53ala mutation), a C-terminal 6xHis purification 
tag, and 3’ and 5’ overlaps for insertion into the pSX2 expression vector (Scarab Genomics).    The gene 
strands were cloned into KpnI and SacI-digested pSX2 using the NEBuilder® HiFi DNA Assembly Cloning 
Kit (New England Biolabs), followed by transformation into 5-alpha competent E. coli.  The sequence of 
each plasmid was verified by PCR and sequencing before it was cloned into chemically competent 
MDS42 E. coli (Scarab Genomics).  One liter flasks of Terrific Broth containing kanamycin (50 µg/mL) 
were seeded with 10 mL of the transformed MDS42 E. coli grown overnight in the same culture.   The 
bacteria were grown at 37°C to an OD600 of approximately 1.0, and PAD fusion protein expression was 
induced by adding isopropyl-1-thio-β-D-galactopyranoside (IPTG) (Sigma-Aldrich) to a final concentration 
of 1 mM, and left to grow at either 30°C or 37°C (optimal post-induction temperatures and incubation 
times were determined for each construct using SDS-PAGE analysis).   
Harvesting and lysis of bacterial cells 
After induction, E. coli cells were separated from the culture media by centrifugation at 10,000 x 
g for 10 min at 4°C.  The supernatant was discarded, and the pelleted cells were washed with cold wash 
buffer (50 mM Tris, 300 mM NaCl, 20 mM BME, 0.2% Tween, pH 7.5), and centrifuged again at 5,000 x g 
for 20 min at 4°C.  The cell pellet was washed again and centrifuged at 3,000 rpm for 25 min at 4°C.  The 
cell pellet was resuspended in lysis buffer (10 mM Tris, pH 8, 0.1 M NaCl, 1 mM PMSF) plus 1 µg/mL 




sonication on ice to degrade DNA.  The resulting lysate was centrifuged at 14,000 x g for 5 min at 4°C, 
and the lysate pellet and supernatant were analyzed by SDS-PAGE and western blot.     
Purification of His-tagged PA domain fusion proteins   
The majority of the his-tagged PA domain fusion proteins were found in the lysate pellet, and 
thus were solubilized in binding buffer with urea (6 M urea, 20 mM Tris, 0.5 M NaCl, 1 mM BME, 5 mM 
imidazole) prior to refolding on a HisTrap ™ HP column (GE Healthcare) using a 6-0 M urea step gradient 
followed by elution with a imidazole gradient 666.  Purification was monitored by SDS-PAGE and/or 
western blotting.  Dialysis was performed on the pooled elution fractions that contained the PAD fusion 
protein using either SnakeSkin™ Dialysis Tubing (Thermo Scientific) or a Float-A-Lyzer (Spectrum Labs) 
with a MWCO of 10 kDa and then concentrated using Vivaspin® Centrifugal Concentrators (Sartorius).  
For soluble fusion proteins, the lysis supernatants were clarified by ammonium sulfate fractionation and 
membrane filtration prior to purification on HisTrap ™ HP columns (GE Healthcare) per the 
manufacturer’s recommendations 667.  Protein concentrations were determined using the Pierce BCA 
Protein Assay Kit (Thermo Scientific) with BSA (BioRad) as the standard.   
Addition of a PelB leader sequence and secretion into the periplasmic space 
Additional E. coli expression vectors for PAD1 and PAD1’ were designed and cloned as above, 
except with a PelB leader sequence added to the N-terminal end of the GeneStrands ordered from 
Eurofins Genomics.  Cultures were grown and induced as above, followed by harvesting of the 
periplasmic proteins by selective disruption of the outer membrane and peptidoglycan layer as 
described in Wingfield et al. 668,669.  Subsequent purification and analyses were performed as above.  
Addition of MBP fusion protein partner 
The sequences for the His-tagged PAD1 and PAD1’-InaD fusion proteins were PCR amplified with 
vector overlaps to IPTG-inducible expression vector containing maltose-binding protein (MBP) with a C-




from Scott Gradia, Addgene plasmid # 29721).  The vector was digested using XhoI and SspI, and the 
PCR-amplified inserts were cloned in using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England 
Biolabs), followed by transformation into competent DH5α E. coli.  After confirming the correct insertion 
of the PAD-InaD sequences by colony PCR, the plasmids were transformed into chemically-competent T7 
Express E. coli (New England Biolabs) for MBP-PAD-InaD fusion protein expression.  
One liter flasks rich media (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L NaCl) containing 
kanamycin (50 µg/mL) and glucose (2 g/L) were seeded with 5 mL of overnight cultures, followed by 
incubation at 37°C until an optical density of 0.5 at 600 nm (OD600 of 0.5) was reached.  Expression was 
induced with 1 mM IPTG for 3 hr at 37°C, the cultures were centrifuged at 4,000 x g for 20 min at 4°C, 
and the cell pellets were resuspended in lysis buffer (20 mM Tris, pH 8, 100 mM NaCl, 1 mM EDTA).  
Lysis, sonication, and analysis were performed as above, followed by solubilization, purification, and 
refolding on Ni-NTA resin as above.  MBP was cleaved from the MBP-PAD-InaD fusion proteins in 
solution using the Pierce ™ HRV 3C Protease Kit (Thermo Scientific) following the manufacturer’s 
recommendations 670.  The HRV3C protease was removed using Pierce® Glutathione Agarose (Thermo 
Scientific) and Pierce™ Centrifuge Columns (Thermo Scientific) per the manufacturer’s 
recommendations 671.  MBP was removed using amylose resin (New England Biolabs) as described in the 
manufacturer’s instructions 672, followed by dialysis and concentration of the PAD-InaD fusion proteins 
using Vivaspin® Centrifugal Concentrators (Sartorius).      
Analysis by SDS-PAGE and western blotting 
The different stages of purification of all fusion proteins (e.g. metal ion affinity chromatography 
using Ni-NTA resin) were monitored by SDS-PAGE and western blot.  Some samples were concentrated 
by acetone precipitation prior to analysis, as described in Fic et al. 673.  Protein process samples were 
diluted with Laemmli Sample Buffer (BioRad) containing 355 mM BME, followed by heating at 100°C for 




were loaded into 4-20% Mini-PROTEAN® TGX™ Precast Gels (BioRad), ran at 100 volts for 75-90 min, 
then either stained with Bio-Safe™ Coomassie Stain (BioRad) or transferred to a nitrocellulose 
membrane for western blotting.    
SDS-PAGE gels were transferred to 0.2 µm or 0.45 µm Nitrocellulose Membrane (BioRad) for 2 
hr at 150 mAmps, followed by blocking with 5% (w/v) non-fat milk in TBS for 1 hr at room temperature 
and incubation with primary antibody diluted in blocking buffer overnight at 4°C.  After washing the 
membranes three times with TBST and one time with TBS, the appropriate secondary antibody diluted 
in blocking buffer was added, and the membrane was incubated 1-2 hr at room temperature.  Following 
an additional round of washing, the membrane was incubated with either a chromogenic or 
chemiluminescent HRP substrate.  Membranes were incubated with a mixture of hydrogen peroxide and 
a 4-Chloro-1-Naphthol solution (Opti-4CN™ Substrate Kit, BioRad) at room temperature until the desired 
color was obtained, and then rinsed with water to stop the reaction.  Alternatively, Clarity™ Western 
ECL Substrate (BioRad) was added, the membrane was incubated for 5 min at room temperature, and 
the resulting chemiluminescent signals were documented using the Azure c500 (Azure Biosystems, 
Dublin, CA).  The primary antibodies used for western blotting were polyclonal goat anti-PA83 (List 
Biological Laboratories) and monoclonal mouse anti-MBP (New England Biolabs); the secondary 
antibodies used were rabbit anti-goat IgG (Invitrogen) and goat anti-mouse IgG (BioRad), respectively.  
PA83 (recombinant anthrax protective antigen, List Biological Laboratories) was used as a positive control 
for the anti-PA83 blots.  
Analysis by ELISA 
Endpoint titers to the PAD-InaD fusion proteins were determined using goat polyclonal antibody 
from List Biologics (product #771B).  Briefly, 96-well half area plates (Corning) were coated with PAD-
InaD fusion proteins diluted in carbonate buffer (0.03 M Na2CO3/0.07 M NaHCO3, pH 9.6) to 10 µg/mL, 




incubation with serially diluted polyclonal goat anti-PA83 diluted in blocking buffer overnight at 
4°C.  Following three washes with PBS, the plates were incubated with HRP-conjugated rabbit anti-goat 
IgG (1:2,000, Invitrogen) for 1.5 hr at room temperature then washed three times with PBS.  OPD 
substrate (Sigma) was added and the absorbance at 450nm was measured on a SpectraMax Plus plate 
reader (Molecular Devices).  Endpoint titers were defined as the reciprocal of the highest antibody 
dilution that gave a reading above the cutoff.  Cutoff values were determined for each fusion protein, 
and each antibody dilution using Normal Goat Serum (Calbiochem)  as described in Frey et al. 482.  
Docking reactions to create TMV-PAD viral nanoparticles 
VNPs were prepared using the Dock-and-Lock method to covalently attach the PA-InaD fusion 
proteins to the TMV-EFCA scaffold 664.  The purified PAD-InaD fusion protein was diluted in 2x reaction 
buffer (100 mM Tris, pH 8, 0.008% BME), mixed with purified TMV-EFCA, and incubated at room 
temperature for 30 min.  VNPs were then separated from unbound PAD-InaD by precipitation of the 
virions with 0.5 M NaCl/4% PEG, incubation on ice for 1 hr, and centrifugation at 10,000 x g for 15 min at 
4°C.  The supernatant was removed, and the virus-containing pellet was resuspended in PBS.  Docking 
was confirmed on SDS-PAGE gels using both reduced and non-reduced samples.  Purified green 
fluorescent protein (GFP)-InaD fusion protein (provided by Novici Biotech) used as a positive control for 
docking reactions.  
RESULTS 
Expression of PA domain fusion proteins in Nicotiana benthamiana 
The five PAD-InaD constructs were successfully cloned into the DL24 expression vector and 
transformed into 5-α competent E. coli.  The PAD1’ and PAD1 fusion protein expression vectors were 
transformed into A. tumefaciens, and agrobacterium cultures were used to agroinfiltrate N. 




mortar and pestle to lyse the cells.  The cell lysate was clarified by centrifugation and filtration, and the 
His-tagged PAD fusion proteins were purified using affinity chromatography.  SDS-PAGE analysis of the 
lysate and column chromatography samples for PAD1’-InaD did not reveal any significant bands that ran 
at the estimated molecular weight of PAD1’-InaD (22 kDa) (Figure 28a), but western blotting with an 
anti-PA83 antibody did show a band with an apparent molecular weight of 25 KDa of in the column 
elution fractions (Figure 28b).  A smaller band, with an apparent molecular weight of 16 kDa, also 
appeared on the western blot in the elution column fractions (Figure 28a, b); this may have been a 
partially degraded or truncated form of the PAD1’ fusion protein.  In an attempt to minimize in planta 
and ex planta degradation, leaf punch samples or agroinfiltrated leaves were harvested at various DPIs 
and the pH and the composition of the grind buffer, including the addition of various protease 
inhibitors, was investigated.  However, none of these changes led to any significant improvement in 
yield (data not shown), suggesting that the PAD1’ fusion protein was not being expressed at high levels 
in N. benthamiana.  Furthermore, while the western blot showed that the highest concentration of the 
PAD1’ fusion protein was in 75 mM imidazole and 100 mM imidazole elution fractions, the SDS-PAGE gel 
showed that these elution fractions also contained high levels of impurities (i.e., co-purifying host-cell 
proteins).  The yield of “purified” PAD1’-InaD was estimated to be 24 ng of protein per gram of leaf 
tissue.   
The expression of PAD1-InaD proved to have similar issues. SDS-PAGE (Figure 29a) and western 
blot analysis (Figure 29b) demonstrated that PAD1-InaD was expressed at very low levels and, after 
affinity chromatography, it migrated mostly as a single band with an apparent molecular weight of 42 
kDa (although several degradation products appear to be present in some of the elution fractions).  
While the PAD1-InaD elution fractions do not contain as many co-purifying host-cell proteins as the 
PAD1’ fusion protein, they are still present at moderate levels (Figure 29a).  The yield of “purified” 






Figure 28. SDS-PAGE and western blot analysis of purified PAD1’-InaD expressed in Nicotiana benthamiana. a) SDS-PAGE 
analysis of crude cell lysates and affinity chromatography process samples. b) Western blot analysis of affinity chromatography 








Figure 29. SDS-PAGE and western blot analysis of purified PAD1-InaD expressed in Nicotiana benthamiana. a) SDS-PAGE 
analysis of affinity chromatography process samples. b) Western blot analysis of clarified cell lysate and affinity 
chromatography process samples using an anti-PA83 primary antibody, followed by a HRP-conjugated secondary antibody and 
chromogenic substrate.  
Expression and purification of PA domain fusion proteins in E. coli 
All five PAD-InaD constructs were successfully cloned into the pSX2 expression vector and 
transformed into MDS42 E. coli for expression.  Following cell lysis, the crude cell lysate was centrifuged 
to separate the soluble proteins (i.e., the proteins present in the supernatant) and insoluble proteins 




confirmed that the PAD2, PAD3, and PAD4 fusion proteins were being expressed at relatively high levels 
as insoluble proteins, while PAD1’ and PAD1 were expressed at low levels as partially soluble proteins.  
As an example, Figure 30a demonstrates that PAD3-InaD and PAD4-InaD end up in the cell lysate pellets 
with molecular weights of 25 kDa and 28 kDa, respectively.  Both of these fusion proteins can easily be 
seen on a Coomassie-stained SDS-PAGE gel, indicating that they are being expressed at relatively high 
levels.  In contrast, PAD1’-InaD, with an apparent molecular weight of 25 kDa, was not made as an 
inclusion body (Figure 30a) and ended up mostly in the cell lysate supernatant and was expressed at 
very low levels (Figure 30b).   
The insoluble fusion proteins that ended up in the lysate pellets (i.e., PAD2, PAD3, and PAD4) 
were solubilized upon resuspension in buffer containing 6 M urea, refolded on a Ni-NTA column using a 
6-0 M urea step gradient, and then eluted with an imidazole gradient.  The refolded and purified fusion 
proteins were then dialyzed to remove the imidazole, concentrated with ultrafiltration centrifugal 
devices (data not shown).  SDS-PAGE analysis of the purified and concentrated PAD2-InaD, PAD3-InaD 
and PAD4-InaD shows that they are present at high concentrations with almost no contaminating host-
cell proteins and run at 36 kDa, 25 kDa, and 28 kDa, respectively (Figure 31a).  Subsequent western blot 
analysis demonstrated that all three fusion proteins were detected by the anti-PA83 antibody at their 
respective molecular weights, and while there were no apparent degradation products, the fusion 
proteins did appear to be former dimers, as shown by the bands that ran at twice their respective 
molecular weights (Figure 31b).  The concentrations of the purified PAD2-InaD, PAD3-InaD, and PAD4-
InaD proteins were calculated using a BCA assay, and final product yields were estimated at 62, 30, and 
85 milligrams of protein per liter of cell culture, respectively.  
The initially soluble but poorly expressed fusion proteins that ended up in the lysate 
supernatant (i.e. PAD1’ and PAD1) were purified on Ni-NTA columns followed by dialysis and 






Figure 30. SDS-PAGE and western blot analysis of crude cell lysates for PAD1’, PAD2, and PAD4 fusion proteins expressed in E. 
coli. a) SDS-PAGE analysis of crude cell lysate pellets from clones expressing PAD3-InaD, PAD4-InaD, or PAD1’-InaD. b) Western 
blot analysis of cell lysate supernatants from clones expressing PAD1’-InaD using an anti-PA83 primary antibody, followed by a 
HRP-conjugated secondary antibody and chemiluminescent substrate.  
samples.  To determine if the fusion proteins remained in the soluble fraction or had become insoluble, 
the particulates were separated from the soluble proteins by centrifugation.  Subsequent SDS-PAGE and 
western blot analysis of both the supernatants and the resuspended pellets revealed that both PAD1-
InaD and PAD1’-InaD were partially insoluble, but the majority of the PAD1 fusion protein was present in 
the pellet (i.e., insoluble) while the PAD1’ fusion protein was equally split between the pellet and the 
supernatant (Figure 31a, b).  Although the expected molecular weight of PAD1-InaD was 42 kDa (Figure 




degradation products in the insoluble fraction (Figure 31b).  PAD1’-InaD was present at only moderate 
concentration and co-purified with various host-cells proteins, but ran at its expected molecular weight, 
25 kDa, with minor degradation products (Figure 31a, b).  The presence of host-cell proteins and 
degradation products, as well as the partially insoluble nature of both PAD1-InaD and PAD1’-InaD, made 
it difficult to determine final yields, but both were estimated to be approximately 0.6 milligrams of 
protein per liter of cell culture. 
 
Figure 31. Analysis of purified and concentrated PA domain fusion proteins expressed in E. coli.  a) SDS-PAGE analysis of 
purified and concentrated PAD2, PAD3, and PAD4 fusion proteins, as well as the insoluble and soluble fractions of the purified 
and concentrated PAD1 and PAD1’ fusion proteins.  b) Western blot analysis of the same samples using an anti-PA83 primary 





Periplasmic expression of PAD fusion proteins using PelB 
PelB is a naturally-occurring signal sequence from the secreted PelB protein of the bacterium 
Erwinia carotovora that has been used in E. coli expression systems to target proteins to the periplasmic 
space 674.  Advantages of targeting proteins to the periplasm can include more straightforward 
purification, less proteolysis, and improved folding 675.  The PelB signal sequence was added to the 
amino terminus of the PAD1 and PAD1’ constructs to target the fusion proteins for secretion into the 
periplasm.  After inducing protein expression with IPTG, the cells were cultured at either 30°C or 37°C 
overnight.  Following centrifugation, the cell pellet was subjected to cellular fractionation to determine 
the compartment in which the fusion proteins were being expressed.  First, the cell pellet was 
resuspended in a buffer containing EDTA and sucrose to release the periplasmic fraction.  After 
centrifugation, the resuspended spheroplast pellet was subjected to freeze-thaw cycles to lyse the cells, 
and then centrifuged again to separate the cytoplasmic proteins (supernatant) from the membranes and 
insoluble proteins (pellet).   
Acetone precipitation was used to concentrate process samples that were expected to contain 
low levels of protein (i.e., the culture supernatant and the sucrose supernatant).  Western blotting with 
an anti-PA83 antibody revealed that the PAD1 fusion protein seemed to be expressed at approximately 
the same level whether induced at 30°C or 37°C and that the addition of a PelB leader sequence did not 
result in PAD1-InaD being efficiently secreted into the periplasm, as it was present in multiple cellular 
fractions (Figure 32a).  The expression of PAD1’-InaD with the PelB signal sequence also showed 
inefficient secretion and even lower levels of expression than the PAD1 fusion protein (Figure 32b).  The 
presence of the fusion proteins in the lysis pellets suggests that they may be partially insoluble, which is 
supported by previous attempts at expression without the PelB leader sequence (Figure 31).  Due to the 
inefficient secretion of both PAD1’-InaD and PAD1-InaD, all cell fractions containing the respective 




estimated yield of PAD1’-InaD was 0.6 mg/L, and PAD1-InaD was 0.75 mg/L.  Thus, the addition of the 
periplasmic secretion signal did not solve the low yield problem and pooling the fractions reintroduced 
the same co-purifying host-cell proteins seen in the prior expression of the PAD1’-InaD and PAD1-InaD 
constructs that lacked the PelB signal sequence.   
 
 
Figure 32. Western blot analysis of the expression of PAD1-InaD and PAD1’-InaD with a PelB periplasmic secretion signal. 
Cellular fractions from  E. coli cultures expressing PAD1-InaD (a) or PAD1’-InaD (b) were grown at 30°C or 37°C and then 
analyzed by western blot using an anti-PA83 primary antibody, followed by a HRP-conjugated secondary antibody, and 
chemiluminescent substrate. The culture supernatants and sucrose supernatants were concentrated using acetone 




Expression of MBP fusion proteins 
Maltose-binding protein (MBP) is a component of the transport system for malto-
oligosaccharides in E. coli, and due to its high stability, it is widely used as a fusion protein partner 676,677.   
Fusion partner proteins can stabilize proteins that are difficult to express while also conferring high 
solubility and facilitating protein purification with amylose resin 677.  The codon-optimized sequences for 
PAD1’-InaD and PAD1-InaD with a C-terminal 6xHis purification were cloned into a pET expression vector 
containing an IPTG-inducible N-terminal MBP with HRV 3C protease recognition sequence to remove the 
MBP during purification.  After culturing and centrifugation, the resuspended cells were lysed and 
centrifuged again to separate the insoluble and soluble components.  SDS-PAGE analysis demonstrated 
that MBP-PAD1-InaD ran at a molecular weight of 86 kDa, while MBP-PAD1’-InaD ran at 68 kDa (Figure 
33).  Reasonable amounts of soluble MBP-PAD1’-InaD and MBP-PAD1-InaD were present in the lysis 
supernatants, although approximately half of the MBP fusion proteins appeared to be in the lysis pellets, 
and therefore were presumably insoluble (Figure 33).  
 




Following cell lysis, the MBP fusion proteins were purified on Ni-NTA resin, and MBP was 
cleaved off using GST-tagged HRV 3C protease.  Cleavage with HRV 3C proved to be reasonably efficient, 
and following cleavage the GST-tagged HRV3C protease was removed using glutathione agarose (data 
not shown).  Cleaved MBP and any remaining uncleaved MBP fusion proteins were then removed using 
amylose resin.  However, this process was not efficient as western blot analysis using both anti-PA and 
anti-MBP antibodies revealed that the amylose resin was not efficiently capturing the cleaved MBP and 
the uncleaved MBP fusion proteins (Figure 34).   
 
Figure 34. Western blot analysis of the removal of MBP using amylose resin.  After HRV 3C cleavage, the proteins were dialyzed 
into column buffer, and this served as the starting material for MBP removal by on the amylose column.  Column fractions were 
analyzed by western blot using an anti-PA83 primary antibody (a) or an anti-MBP primary antibody (b) followed by HRP-




The amylose column flow-throughs had to be run at least three consecutive times on amylose 
resin to remove the majority of the MBP.  After diafiltration and ultrafiltration (DF/UF), the process 
samples were analyzed by SDS-PAGE and western blot, which revealed that the purified PAD1’-InaD 
contained no visible no host-cell proteins (Figure 35a), but did contain residual MBP (Figure 35c).  PAD1’-
InaD showed signs of degradation (Figure 35a, c), and was not very concentrated (Figure 35a).  The 
purified and concentrated PAD1-InaD contained no visible host-cell proteins (Figure 35a), but still 
contained quite a bit of residual MBP (Figure 35c).  Also, because PAD1’-InaD and MBP had the same 
apparent molecular weight of 45 kDa (Figure 35b, c), the 45 kDa band, that is supposedly purified and 
concentrated PAD1-InaD, is really a mixture of the two proteins.  The estimated final yields for this 





Figure 35. SDS-PAGE and western blot analysis MBP-PAD1-InaD and MBP-PAD1’-InaD purification process samples. a) Process 
samples from the 3rd consecutive amylose column for PAD1-InaD and the 4th column for PAD1’-InaD and a subsequent 
ultrafiltration and diafiltration (UF/DF) step were analyzed SDS-PAGE.  Western blotting of the same samples using an anti-PA83 
primary antibody (b) or an anti-MBP primary antibody (c) followed by HRP-conjugated secondary antibodies, and 










Table 11. Final yields and total amounts of purified PA domain fusion proteins. 
Fusion 











benthamiana) - 24 ng/g* 1.4 ug 
Bacterial (E. coli) 
- 0.6 mg/L 420 µg 
PelB 0.6 mg/L 250 µg 
MBP 2.6 mg/L 34 µg 
PAD1-InaD 
Plant (N. 
benthamiana) - 95 ng/g * 30 µg 
Bacterial (E. coli) 
- 0.6 mg/L 610 µg 
PelB 0.75 mg/L 375 µg 
MBP 3.3 mg/L 43 µg 
PAD2-InaD Bacterial (E. coli) - 62 mg/L 1,250 µg 
PAD3-InaD Bacterial (E. coli) - 30 mg/L 1,800 µg 
PAD4-InaD Bacterial (E. coli) - 85 mg/L 5,100 µg 
*Estimated based on western blot analysis with a known amount of the positive control protein, PA83.  However, 
only a fraction of the anti-PA83 antibodies used bind to each domain of PA, so actual yields are likely lower than 
these estimates. 
a For plant-based expression, final yields are in units of nanograms of protein per gram of fresh weight leaf tissue.  
For bacterial expression, final yields are in units of milligrams of protein per liter of cell culture.  
b Amount of purified product prior to analysis by SDS-PAGE, western blot, and BCA.  Thus, less protein was 
available for subsequent docking reactions.  
Functional analysis by ELISA Production and purification of TMV-EFCA 
In addition to western blotting, the purified PAD2-InaD, PAD3-InaD, and PAD4-InaD were 
analyzed by indirect ELISA to check whether they could be recognized by goat anti-PA83 polyclonal IgG 
antibodies.  Endpoint titers, defined as the reciprocal of the highest antibody dilution that gave a 
reading above the cutoff, were determined to provide a semi-quantitative measure of the proportion of 
the polyclonal anti-PA83 antibodies bound to each fusion protein.  Figure 36 shows how the signal (i.e., 
absorbance at 450 nm) decreases with each successive dilution of the anti-PA83 primary antibody or, in 
the case of the cutoffs, normal goat serum.  The estimated endpoint dilutions for the PAD2, PAD3, and 
PAD4 are 1.64 x106, 8.19 x 105, and 4.10 x 105, respectively (Figure 36).  This suggests the PAD2 region of 




elicited more antibodies.  Alternatively, it could indicate that the PA portion of the PAD2-InaD fusion 
protein retained more of its native structure, and therefore was able to bind more of the anti-PA83 
antibodies.  Although, perhaps the most likely explanation comes from the fact that domain 2 contains 
more amino acids than domain 3 or domain 4.  Nevertheless, along with the western blots, the ability of 
the anti-PA83 serum to bind to all three fusion proteins verifies that the purified fusion proteins contain 








Figure 36. Analysis of purified PAD fusion proteins by ELISA. Purified PAD2-InaD (a), PAD3-InaD (b), or PAD4-InaD (c) fusion 
proteins were used to coat a 96-well plate.  Serially diluted anti-PA83 serum was added followed by incubation with an HRP-
conjugated secondary antibody and the addition of OPD substrate.  Cutoff measurements were obtained using serum from an 
unvaccinated goat in place of the primary antibody.  Each data point represents the average of triplicate wells.   
Production and purification of TMV-EFCA 
To create the PA domain-TMV viral nanoparticles, a large stock of TMV-EFCA was first made by 
rub-inoculating purified TMV-EFCA onto the leaves of N. benthamiana plants.  Following PEG 
precipitation, SDS-PAGE analysis showed that the majority of TMV-EFCA was in the clarification 
supernatant, although the addition of the EFCA residues did not change the molecular weight of the 
TMV coat protein enough to show a visible difference between TMV-EFCA and wild-type TMV on a 
Coomassie-stained gel (Figure 37a).  Thus, to confirm the presence of TMV-EFCA, the clarification 
supernatant was used in docking reaction with GFP-InaD.  GFP-InaD was added to TMV-EFCA followed 
by PEG-precipitation and centrifugation.  Any undocked fusion protein remained in the supernatant, 
while any decorated or undecorated viral particles were found in the pellets.  An SDS-PAGE analysis of 
the non-reduced reaction samples demonstrated that the newly-made TMV-EFCA was able to dock and 
lock to the GFP-InaD fusion protein (Figure 37b).  The docked GFP-InaD band had an apparent molecular 
weight of approximately 60 kDa, while alone TMV-EFCA ran at 18 kDa and undocked GRP-InaD ran at 35 






Figure 37. SDS-PAGE analysis of TMV-EFCA.  a) TMV-EFCA and wild type TMV were extracted from N. benthamiana and purified 
by PEG precipitation, reduced samples from the subsequent clarification process were analyzed by SDS-PAGE.  b) GFP-InaD was 
docked onto TMV-EFCA, followed by PEG precipitation and centrifugation to pellet the viral nanoparticles.  Non-reduced 
samples from the docking reaction as well as the individual components of the docking reaction were analyzed by SDS-PAGE.  
Dock-and-Lock reactions to create VNPs 
To create PAD-TMV viral nanoparticles, dock-and-lock reactions were performed to covalently 
attach the PAD-InaD fusion proteins expressed in E. coli (Table 11) to the TMV-EFCA virus scaffold.  
Docking tests were performed by adding 10 µg of the virus scaffold to a molar excess of purified PAD 




were precipitated by adding PEG to a final concentration of 4% and NaCl to 0.6 M.  After incubating the 
mixture on ice, centrifugation separated the precipitated viral particles (pellet) from any undocked PAD 
fusion proteins (supernatant) and SDS-PAGE was used to analyze the results.  Figure 38a demonstrates 
that docking purified PAD1-InaD to TMV-EFCA produced VNPs with coat proteins of approximately 70 
kDa and that in the presence of a reducing agent, the PAD1-TMV coat proteins is reduced to its 
constituent parts.  In contrast, the E. coli -produced PAD1’ fusion protein was not very concentrated and 
contained high amounts of co-purifying host-cell proteins, and these factors likely prevented PAD1’-InaD 
from docking to TMV-EFCA (Figure 38b).  Interestingly, the co-purifying host-cell proteins were present 
in the “viral” pellet following PEG precipitation, suggesting that they may have been forming insoluble 
aggregates.  If PAD1’-InaD were part of this insoluble aggregate, it would explain why it was unable to 
dock.  Although the PAD2, PAD3, and PAD4 fusion proteins contained few host-cells proteins and were 
used at relatively high concentrations in the docking reactions, SDS-PAGE analysis revealed that the 
docking process was inefficient (Figure 38c, d), even though a concurrent GFP docking reaction worked 
well (Figure 38d).  Additional docking reactions were performed with the PAD2, PAD3, and PAD4 fusion 






Figure 38. SDS-PAGE of docking reaction for E. coli-expressed PAD fusion proteins. Docking reactions were performed using 
TMV-EFCA and various fusion proteins, followed by PEG precipitation and centrifugation to pellet the viral nanoparticles.  The 
purified fusion proteins, along with non-reduced and reduced samples from the docking reactions were run on SDS-PAGE.  a) 
PAD1-InaD. b) PAD1’-InaD. c) PAD2-InaD and PAD3-InaD. d) PAD4-InaD and GFP-InaD. Where applicable, black arrows indicate 





As an alternative to the viral nanoparticles discussed in the previous chapter, in which small 
linear epitopes were genetically fused to the TMV coat protein, this chapter explored the Dock-and-Lock 
system.  The potential advantages of this method include the ability to display epitopes on TMV that 
might otherwise cause necrosis or inhibit viral assembly and the capacity to attach large, structurally 
complex antigens to the surface of TMV.  However, this method necessitates the production and 
purification of fusion proteins in an appropriate expression system.  Selecting an expression system for 
the production of recombinant proteins depends on several factors, including posttranslational 
modifications, disulfide bonds, and the destination of the expressed protein 678.  The PA domain portion 
of the fusion protein is prokaryotic, and the InaD portion is eukaryotic, which suggested it could be 
expressed in either a prokaryotic or eukaryotic expression system.  Thus, eukaryotic plant-based 
expression in N. benthamiana and prokaryotic expression in E. coli were attempted.   
Plant-based Expression of PA Fusion proteins 
While protein expression levels in N. benthamiana using TMV expression vectors is dependent 
on the recombinant protein being produced, yields between 100 µg and 5 mg of protein per gram of 
fresh leaf biomass are common 138,176,679,680.  Smith et al. used a TMV vector to produce streptavidin-
antigen fusion proteins in N. benthamiana and recovered 60–120 µg of functional protein per gram of 
leaf tissue 681.  The estimated yields for the two PAD fusion proteins expressed in N. benthamiana, which 
were on the order of ng/g (Table 11), proved to be at least an order of magnitude lower than the 
customary yield from this production system.  The low yields for PAD1’-InaD and PAD1-InaD were 
initially ascribed to either in planta degradation or low expression levels, and expression of the PAD2, 
PAD3, and PAD4 fusion proteins in N. benthamiana was not attempted until a solution could be found to 




adding protease inhibitors to the plant cell extracts did not increase the yields of PAD1’-InaD and PAD1-
InaD (data not shown), the addition of signal sequences was considered.  For example, adding regulatory 
elements, such as PR1a and KDEL, has been shown to increase expression levels and improve yields 
682,683.  However, adding these signal sequences would have required re-cloning all five constructs and 
increased yield were not a guarantee.  Neither the PA portion nor the InaD portion of the fusion proteins 
contains post-translational modifications, so a prokaryotic expression host was used as an alternative.    
E. coli-based Expression of PA Fusion Proteins 
The advantages of using an E. coli- based expression system include ease of transformation, 
rapid growth, straightforward culturing techniques using inexpensive media, and high yields 684.  
However, recombinant proteins expressed at high levels in the cytoplasm are prone to aggregation and 
can form inclusion bodies in which proteins are not properly folded, are insoluble, and/or have incorrect 
disulfide bonds.  While inclusion bodies can protect proteins from proteolysis, the denatured proteins 
must be extracted using denaturing agents and then refolded into a more native conformation, which 
can lead to low final yields 669.  The PAD2, PAD3, and PAD4 fusion proteins were found in the insoluble 
fraction after cell lysis and thus had likely formed inclusion bodies.  However, this was not a problem as 
native PA83 contains no cysteine residues (i.e., does not contain disulfide bonds) and the portion of InaD 
used for dock-and-lock contains only one cysteine residue. 
Furthermore, the insoluble PAD fusion proteins were easily denatured with urea and then 
refolded on the Ni-NTA column with final yields of purified protein in the milligrams per liter range.  
While yields from E. coli are process and protein-dependent, they generally range from 0.1 mg to 1 g of 
protein per liter of cell culture 680,685-689, and recombinant soluble PA has been expressed in E. coli at 1.5 
to 125 mg/L 690,691.  Other studies have shown that PA domains can be successfully produced in E. coli at 
yields ranging from 1-43 mg/L 692,693.  Given all this, it is fair to say that the yields of recombinant PAD2-





A variety of strategies can be employed to overcome low expression problems in E. coli including 
the use of different promoters, the use of different host strains, co-expression of chaperones, reduction 
of culture temperature, and the use of secretion signals to target the proteins to the periplasm or 
culture medium 694.  Although the focus of this project was not the optimization of protein 
production/purification, several different strategies were employed to increase the yield of the PAD1’ 
and PAD1 fusion proteins.  Although protease inhibitors were used during the purification processes for 
PAD1’-InaD and PAD1-InaD, in vivo proteolytic degradation may have been at least partially responsible 
for the low yields that were initially observed.  The periplasmic space contains less proteolytic enzymes 
and other host cells proteins than the cytoplasm 694, and a secretory signal sequence, such as the PelB 
sequence from Erwinia carotovora, can be added to the N-terminus of a recombinant protein to direct it 
to the periplasmic space in E. coli.  Following secretion into the periplasm, the secretory signal is cleaved 
off by a signal peptidase, and the recombinant protein can be harvested by disrupting the outer 
membrane to and separating the periplasmic proteins from the spheroplasts.  While using PelB to target 
PAD1’-InaD and PAD1-InaD to the periplasmic space did result in less host-cell protein contaminants, 
only a fraction of the fusion proteins was actually secreted into the periplasmic space.  To ensure 
maximum yields of the problematic fusion proteins, the periplasmic fractions and the insoluble cell 
pellets were combined before purification.  In summary, although the final yields from adding PelB 
signal sequence ending up being similar to the yields seen before PelB was added, inefficient secretion 
into the periplasmic space meant that these yields could not be achieved without using other fractions 
containing the same host cell proteins that were a problem in the first place.   
MBP 
Adding MBP to the N-terminus of the PAD1’ and PAD1 fusion proteins led to increased 




improvement over the crude yields seen with the previous constructs.  In addition, reducing the 
temperature to 15°C after IPTG induction or optimizing protein folding may have resulted in increased 
solubility 695.  Purification on Ni-NTA resin was efficient, but the subsequent HRV 3C cleavage, while 
highly specific, proved to be only partially effective.  Adding additional protease may have resulted in 
more efficient cleavage, but the GST-tagged HRV 3C protease and the glutathione resin required to 
remove the protease are quite expensive, so this was not attempted.  The third step in the purification 
process, removing cleaved MBP and the remaining uncleaved MBP fusion proteins using amylose resin, 
proved to be the most inefficient step as the MBP didn’t bind well to the resin.  This could have been 
caused by low intrinsic affinity of the MBP fusion proteins to the amylose or the presence of cellular 
components or buffer reagents that interfered with binding 695, but glucose was added to the culture 
media to repress amylase expression, and the column buffer did not contain nonionic detergents.  Thus, 
low intrinsic affinity caused by the PAD-InaD fusion proteins blocking or distorting the maltose-binding 
site may have been the problem.  In summation, the MBP fusion protein constructs led to moderate 
expression of soluble MBP-PAD1’-InaD and MBP-PAD1-InaD, however, the multistep purification process 
and inefficient binding of residual MBP to the amylose column ultimately resulted in low yields and the 
presence of both MBP-related contaminants as well as degradation products.   
Ultimately, both PAD1’-InaD and PAD1-InaD proved challenging to express.  Because the other 
fusion proteins (i.e., PAD2-InaD, PAD3-InaD, and PAD4-InaD) were efficiently expressed in the pSX2 
vector, the vector was not likely the problem.  Instead, the low yield may have been due to issues with 
the stability and translational efficiency of the mRNA, in vivo degradation by host cell proteases, or the 
inherent toxicity of the protein to the host.  Strategies such as enhancing mRNA stability, targeting 
proteins to different cellular compartments, codon optimization, using molecular chaperones or fusion 
partner proteins, and/or increasing the stability of the protein to minimize proteolysis may have yielded 




to create VNPs using the Dock-and-Lock method.  Interestingly, other groups have not had the same 
problems expressing PA domain 1 646,692,693,697, although one group did note that three of their domain 1-
containing constructs were particularly susceptible to degradation 693.   
While the development of these PAD viral nanoparticle vaccines could proceed without the 
PAD1 and PAD1’ VNPs, domain 1 accounts for more than a third of the molecular weight of PA83 and 
multiple studies have shown that this domain contains neutralizing epitopes.  Abboud et al. found PAD1, 
and particularly the area around the furin cleavage site, to be highly immunogenic in mice and capable 
of eliciting LT-neutralizing antibodies 646.  This is in line with other studies that have reported similar 
observations about the ability of PA domain 1 epitopes to elicit LT-neutralizing antibodies 651,693,698,699.  
On the other hand, Crowe et al. noted that antibodies directed to the furin cleavage site only provided 
moderate protection to mice, suggesting that furin cleavage and subsequent binding of LF may occur 
before the PAD1 antibodies can bind to their target 651.  Instead, antibodies targeting epitopes in the 
receptor-binding portion of PAD4 and the LF-binding region of PAD1’ were shown to provide more 
robust in vivo protection against an LT challenge.  Results from other in vivo challenge studies have 
suggested that neutralizing epitopes are primarily found in PA domains 1, 2, and 4 693,700, and the 
contributions of PAD1 to protective immunity cannot be discounted. 
Docking reactions 
Chemically conjugating heterologous protein antigens to the surface of TMV avoids the 
potentially destabilizing effects of genetically fusing antigens to the coat protein 701.  Such chemical 
conjugation is facilitated by the presence of reactive side chains, like those found in cysteine, lysine, and 
glutamate; however, none of these reactive side chains are present on the outer surface assembled 
TMV virions 183.  In the Dock-and-Lock system, a cysteine residue is added to the C-terminus of the TMV 
coat protein, and recombinant protein antigens that also contain free cysteine residues can then be 




production of such VNPs ultimately depends on the efficiency with which the purified fusion proteins 
could be docked to TMV-EFCA.  Issues with process impurities and low final concentration resulted in 
inefficient docking of PAD1’-InaD, whether it was expressed in N. benthamiana or E. coli.  Given the 
slightly higher yields and lower levels of impurities, the E. coli-produced PAD1-InaD was able to be 
concentrated more than PAD1’-InaD during the purification process, which resulted in more efficient 
docking (Figure 38a).  Docking proteins to TMV-EFCA seems to work best when the InaD fusion protein is 
highly concentrated, soluble, and relatively free of process impurities.  In our study, GFP-InaD was 
provided at a concentration of 2.7 µg/µL, was soluble in the docking reaction buffer, and docked well 
(Figure 37b).  In addition, the free cysteine residue on both TMV-EFCA and the InaD fusion protein needs 
to be available for docking to occur.  Using antioxidants or reducing agents during extraction and 
purification minimizes unwanted crosslinking among fusion proteins or between the fusion proteins and 
host-cell proteins prior to docking.  Although BME was used during extraction/purification of the fusion 
proteins, BME is volatile and may have evaporated, leading to an oxidizing environment in which these 
unwanted disulfide bonds could form. 
Additionally, if the cysteine-containing region of the InaD fusion protein is sterically hindered, 
docking efficiency would likely decrease.  Such hindrance could be caused by the three-dimensional 
structure formed by the individual fusion protein or be caused by aggregation (with or without host cells 
proteins).  Li et al. also demonstrated that regardless of the location, adding foreign cysteine residues to 
TMV led to the formation of distorted and unstable viral particles 702, so it may be the TMV-EFCA rather 
than the fusion proteins that are responsible for inefficient docking.  However, if this were the case, one 
would expect to see inefficient docking with all fusion proteins rather than just a few.   In summation, if 
inefficient docking is not caused by the inherent properties of the fusion protein, then optimizing the 
concentration and solubility of the fusion protein and ensuring the fusion protein is in a reduced state 




Dock-and-Lock is not the only means of conjugating antigens to the surface of TMV though.  The 
tyrosine 139 residue on wild-type TMV has been used to facilitate functionalization through diazonium-
coupling 703 and copper(l)-catalyzed azide-alkyne cycloaddition 704.  Other groups have genetically 
modified TMV to contain surface-exposed lysine residues 183,681,705 or cysteine residues 183,186,190 and used 
N-hydroxysuccinimide(NHS) ester, thioether, or hydrazone linkages to conjugate antigens to the surface 
of TMV.  For example, Smith et al. produced TMV-lysine virions with an NHS-biotin linkage and then 
chemically conjugated it to streptavidin fusion proteins containing the papillomavirus L2 epitope 681.   
These systems have their own problems as TMV surface modifications tend to reduce the yield of 
virions, make them more prone to aggregation, and decrease their solubility 681,702,705.  Furthermore, 
when McCormick et al. compared the immune response characteristics to TMV-epitope conjugates and 
same epitope that had been genetically fused to the TMV coat protein, they found that the genetic 
fusion was vastly superior 183.  
Animal studies 
The western blot and ELISA data presented here show that anti-PA83 antibodies are able to bind 
to recombinant PAD fusion proteins, suggesting they may be in their native conformation, or at least 
close to their native conformation.  Once sufficient quantities the PAD-TMV viral nanoparticles are 
prepared, the next steps would be to test their immunogenicity in mice and then conduct challenge 
studies.  Such studies by other groups have already shown that recombinant PA domains are 
immunogenic in mice and induce the production of high levels of IgG with a strong bias toward a Th2 
type response (i.e., IgG1)646,692,693,697, and repeating such experiments might be unnecessary. 
Abboud et al. demonstrated that PA domain immunogenicity seems to be more a  function of 
the genetic background of the mouse rather than the characteristics of the domains themselves 646.  
Indeed, when it comes to post-vaccination challenge studies, the protection provided by PA-based 




mechanisms differ from species to species 571,706,707.  For example, in mice, the PGA capsule of B. 
anthracis is more virulent than the toxins, and AVA immunizations were not able to protect mice from a 
spore challenge 707-709.  Any future animal studies using these PAD-TMV VNPs would have to take these 
factors into account.  If anything, the primary aim of animal studies using these VNPs would be to 
provide insight into the increased immunogenicity of the domains when displayed on TMV and their 
ability to induce a cellular immune response, which is currently lacking in current PA-based vaccines 710.     
Alternative B. anthracis antigens 
AVA and the U.K.-licensed anthrax vaccine precipitated (AVP) both induce PA-specific antibody 
responses that are presumably the primary mediators of protection.  However, while AVA contains only 
trace amounts of LF and EF 605, AVP contains detectable levels of both LF and EF 711.  LF-specific 
antibodies induced by immunization with AVP have been shown to predict in vitro neutralization of LT 
712, and LF-based vaccines conferred complete protection in mice challenged with B. anthracis spores 713.  
LF is also the main target of T cell immunity, and researchers have noted strong CD4+ T cell responses to 
LF following natural cases of cutaneous anthrax infection as well as in AVP vaccinees 537.  However, while 
natural cases of anthrax lead to abroad T cell response that includes a variety of Th subsets and 
cytokines, the T cell response in AVP vaccinated individuals is significantly reduced with a skewed 
cytokines response and helper T cell polarization 614,714-716.  Infected individuals also have a strong CD4+ T 
cell response to PA, but vaccinees had a very low response 614, which may be why PA-based vaccines do 
not elicit long-lasting protection.   Coupled with data showing that there is a significant correlation 
between the duration of infection and T cell immunity to PA, these data suggest that T cell immune 
responses are just as crucial as B cells responses and that LF-specific immune responses should not be 
discounted.  EF-specific antibodies may also contribute to edema toxin neutralization, although their 
overall contribution to survival has not been determined 717.  In addition, several groups have developed 




anthracis 639,718,719 and spore antigens 537,720, which have shown to provide protection in animal models.  
Overall, these studies suggest that including LF/EF antigens, recombinant spore antigens, peptidoglycan 
antigens, and T cell antigens in candidate anthrax vaccines may confer an increased level of protection 
and elicit longer-lasting immune responses than vaccines based solely on PA.  Thus, if subsequent animal 
studies show that the PAD-TMV VNPs do not elicit a protective and long-lasting immune response, 
including alternative B. anthracis antigens may be beneficial.   This could be accomplished by creating 
additional TMV VNPs displaying these alternative antigens and including them in a multivalent vaccine 
with the PAD-TMV VNPs.  
CONCLUSION 
The Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism 
has stated that medical countermeasures, such as vaccines, are critically important to protect civilians in 
the event of a bioterror attack, and that the United States is “seriously lacking” in this vital capability 721.  
Currently, the only U.S.-licensed anthrax vaccine is AVA, which is expensive to produce and has 
questionable safety and efficacy.  AVA is primarily composed of PA, which plays a critical role during 
anthrax infection as heptameric PA63 forms the pore that allows the EF and LF toxins to enter host cells 
and exert their cytotoxic activities.  TMV viral nanoparticles displaying PA domains could potentially 
provide a safer, more effective, and economical alternative to AVA, and so we employed the Dock-and-
Lock system to create these PAD-TMV VNPs.  While difficulties were encountered in the expression of 
PAD1’-InaD and PAD1-Inad, recombinant PA domain 2, 3 and 4 fusion proteins were successfully 
expressed as inclusion bodies in an E. coli host and then refolded on Ni-NTA columns.  All three fusion 
proteins were recognized by an anti-PA83 antibody in both western blots and ELISAs, suggesting near-
native conformations were maintained.  Conjugating these fusion proteins to TMV was accomplished 




bifunctional chemical cross-linking used to create other VNP vaccines.  This investigation has laid the 
groundwork for testing these VNPs in vivo to determine their utility as anthrax vaccine candidates.  In 
addition, this method could easily be applied to attach other anthrax antigens, such as those found on 
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